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Abstract 
The goal of this thesis was to investigate flattening filter free (FFF) beams produced by medical 
linear accelerators for radiotherapy applications, from their initial setup through to their clinical 
implementation. This was split into four sections that comprise the main experimental chapters 
of this thesis. The characteristics of FFF beams both matched (by tuning beam quality to the 
equivalent cFF beam) and unmatched were compared to conventional flattening filter (cFF) 
beams. The characterisation of FFF beams highlighted inconsistencies with the current 
parameters used for the description and quality assurance (QA) of cFF beams.  New methods 
suitable for the QA of both cFF and FFF beams were investigated and proposed.  The use of 
Monte Carlo (MC) modelling was investigated to determine how to model an FFF beam and 
facilitate further investigations.  Treatment planning studies were performed for lung 
stereotactic ablative radiotherapy (SABR), pelvic SABR and Head and Neck volumetric 
modulated arc therapy (VMAT). The planning work concluded that clinically acceptable plans 
were achievable through the use of FFF beams and provides a solid basis for clinical 
implementation.  The work overall provides a comprehensive set of practical data and methods 
to support the use of FFF beams in clinical practice.   
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1. Introduction 
1.1. Overview of Radiotherapy 
There were over 280,000 cases of cancer diagnosed in 2012 in the UK, this has risen by 2% per 
annum and is predicted to reach 360,000 by 2030. Of the cases diagnosed with cancer 
approximately 50% will have radiotherapy as part of their treatment (Independent Cancer 
Taskforce, 2015). Radiotherapy is the use of ionising radiation to induce cell death in tumour 
cells. This is achieved through the use of radioisotopes, x-ray beams and particle beam therapies. 
With an increase in demand for radiotherapy, additional capacity is required, which can be 
achieved through increased treatment machine provision, extended treating hours, or through 
efficiency improvements utilising improved treatment delivery technology such as Flattening 
Filter Free (FFF) beams and techniques such as those covered in section 1.4. 
1.2. Linear accelerator design 
The majority of external beam radiotherapy is delivered using C-arm linear accelerators (LINACS). 
These Linacs accelerate electrons to high energies (in the region of 4-25MeV) which are diverted 
towards the patient to treat with an electron beam or directed so that they strike an x-ray target 
producing bremsstrahlung radiation. These energies are sufficient to penetrate to the required 
depths within the body. The linear accelerator is mounted as part of a rotating gantry so that 
the beam can be directed from any direction around the patient. The main components of an 
Elekta linear accelerator with Agility head (Cosgrove et al., 2009) are briefly described and shown 
(Figure 1) below (Podgorsak and International Atomic Energy Agency., 2005). 
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Figure 1: Diagram of Elekta Linear accelerator. 
 
 The pulse forming network generates a high voltage pulse (A) that is used to provide 
power to a magnetron (B) and an electron gun (C). 
 The magnetron (B) produces the high frequency microwaves that are injected into the 
waveguide (D). 
 The electron gun (C) provides a pulse of electrons that are accelerated into the travelling 
waveguide (D). 
 The travelling waveguide (D) accelerates the electrons produced by the electron gun (C). 
These electrons are focussed along the waveguide by two sets of focussing magnetic 
coils and steered by two sets of steering coils (E). The electrons exit the travelling 
waveguide into the flight tube (F) with the required energy for the radiotherapy 
treatment. The excess energy from the microwave is terminated in an RF load or can be 
recycled through a coupling waveguide back into the travelling waveguide. 
 The flight tube (F) contains a set of three bending magnets in a slalom with a total angle 
of bend of 112° that focus the electron beam onto the target or exit window and act as 
an energy selector. The magnetic field is adjusted by setting the bending currents, 
bending coarse and bending fine. Bending coarse applies the current to all three bending 
magnets and bending fine applies the current to the final bending magnet only. 
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 For the production of MV photons used for radiotherapy the high energy electron beam 
is focussed to be incident on a tungsten target (G). The electrons decelerate creating 
Bremsstrahlung radiation. In order to conserve momentum the radiation is produced 
with a forward directional bias. The higher the beam energy the greater the forward 
bias. 
 The radiation emitted that is not directed towards the treatment area is collimated by a 
fixed size primary collimator to reduce the dose outside of the treatment area. 
 Beyond the primary collimator is the flattening filter (H); this conical filter attenuates 
the centre of bremsstrahlung radiation and results in a flattened beam profile. For FFF 
machines this conical filter is replaced by a flat filter plate (Figure 2).By removing the 
flattening filter a source of attenuation within the beam is removed, increasing the 
intensity (dose rate) of the treatment beam. 
 
Figure 2: Diagram of the effect of removing the flattening filter on the beam profile 
 Once the beam has passed though the filter it passes through the monitor chamber (I). 
The monitor chamber contains three ionisation chambers. Two for measuring the 
amount of radiation delivered and a segmented ion chamber for measuring beam 
asymmetry in both the radial and transverse directions and for measuring the difference 
With Flattening Filter Flattening Filter Free
Beam Profile
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between the outer and inner parts of the beam, which is used as a surrogate for energy 
changes of the beam.  
 An LED optical system uses visible light to form the light field to demonstrate the beam 
position. The optical system also has an infra red camera that is used to track the Multi 
leaf collimator (MLC) positions (J). The optical system floods the MLCs with ultra violet 
light that causes the ruby reflectors on the MLC leaf tips to fluoresce in the infra red 
spectrum. 
 The MLC on the Agility head contains 160 tungsten leaves arranged in 80 pairs. Each leaf 
has a projected size at 100cm from the x-ray target of 0.5cm. The leaves are used to 
collimate the beam and can be used to create irregular shapes, these irregular shapes 
are required for the delivery of Intensity Modulated Radiotherapy (IMRT), which will be 
covered in a following section. 
 Below the MLC are two tungsten diaphragms (K) that collimate the beam perpendicular 
to the MLC travel direction, these are often referred to as ‘jaws’ 
 The beam exits the treatment head through a fixed aperture that is sealed with a Mylar 
window. This has crosshairs marked on it that identify the position of the central axis of 
the beam. 
The above description is of an Elekta linear accelerator, the other major manufacturer of Linacs 
is Varian. In the Varian design the microwaves are produced by a klystron and rather than a 
travelling waveguide system a standing waveguide is used. Details of the head design differ 
(Mohan et al., 2008), the leaf positions are determined through an optical encoding system 
rather than the optical system used in Elekta machines. 
C-arm Linacs have traditionally used a flattening filter to produce a uniform beam profile 
(conventional flattening filter (cFF) flattened beam) in order to simplify plan calculations and 
deliver uniform doses across individual beams. With the advent of IMRT (covered in section1.4) 
and inverse planning the flattening filter is no longer required, as beam profile variations can be 
compensated for by the MLCs. With the removal of the flattening filter a large source of 
attenuation (and scatter) in the beam path is removed, increasing the efficiency of the Linac and 
increasing the available doserate for FFF beams. The use of Linacs for cFF treatments is well 
established including the Quality Assurance (QA) tests required for maintaining the beams 
within clinical tolerances. The use of FFF beams in clinical practice with respect to C-arm Linacs 
is not well established, with commercially available clinical systems only available since 2011 
(Varian TrueBeam) and 2013 (Elekta VersaHD). These two manufacturers have implemented FFF 
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through different approaches, therefore in order to ensure safe clinical use an appropriate 
system of beam characterisation and QA needs to be investigated. 
1.2.1. FFF implementations 
There have been two approaches to the implementation of FFF beams. The differences in these 
approaches have significant impact on the properties of the beam such that two beams referred 
to as 6/10MV FFF differ depending on the implementation used. One approach is to remove the 
flattening filter and use the same settings for producing the MV beam. This implementation 
results in a beam with a softer spectrum and reduced penetration. This ‘unmatched’ approach 
is the implementation deployed with the Varian TrueBeam Linacs. The second approach is to 
additionally change the settings such that the accelerating potential is increased in order to 
produce a FFF beam that more closely matches the penetration of the associated cFF beam. This 
approach has been deployed with the Elekta VersaHD Linacs. The differences between these 
approaches are investigated in Chapter 3 
1.3. Clinical aims of radiotherapy 
The aim of radiotherapy is to damage tumour cells. The mechanism for this is that the ionisation 
within cells produced by the radiotherapy treatment creates free radicals, and these free 
radicals cause chemical interactions within the cell resulting in DNA damage. Cells contain 
mechanisms for repairing this chemical damage, but if sufficient damage to the DNA within the 
nucleus can be accumulated, cell death can be induced. A dose of 1Gy results in approximately 
1000 single strand breaks and 40 double strand breaks in the nucleus of a cell. Higher radiation 
doses increase this number and reduce the possibility of the cell repair mechanisms being 
successful. This relationship between increasing dose and a reduction in the survival of cells is 
characterised by the linear quadratic model. 
Equation 1: 𝑺 = 𝐞𝐱𝐩 [−(𝜶𝑫 + 𝜷𝑫𝟐)] 
Where S is the surviving fraction of cells, D is the dose delivered and α and β are constants 
relating to the type of tissue being irradiated. 
The relationship between these constants is often referred to as the α/β ratio. Tissues with a 
low α/β are typically normal tissues and are more sensitive to the linear component of the model 
requiring lower doses per fraction with more effective cell repair mechanisms. Tissues with a 
high α/β ratio are less sensitive to fraction size and represent tissues with fast growth such as 
tumour cells (Mayles et al., 2007). 
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As radiation damages both tumour cells and normal healthy cells, it is important that treatments 
conform closely to the target volume and do not irradiate normal tissues more than is required.  
Conformality, to match high dose volumes to the target and minimise doses to nearby organs at 
risk (OAR) has been a driving force in developments in radiotherapy delivery technology and 
treatment techniques. This has developed from 2D planning on a patient outline to 3D conformal 
radiotherapy (3DCRT) planning using the patient’s CT dataset and to the current state of the art 
IMRT (Brahme et al., 1982) and Volumetric Modulated Arc Therapy (VMAT) (Teoh et al., 2011) 
with on treatment imaging. 
1.4. Intensity Modulated Radiotherapy 
Treating areas of Planning Target Volume (PTV) with high dose radiotherapy often requires the 
ability to reduce dose to OARs in close proximity to the treated volume. A method of achieving 
this is by the application of a non-uniform dose profile applied at multiple beam angles that 
when combined in superposition produces a dose distribution with the required shape in 3D 
(Brahme et al., 1982). The technique of using non-uniform radiation fluence to produce the type 
of desired dose distributions is referred to as IMRT. With the advent of MLCs that can shape the 
radiation beam and computer algorithms that can determine the required radiation fluence to 
produce the desired dose distribution, IMRT has become routinely provided in most 
radiotherapy centres. Further developing on IMRT is the delivery of VMAT where the gantry is 
in constant rotation with both the MLCs moving and the dose rate increasing or decreasing to 
provide the desired radiation fluence. The advantages of VMAT over IMRT are an increased 
flexibility to deliver the dose from multiple angles and the reduction of treatment delivery times 
(Teoh et al., 2011). With the increased prevalence of these techniques it is no longer necessary 
for the photon fluence from the linear accelerator to be uniform and therefore treating without 
the flattening filter in the beam path becomes a possibility. IMRT techniques take longer to treat 
than 3DCRT, this has the potential to introduce problems with patient immobilisation and 
movement during treatment, VMAT techniques reduce this treatment time and the use of FFF 
beams with VMAT delivery can potentially reduce treatment times further. 
1.5. Monte Carlo simulation 
Monte Carlo simulation can be a powerful tool for investigating the stochastic processes of 
radiation beam interactions and characteristics.  An appropriately benchmarked Monte Carlo 
simulation can be used for investigations that might otherwise prove difficult practically either 
by their implementation or through access to a dedicated research Linac (Cranmer-Sargison et 
al., 2012; Muir et al., 2011; Titt et al., 2006b). The first Monte Carlo publication was in 1949 
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(Metropolis and Ulam, 1949) and described a statistical method for mathematically solving 
physics problems (Seco and Verhaegen, 2013). The premise of Monte Carlo is that when the 
probability of each of the interactions is known to sufficient precision then after a sufficient 
number of random interactions are modelled; the modelled results approach the true result. For 
radiation physics these are interaction cross sections for radiation with matter. There are a 
number of Monte Carlo codes available (EGSnrc, GEANT, PENELOPE, MCNPX) (Agostinelli et al., 
2003; Baro et al., 1995; Waters et al., 2007; Rogers, D. W. O. and Bielajew, 1984). The Electron 
Gamma Shower (EGS) code was first developed in 1978. It has undergone many developments 
from the EGS3 code to EGSnrc that is openly available today. The EGSnrc code has a specific user 
code BEAMnrc (Rogers, D.W. et al., 1995) that was developed between 1990 and 1996. This 
additional code was specifically developed for the modelling of Linacs and will be used for the 
Monte Carlo work in this thesis. 
1.6. Scope of Work 
Given the increasing availability and use of FFF beams, the aim of this thesis is to investigate FFF 
beams from the initial characterisation through to the final implementation in the clinical setting, 
to provide new knowledge to underpin the basis of their use.  This is done through answering a 
number of research questions. 
 What are the properties of FFF beams and do these properties differ between the two 
implementations? 
 Can suitable definitions be determined in order to characterise and QA all radiotherapy 
photon beams, cFF and both implementations of FFF? 
 Can existing Monte Carlo packages be used to accurately model FFF beams? 
 How can FFF beams be implemented in the clinic and are they suitable for a range of 
treatment sites? 
 This will be done through the following chapters; 
1. A literature review of current publications and their findings with respect of FFF 
beams, identifying gaps and required information to support clinical use. 
2. The characterisation of the two implementations of FFF beams by the two main 
manufacturers of Linacs. 
3. The setup and quality assurance of FFF beams and proposed new suitable definitions 
of beam parameters. 
4. The Monte Carlo modelling of FFF beams and how this can be achieved. 
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5. The implementation of FFF beams in a clinical setting including feasibility studies for 
different treatment sites and dose fractionations. 
1.6.1. Cyberknife and Tomotherapy 
Predating the implementation of FFF on conventional c-arm linear accelerators there exist two 
commercially available radiotherapy treatment machines that utilise FFF beams. The Cyberknife 
system (Accuray Inc., Sunnyvale, California, USA) is a 6MV linear accelerator mounted on a 
robotic arm with 6 degrees of freedom. The system has a maximum field size of 60mm resulting 
in radiotherapy beam profiles comparable to a cFF beam. The beam operates with a maximum 
doserate of 1000MU/minute. The system is designed for radiosurgical treatments and is not 
included in the scope of this work (Adler et al., 1997). 
The second commercially available system is TomoTherapy (TomoTherapy Inc., Madison, WI, 
USA). This system uses a 6MV linear accelerator mounted on a rotating gantry similar to a CT 
scanner. The maximum field size of the beam is 40cm x 5cm and therefore the profile shape only 
differs from that of a conventional cFF beam in the lateral direction (Jeraj et al., 2004). The 
output of the radiation beam is 1000MU/min. Due to the fan shaped beam used on the 
TomoTherapy system the treatments are delivered by helically irradiating the patient through a 
combination of rotating the gantry and moving the treatment couch. 
Each of these systems whilst sharing some characteristics with the FFF beams produced by 
conventional c-arm linear accelerators deliver their treatments in a significantly different 
manner and therefore are not included in the scope of this work. 
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2. Literature review 
Radiotherapy Linacs produce an x-ray beam that is forward peaked when the electron beam 
interacts with the target. This forward peaked distribution is conventionally directed to be 
incident on an attenuating flattening filter to produce a flat photon beam. Until recently, almost 
all Linacs used in radiotherapy utilise a flattening filter, where the aim of their design is such that 
the beam profile would be flat at a depth of 10cm in water (Dalaryd et al., 2010; Mesbahi, 2007; 
Khan, 2003), in order to help ensure a uniform coverage of the target. An example of a cFF 25cm 
x 25cm beam and its FFF equivalent are shown in Figure 3. 
With the improvements in computer technology more complex dose calculations can be 
performed and this has led to treatments such as IMRT, VMAT, radiosurgery and stereotactic 
ablative radiotherapy (SABR). With the increase of these advanced techniques there has been 
an increased interest in the operation of Linacs with the flattening filter removed. There are a 
number of reasons behind this interest. The flattening filter attenuates a large proportion of the 
beam incident on it thereby reducing the efficiency of the linear accelerator. The removal of the 
flattening filter results in an increase of the available doserate of the beam. Radiosurgery 
generally uses small fields (< 5cm x 5cm) and large doses per fraction requiring high numbers of 
monitor units per beam. Due to the small beam widths, FFF small fields have a comparable 
profile with the flattening filter removed as when it is present (Mesbahi, 2007) as well as having 
an increased doserate that may increase the treatment delivery speed. IMRT uses the MLC to 
produce non-uniform beam fluence. Therefore it is not a requirement that the beam has a 
uniform profile before the modulation procedure. 
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Figure 3: A 25cm x 25cm 6MV cFF beam (above) and a 25cm x 25cm 6MV FFF beam 
(below) measured at 100cm SSD and a depth of 10cm in water 
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Figure 4: A 3cm x 3cm cFF beam (above) and a 3cm x 3cm FFF beam (below) measured 
at 100cm SSD at a depth of 10cm in water. 
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In addition, there have been a number of Monte Carlo studies that have demonstrated that the 
flattening filter is the dominant source of scattered radiation in the linear accelerator treatment 
head (Dalaryd et al., 2010; Titt et al., 2006a). The scatter produced in the treatment head 
increases the complexity of modelling off-axis fields which are frequently used in IMRT 
treatments and SABR treatments. The flattening filter also produces a variation in beam quality 
with off-axis distance, due to the variation in beam-hardening effects caused by the conically 
shaped flattening filter. This produces a treatment beam with variable energy spectra as you 
move away from the central-axis. The removal of the flattening filter could potentially result in 
improved dose calculations for IMRT plans due to the simplification of off-axis calculations 
compared to delivery with the flattening filter in situ (Cashmore, 2008) and the reduction in 
scatter from the treatment head may reduce the unwanted out-of-field dose.  
Thirdly, the softer spectrum of the FFF beam has been used as an indication that FFF beams 
could prove beneficial for MV imaging and portal dosimetry (Tyner et al., 2009). This softer 
spectrum would improve the low contrast resolution of MV imaging and have the potential to 
increase the sensitivity of portal imaging through greater attenuation of the low energy photons 
contained in the beam.  
2.1. Second Cancer induction following radiotherapy 
With improved radiotherapy treatments resulting in greater cancer control and increased long 
term survival rates, the risk of developing second primary malignancies due to the irradiation of 
normal tissue has become an area of concern (Hall, 2006; Dorr and Herrmann, 2002). The 
cumulative incidence of second primary cancers could be as high as 20% of patients receiving 
radiotherapy treatment (Tubiana, 2009). A study by Brenner et al. (2000) concluded that 
following radiotherapy to treat prostate cancer the relative risk of developing a second 
malignancy was 6% higher than those who were treated surgically, this increases to 15% and 34% 
following 5 years and 10 years survival, respectively. In absolute terms, the estimated risk of 
developing a radiation-associated second malignancy was 1 in 290 for all prostate carcinoma 
patients treated with radiotherapy, increasing to 1 in 70 for long term survivors (> 10 years). The 
majority of the increased risk was carcinomas of the bladder, rectum and lung. The use of FFF 
treatments can reduce the whole body dose to the patient and reduce the out of field dose, 
potentially reducing the risk of these incidences. 
IMRT treatments can increase the number of monitor units delivered by a factor of 2-10 (Klein 
et al., 2006; Mansur et al., 2007) compared to 3D conformal treatment approaches. This increase 
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will also increase peripheral dose from leakage through the linear accelerator head. This could 
be reduced through the removal of the flatting filter.  
The majority of second cancers are located within the margins of the radiotherapy treatment 
field. However, second cancers can still be located in the periphery of the patient (Chofor et al., 
2010). A study by Dorr and Herrmann (2002) looked at where second cancers occurred following 
radiotherapy. The findings were that 50% of new tumours occurred in the margins of the 
previous radiotherapy treatment, where the margin is defined as the distance -2.5cm inside the 
nominal field edge to 5cm outside the nominal field edge. This is compared to 10% of second 
tumours located in the field and 10% in the adjacent area (5cm to 20cm from the field). The 
study also found that 30% of the tumours were located at distances greater than 20cm from the 
field. The dose delivered to 58% of the sites was less than 6Gy, demonstrating the importance 
peripheral doses can have in radiotherapy treatments.    
The sources that contribute to peripheral doses, distant from the site of treatment are head 
leakage, head scatter and phantom scatter i.e. scatter within the patient from the primary 
treatment area. It may be possible to reduce the first two sources through the removal of the 
flattening filter from the treatment head as the interaction of the photon beam with the 
flattening filter causes additional scatter. Phantom scatter will vary as a function of the mean 
energy of the primary photon beam. Removal of the flattening filter will have an effect on this. 
Out of field dose has been linked to the induction of secondary cancers following radiotherapy 
treatment. A reduction in out of field dose could potentially reduce the incidence of radiation 
induced second cancers. Titt et al. (2006a) stated that out of field doses were reduced with the 
flattening filter removed whereas Kry et al. (2010) reported that out of field doses were 
comparable near the treatment site and were reduced by 30% at distances greater than 20cm 
from the treatment site, this reduction is as a result of the reduced head leakage when using FFF 
beams. A reduction in peripheral doses was also observed by Dobler et al. (2017) when 
delivering head and neck VMAT. 
Cashmore et al. (2011), Murray et al. (2015), Bouchta et al. (2018) and Moret et al. (2018)  
performed studies looking at the risk of second cancer induction following radiotherapy with 
both FFF and cFF beams. The study by Cashmore et al. (2011) was performed on an Elekta Precise 
linear accelerator with an MLCi treatment head whereas the studies by Murray et al. (2015) and 
Moret et al. (2018) were performed on an Elekta Synergy model with an Agility treatment head. 
The study by Bouchta et al. (2018) was performed on a Varian TrueBeam.  All Elekta studies used 
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energy matched FFF beams, with Murray et al. (2015) and Moret et al. (2018) matching at 10cm 
deep as per the current matching advice for Elekta FFF. Cashmore et al. (2011) stated that the 
match was performed at both 10cm deep but also as a Tissue Phantom Ratio (TPR) TPR20/10 
match. The study by Bouchta et al. (2018) used unmatched FFF beams. The sites investigated 
were paediatric cranial IMRT (Cashmore et al., 2011), paediatric cranial VMAT (Moret et al., 2018; 
Bouchta et al., 2018) and prostate 3DCRT, VMAT & SABR (Murray et al., 2015). Plans were 
produced in the Xio Treatment Planning System (TPS) version 4.34.02 (Cashmore et al., 2011), 
Monaco version 3.3 (Murray et al., 2015), Oncentra External Beam version 4.5.2 (Moret et al., 
2018) and Eclipse verson 11 (Bouchta et al., 2018) each with a 2mm dose grid. Cashmore et al. 
(2011) optimised the plans for 6MV cFF and then re-optimised with the same parameters for 
FFF. The other studies optimised all plans individually. All studies found that plan quality was 
comparable with cFF and FFF beams. Two studies measured doses in  anthropomorphic 
phantoms, the anthropomorthic paediatric phantom (CIRS Inc, VA, USA) (Cashmore et al., 2011) 
and the Rando phantom (The Phantom Laboratory, USA) (Murray et al., 2015). Each study found 
that peripheral doses were reduced with the use of FFF beams, by up to 70% (Cashmore et al., 
2011), 55% (Murray et al., 2015), 25.6% (Bouchta et al., 2018) and 25% (Moret et al., 2018). 
Although this relative reduction is large, the change in absolute risk of cancer induction was 
determined to be 0.0023 per 10000 (Murray et al., 2015). The absolute risk for this cohort of 
patients was low as it factored life expectancy into the calculation, had the calculation of 
absolute risk been evaluated for paediatric patients the absolute risk would have been greater.  
2.2.  Monte Carlo studies on FFF Linacs 
A number of studies have been performed on the operation of a linear accelerator without the 
flattening filter in situ. A large proportion of these studies have been performed via Monte Carlo 
methods such that the authors do not need a working FFF machine to perform the investigations.  
2.2.1. Beam Quality 
Xiong and Rogers (2008) performed a study comparing the beam quality specifiers %dd(10)x and 
TPR2010 in terms of the Spencer-Attix water to air restricted mass collision stopping power-ratio. 
Current dosimetry standards and protocols use a correction factor relating to these beam quality 
specifiers to determine the dose to water measured with an ionisation chamber. It was proposed 
that the change in spectrum caused by the removal of the flattening filter could result in 
differences between the appropriate calibration factor for a measured beam quality. The Monte 
Carlo software used for the study was BEAMnrc/EGSnrc, the 9 Linacs modelled had been verified 
in prior studies. The stopping power ratios calculated agreed closely with the relationship used 
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in TG-51 for %dd(10)x to the stopping power ratio for the beams with a flattening filter. The 
largest deviation from the relationship used in TG-51 was a route mean square deviation (RMSD) 
of 0.0028. For beams without the flattening filter the maximum RMSD was 0.0041. The change 
in kQ would be a maximum of 0.2% if the TG-51 relationship was modified for the FFF beams. 
When comparing the stopping power ratio to TPR measurements for cFF and FFF beams the 
stopping power ratio can differ by between 0.4-1% for the same TPR value. This demonstrates 
that TPR may not be as suitable a beam quality measure for Linacs operating without a flattening 
filter. The work published by the IPEM working party (Budgell et al., 2016) proposed a new factor 
when calibrating FFF beams, this factor of 0.997 corrects the TPR value for the softer photon 
spectrum when using FFF beams. 
Ceberg et al. (2010) performed a Monte Carlo simulation using the BEAMnrc/EGSnrc software 
package. The study suggested a new beam quality specifier that may be more appropriate for 
FFF beams. Although %dd(10)x can be used with acceptable deviations for FFF beams, TPR 
cannot (Ceberg et al., 2010). The subsequent work published as part of the IPEM working party 
(Budgell et al., 2016) provides a correction factor that corrects for this change in spectrum 
allowing TPR to be used as a beam specifier. Ceberg et al. (2010) propose that the mean energy 
of the beam and the coefficient of variation could be more appropriate measures of beam 
quality. The mean energy and coefficient of variation was determined from phase space files 
produced by the BEAMnrc/EGSnrc software. The authors did not indicate how these values 
could be measured in an empirical method. The relationship between the stopping power ratio 
and the mean energy and coefficient of variation was determined to be: 
Equation 2: (?̅? 𝝆⁄ )
𝒂𝒊𝒓
𝒘𝒂𝒕𝒆𝒓
= 𝒃𝟏 + 𝒃𝟐?̅? − 𝒃𝟑?̅?
𝟐 + 𝒃𝟒?̅?
𝟑 − 𝒃𝟓𝒄𝒗 
Where μ is the mean energy, cv is the coefficient of variation and bx are coefficients. 
The stopping power ratios were calculated from the data produced using EGSnrc/BEAMnrc and 
compared to data previously measured by Xiong and Rogers (2008). The maximum deviation 
from the calculated stopping power ratio and those determined previously was 0.13%. 
2.2.2. Beam Penumbra 
The profiles of FFF beams are significantly different than cFF beams for field sizes of greater than 
4cm2. This is problematic when comparing beam penumbra as the 80%-20% dose values used 
for cFF beams are not appropriate as the 80% dose may be located within the FFF beam profile. 
Ponisch et al. (2006) proposed a method for measuring the penumbra of an FFF beam that 
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normalises the profile to a cFF profile. The normalisation points used are the inflection points of 
the profiles (Figure 5). 
 
Figure 5: 20cm x 20cm FFF profile taken at 100cm SSD at a depth of maximum dose in 
water. The inflection points use for normalisation are marked by vertical lines. 
 
 The penumbra of the FFF beam is measured as the distance between the 80% and 20% of the 
normalised dose. The normalised dose is given by: 
Equation 3: 𝑫𝒏 =
𝑫𝒖
𝑫𝒇
𝑫𝑪𝑨𝑿 
Where Dn is the normalised dose, Du is the dose at the inflection point on the FFF beam, Df is the 
dose at the inflection point of the cFF beam and DCAX is the dose at the central axis for the FFF 
beam.  
This normalisation method is not universally adopted throughout the literature but as accepted 
guidelines on the beam parameters of FFF beams are not yet agreed, this method will be used 
in this thesis for determining the penumbra of an FFF beam. 
2.2.3. FFF with Varian Linacs 
There have been many papers produced comparing the beams of cFF and FFF beams using 
Monte Carlo simulations of Varian Linacs (Ponisch et al., 2006; Kry et al., 2010; Titt et al., 2006c; 
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Titt et al., 2006a; Vassiliev et al., 2006a; Tsiamas et al., 2011). The FFF mode of a Varian linear 
accelerator does not support the re-tuning of the electron beam before it is incident on the 
target. Therefore, the FFF beam produced has a lower mean energy than the cFF beam. For the 
6MV beam a flat 2mm copper filter is positioned where the flattening filter would have been 
located. The purpose of this is to remove contamination electrons that may have penetrated the 
target through normal use or target damage, whilst also producing sufficient secondary 
electrons for the monitor chambers to respond. The 18MV beam has a thicker target and so no 
filtration is required for the photon beam (Kry et al., 2010). The 18MV beam was produced on a 
prototype machine and has not been released clinically and there are no specifications from the 
manufacturer that provide information on whether a filter plate is included in the clinical 
implementation of FFF beams for Varian machines. The Monte Carlo software used for the 
studies were either BEAMnrc/EGSnrc (Titt et al., 2006a; Vassiliev et al., 2006a; Tsiamas et al., 
2011) or MCNPX (Ponisch et al., 2006; Kry et al., 2010; Titt et al., 2006c; Titt et al., 2006a; 
Mesbahi, 2007).  
Conventional Linacs have been designed to operate with a flattening filter; the beam stability is 
controlled by a series of feedback servos and the dose delivered to the patient is monitored 
through ionisation chambers. It is important to ensure that these mechanisms still function 
correctly for FFF beams. Titt et al. (2006c) performed a study to determine whether the softer 
photon spectrum of the FFF beam would result in sufficient changes in backscatter to the 
ionisation chambers to alter their function. The Monte Carlo code used for this study had 
previously been benchmarked against an earlier backscatter study with the linear accelerator 
operating in normal mode. The Monte Carlo simulation agreed with measurements to within 
<1%. The findings of the study were that for fields larger than 2cm x 2cm at 18MV the change in 
the backscatter to the ionisation chambers was lower than the uncertainty in the Monte Carlo 
calculations demonstrating that no significant change occurs and the ionisation chambers would 
work in the same manner as for a cFF beam. 
The effect on the percentage depth doses (PDD) was studied in each of the Monte Carlo studies. 
The PDDs were noted to have a shape more closely resembling a 4MV cFF beam for a 6MV FFF 
beam and a 15MV cFF beam for the 18MV FFF beam (Vassiliev et al., 2006a). This is due to the 
softer spectrum caused by the higher proportion of low energy photons in the FFF beam that 
would have otherwise been attenuated by the flattening filter. A comparison of the penumbra 
for cFF and FFF beams showed that the penumbra could be reduced by up to 1mm with the use 
of a cFF beam when compared with the normalisation method proposed by Ponisch et al. (2006). 
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It was reported by Titt et al. (2006a) that the penumbrae of FFF and cFF beams were comparable, 
however, no explanation as to how the penumbrae were defined for FFF beams was provided.  
The removal of the flattening filter removes a significant source of photon attenuation and 
therefore increases the maximum doserate available. The increase in doserate has been 
reported as a factor of 2 times (Titt et al., 2006a), 2.3 (Mesbahi, 2007), 1.9 (Tsiamas et al., 2011) 
and has been reported as up to 5.45 times (Vassiliev et al., 2006a). The increase in doserate has 
a possibility of decreasing treatment delivery time, especially for stereotactic radiosurgery 
where large doses per fraction are typically required. 
It was noted by Titt et al. (2006a) that the shape of the profiles were more consistent with 
increasing depth as the off-axis softening is reduced in the FFF mode of operation. Without the 
flattening filter in place the variation of energy spectra with off-axis distance is decreased 
(Vassiliev et al., 2006a). This reduces a variation of 0.33MeV over the range of a 10cm x 10cm to 
40cm x 40cm field for a cFF beam to a variation of 0.02MeV for FFF beams (Mesbahi, 2007). This 
reduction is expected as the flattening filter acts as a differential attenuator across the beam, 
attenuating more of the low energy photons closer to the beam central axis. 
Zavgorodni (2013) and Tsiamas et al. (2011) performed a Monte Carlo study into the feasibility 
of using large electron beam divergence parameters on the target to produce an FFF beam that 
more closely represented a cFF beam. This work used electron beam divergences of up to 20° to 
produce this ‘flattened’ FFF beam. The subsequent Monte Carlo studies into the characteristics 
of the Flat-flattening filter free beams (F4) showed that they maintained some of the 
characteristics of FFF beams such as reduced variation of profile with increasing depth in water, 
reduced out-of-field doses and reduced output factor variation. Tsiamas et al. (2011) concluded 
that divergences of or near 14° caused the electron beam to interact with the primary collimator 
impacting on the doserate to the edge of the profile. They concluded that divergences of 5-10° 
produce fields flat enough for IMRT treatments without compromising the peripheral dose or 
increased doserate.  
2.2.4. Out of field dose and radiation protection considerations 
Kry et al. (2009) performed a Monte Carlo study to investigate how the change in the beam 
parameters affects the shielding requirements for a linear accelerator vault. The tenth value 
layer (TVL), the thickness of attenuating material  that reduces the radiation level by a factor of 
one tenth of the initial level, and the equilibrium TVL, the depth where the radiation directional 
and spectral distributions are practically independent of thickness, were determined for 
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Portland concrete and the patient-scattered radiation was also determined. The shielding 
calculations assumed that the linear accelerator would operate exclusively in FFF mode and each 
patient would receive an IMRT treatment.  
When the linear accelerator was operating without a flattening filter the first and equilibrium 
TVL was reduced by an average of 12%, reflecting the reduced effective energy in Varian FFF 
conditions. The amount of patient scatter was less at an angle of <60° and more for angles >60°. 
If the linear accelerator was operating at only 6MV FFF, the required thickness of primary barrier 
was determined to be 20% thinner and secondary barriers 10% thinner compared to that 
required for a cFF 6MV beam. For the linear accelerator operating with both 6MV and 18MV FFF 
modes, the primary barrier would be 9% thinner and secondary barrier 20% thinner. However, 
the implementation of the FFF mode for Elekta Linacs is different to the method used by Varian. 
The electron beam incident on the target can be tuned on an Elekta linear accelerator so that 
the percentage depth dose at 10cm deep in water for the photon beam produced matches that 
of the cFF beam (ELEKTA, 2010). Therefore, the conclusions of Kry et al. (2009) regarding bunker 
shielding are unlikely to translate to a bunker housing a ‘matched’ FFF linear accelerator. 
Fewer Monte Carlo studies have been carried out on the Elekta implementation of a FFF mode. 
This may be because the model cannot be easily benchmarked against data of a linear 
accelerator operating in flattening filter mode as a new incident electron beam spectra needs to 
be derived. 
Almberg et al. (2012) performed a Monte Carlo study on an Elekta Synergy linear accelerator 
equipped with an MLCi head. The work was performed using the EGS/BEAMnrc Monte Carlo 
user code. This work investigated FFF beams with and without energy matching to an associated 
cFF beam. The paper found that with both types of FFF beam the out of field dose was reduced 
by up to 40% but with a greater reduction of out of field dose near the treatment volume when 
using an energy match FFF beam. The model was a development of an existing Monte Carlo 
model on a cFF beam with the filter replaced by a 2mm stainless steel plate. As with Varian 
Linacs the purpose of this plate is to remove contamination electrons and also act as a source of 
secondary electrons so that the ionisation chamber servo systems can operate correctly. The 
authors did not benchmark the model against measured FFF data and instead stated that the 
cFF model had been benchmarked. 
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2.3. Empirical measurements on FFF Linacs 
2.3.1. Varian accelerators 
Prototype conventional Linacs have been developed to run in a mode where the flattening filter 
is not present in the beamline. The beam parameters of these Linacs have been published by a 
number of authors from different sites (Ponisch et al., 2006; Hrbacek et al., 2010; Kry et al., 
2007a; Vassiliev et al., 2006b; Stathakis et al., 2009).  
The backscatter to the ionisation chambers was found to be comparable with the FFF beam 
compared to the cFF (Zhu et al., 2006). This confirms the results of previous Monte Carlo studies 
(Titt et al., 2006c). The dose-rates measured for FFF beams were reported to increase by a factor 
of 1.99 (Stathakis et al., 2009) to 2.26 (Hrbacek et al., 2010) compared to cFF beams at 6MV and 
3.62 (Stathakis et al., 2009) to 4.03 (Hrbacek et al., 2010) compared to cFF beams at 10MV. As 
with the reported increase in doserate observed from Monte Carlo studies this is expected as 
the flattening filter acts as an attenuator in the beam reducing the doserate. 
The in-air output ratio changes less with field-size for FFF beams compared to cFF beams (Zhu 
et al., 2006), this is expected as the flattening filter is the dominant source of scatter within the 
treatment head with head scatter as the dominant cause of in-air output ratio changes with 
respect to field size. The surface dose for FFF beams was measured to be 10% higher than for 
cFF beams. Also, the depth of maximum dose (dmax) was closer to the patient surface for FFF 
beams (Hrbacek et al., 2010; Vassiliev et al., 2006b; Stathakis et al., 2009).  The increased surface 
and shallower dmax is a result of the higher proportion of low energy photons in the FFF beam. 
The variation of the depth of maximum dose varies less with field size for FFF beams so that a 
40cm x 40cm field has a depth of maximum dose deeper than that for a cFF beam (Hrbacek et 
al., 2010; Vassiliev et al., 2006b). This is due to the reduction in head-scatter associated with FFF 
beams. The profiles of FFF beams are closely matched to cFF beams for field sizes smaller than 
4cm x 4cm. The measured PDDs for a 6MV FFF beam more closely resembled that of a 4MV cFF 
beam with the 18MV profile being more closely matched to that of a 15MV cFF beam (Vassiliev 
et al., 2006b). The penumbrae for 6MV FFF beams were 0.3mm sharper than cFF for depths up 
to 12cm but for depths over that the cFF beams had a sharper penumbra when compared to 
FFF. The penumbrae for 10MV FFF beams were sharper for all depths with the largest difference 
of 0.6mm at the depth of maximum dose (Hrbacek et al., 2010). Other authors stated a reduction 
of penumbrae of 0.6mm for a 6MV beam and 0.9mm with an 18MV beam (Ponisch et al., 2006).  
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The collimator exchange effect describes how the output of an Xcm x Ycm treatment field differs 
from a Ycm x Xcm field, due to the different location in the treatment head of the X and Y 
diaphragms. The effect is reduced in FFF beams, being 1.8% for cFF beams at 6MV and 1.2% for 
FFF beams. The values are 2.4% for cFF and 1.5% for FFF at 10MV (Hrbacek et al., 2010). This is 
likely a result of the reduction in head scatter for FFF beams. 
The measured leakage through the MLC from an FFF beam has been reported as being reduced 
compared to cFF beams: by 0.29% at 6MV and 0.16% at  18MV (Ponisch et al., 2006). This 
reduction is due to the softer energy spectrum of the FFF beams.  
Neutron production in high Z materials within the linear accelerator head can contribute to both 
patient and operator dose. The flattening filter is a significant source of neutron production and 
the effect of the removal of the flattening filter on the number of neutrons produced in an 18MV 
photon beam has been studied (Kry et al., 2007a). The number of neutrons produced for each 
MU was 20% lower with the flattening filter removed. 
Lang et al. (2012b) performed a study on the effects of FFF beams on the collection efficiency of 
ionisation chambers used to measure dose. The collection efficiency was determined using a 
two voltage technique (Lillicrap et al., 1990). The change in collection efficiency with respect to 
dose per pulse changed by 0.8% from the highest dose per pulse measured (1.7mGy per pulse) 
to the lowest dose per pulse (0.4mGy per pulse), the conclusion was that the tested air vented 
ionisation chambers could be used for relative dosimetry without the need for collection 
efficiency to be accounted for. Measurements on matched 6 and 10 MV FFF beams at St James’s 
University Hospital, Leeds yield a change in collection efficiency of 0.3% from 10cm deep to 
20cm deep in water for 6MV FFF and 0.6% for 10MV FFF. The impact on the measured TPR 
results in a change of dosimetric calibration factor of 0% for 6MV FFF beams and <0.1% for 10MV 
FFF beams. 
Many of the quality assurance parameters that are used for cFF beams such as beam flatness 
and current penumbra definitions are not appropriate for FFF beams, mainly due to the 
normalisation of the beams to the central axis as part of the definition. Fogliata et al. (2012b) 
proposed new normalisation and parameters such as unflatness and in-profile slope to 
characterise the FFF beams. The normalisation parameters were field-size dependent and were 
determined through measurements on beam profiles of unmatched FFF beams (Fogliata et al., 
2012b). At this stage no proposal for clinically relevant tolerances were made by the author.  
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Further studies into the quality assurance of FFF beams on Varian accelerators have been 
performed by Clivio et al. (2014). These studies compiled data from 3 different TrueBeam 
machines that used the analysis parameters proposed by Fogliata et al. (2012b) to determine 
the stability of FFF beams over a year and determine reference levels for the QA of these FFF 
beams. The measurements were performed with ion chambers, the Starcheck (PTW,Freiberg) 
detector array and the electronic portal image detector (EPID) panel. The findings of the study 
suggest that the proposed slope parameter is susceptible to the positioning of the measurement 
device. The peak position parameter was also susceptible to variation depending on the 
resolution of the measuring device. Based on this study the tolerances for these measurement 
parameters were found to be a change from baseline of 0.04 for the unflatness value, 0.1%/mm 
for the slope and 1mm for the peak position. This investigation has not been performed on 
‘matched’ FFF beams such as those produced by the VersaHD linear accelerator (Elekta AB, 
Sweden). Further work by Fogliata et al. (2016b) confirmed that the normalisation parameters 
defined in the earlier work were consistent across two additional TrueBeam Linacs. The work 
did conclude that the slope parameter previously described was susceptible to large variations, 
on average 6.3% between the different machines. The suggestion was made that the parameter 
be used as part of the assessment of peak position only. 
2.3.2. Elekta Accelerators 
The tuning method employed on Elekta Linacs produces a harder photon spectrum than that 
produced in the Varian FFF operation and so may change a number of the properties that have 
been previously associated with FFF beams. The recommendation of how the beam should be 
tuned was not agreed when much of the published material was produced. This results in 
discrepancies between the ways that the FFF mode has been implemented in the literature. 
The characteristics of operating an Elekta linear accelerator without a flattening filter and 
without any tuning of the beam energy have been published by a number of authors (Dalaryd 
et al., 2010; Cashmore, 2008; Georg et al., 2010; Kragl et al., 2009). Some publications reported 
on FFF beams that had been tuned so that the TPR2010 matched that of the cFF beam (Dalaryd et 
al., 2010; Georg et al., 2010; Kragl et al., 2009). The associated increase in dose-rate with the 
removal of the flattening filter has been reported as 1.76 (Dalaryd et al., 2010) and 2.3 
(Cashmore, 2008) compared to the cFF doserate for a 6MV beam and 2.66 (Dalaryd et al., 2010) 
for a 10MV beam. These results are consistent with the findings on Varian Linacs and are as a 
result of removing a large source of attenuation from the treatment beam. 
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The ability of the linear accelerator to function safely in clinical mode depends on the ionisation 
chambers within the head to have sufficient response to automatically control or ‘servo’ the 
beam effectively. The number of monitor units (MU) recorded by the chambers was accurate 
down to 2MU (Cashmore, 2008) demonstrating that the chambers can respond to the increased 
dose-rate associated with the flattening filter beam without additional modification for 
sensitivity. The response of the ion chamber is consistent with FFF as a result of adding the flat 
filter plate which helps to remove contamination electrons as well as produce sufficient 
secondary electrons to produce a signal in the ion chamber. 
The beam steering on an Elekta linear accelerator is controlled by a feedback mechanism in the 
monitor chambers. This feedback loop ensures that the beam is incident on the flattening filter 
at the correct position to ensure a symmetrical beam profile. The beam steering showed half 
the variation for the same bending current with an FFF beam compared to a cFF beam 
(Cashmore, 2008), producing a more stable beam. This stability would be expected as the 
symmetry of the beam is no longer affected by the position at which the beam is incident on the 
flattening filter. When beam segments are delivered with IMRT, low monitor units delivered per 
segment are avoided to ensure that beam start-up variations do not affect the intended 
treatment. With the flattening filter removed, the beam is much more stable at delivering low 
MUs. A variation in symmetry of 0.3% for FFF beams compared to 1.5% for cFF was observed 
(Cashmore, 2008). The energy of the photon beam in an Elekta linear accelerator is controlled 
by comparing the response of the inner and outer ion chambers in the monitor chamber; this is 
possible due to the variation of energy across the beam profile caused by the flattening filter. 
With the flattening filter removed, the beam energy does not vary in this way (Cashmore, 2008). 
The energy can still be monitored via this method due to the profile shape of the FFF beams, 
with a higher intensity on the central axis compared to the periphery that is dependent on the 
energy of the electrons striking the target.  
As discussed previously, the softer spectrum of the FFF beam results in a decrease of the 
proportion of leakage radiation. When the beam energy is not tuned, the leakage value was 
measured to have reduced by 44-69% (Cashmore, 2008; Kragl et al., 2011) for a 6MV FFF beam. 
No data has been published on the effect of tuning the radiation beam on the leakage radiation.  
The softer spectrum produced by the FFF beam results in a PDD that is closer to a 5MV cFF beam 
from an Elekta linear accelerator when the FFF beam has not been tuned. This is harder than the 
PDD of an FFF beam produced on a Varian linear accelerator where the PDD was more closely 
matched to a 4MV cFF beam.  
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The variation in the beam spectra with off-axis distance has been measured. The variation of 
mean energy across the beam was reduced by 14% (Dalaryd et al., 2010) for the 6MV FFF beam 
and 8% (Dalaryd et al., 2010) for the 10MV FFF beam. This is consistent with the reduction in 
Varian accelerators and is as a result of the flattening filter producing differential beam 
hardening across the profile of the beam. 
The variation of the half value layer (HVL), the thickness of attenuating material that reduces 
the radiation level by a factor of one half of the initial level, with off-axis distance has also been 
studied. The HVL varied by less than 5% (Kragl et al., 2009) for FFF beams and 11% (Kragl et al., 
2009) for cFF beams. The change in profile for the FFF beams gave a reduction of the penumbra 
by 0.5mm (Cashmore, 2008). This reduction is comparable to those reported for Varian Linacs. 
The head scatter from the photon beam is an important parameter for determining the output 
factor used in the dose calculation. The variation of head scatter over a range of field sizes (4cm 
x 4cm to 40cm x 40cm) was 3% (Cashmore, 2008) for an FFF beam compared to 9% for an 
associated cFF beam. The total scatter demonstrated a comparable effect to the head scatter 
with a variation of 8% (Cashmore, 2008) for the FFF beams over a range of field sizes compared 
with the variation of 15% for a cFF beam. This demonstrates that the other component of total 
scatter (phantom scatter) does not increase for FFF beams when compared to cFF beams. 
With the removal of the flattening filter from the beam path there is an increased number of 
low energy photons present in FFF beams, however, the removal of the filter also reduces the 
number of contaminant electrons produced as the beam passes though the filter. Cashmore 
(2016) looked at the surface dose of a matched 6MV FFF beam compared to a 6MV cFF beam 
and an unmatched 10MV FFF beam compared to a 10MV cFF beam on an Elekta Synergy model. 
The 6MV FFF beam showed an increased surface dose of 3.4% for a 3cm x 3cm field but this 
value decreased to a reduced surface dose of 7.1% for a 40cm x 40cm field. The crossover point 
for this relationship was at a field size of 10cm x 10cm. The unmatched 10MV FFF beam shows 
an increase of 10% for smallest field sizes that decreases to a reduced surface dose of 5% at 
40cm x 40cm. The crossover point for the unmatched 10MV FFF beam is at a field size of 25cm 
x 25cm. With the use of wedges both FFF beams showed a decrease in surface dose when 
compared to the associated cFF beams. With changing SSD the 6MV FFF beam showed similar 
surface doses to the 6MV cFF beam but for the 10MV unmatched FFF beam the cFF beam 
showed a large reduction in surface dose when compared to the FFF beam at SSDs over 60cm. 
Normalisation parameters for VersaHD FFF profiles were evaluated by Fogliata et al. (2016b). 
These normalisation parameters are the same as proposed in their earlier work with Varian 
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machines (Fogliata et al., 2012b) as discussed in the previous section (section 2.3.1). The work 
does not propose any clinical tolerances for these parameters. 
2.3.3. MV portal imaging with FFF 
Tyner et al. (2009) performed a study to investigate the effect of the removal of the flattening 
filter on an a-Si EPID. The linear accelerator used in the investigation was an Elekta Precise model 
with an MLCi beam shaping device and an Elekta iViewGT a-Si EPID. The FFF beam was not tuned 
to the 6MV cFF beam, resulting in a softer spectrum than the 6MV beam, whereas the current 
Elekta guidelines for FFF operation is that the beam should be matched so that the percentage 
depth dose at 10cm deep in water matches that of the cFF 6MV beam.  
An additional 3mm of copper build-up was added to the EPID panel, this additional build-up 
material ensures that the response of the EPID varies by less than 2.5% for an air gap range of 
30-60cm from the exit surface of the patient to the detector. The variation of EPID response 
with field size reduced with the flattening filter removed. The variation of response from the 
detector with increasing dose increased with the linear accelerator operating in FFF mode, 
resulting in an improvement in the detection of small dose deviations, possibly improving portal 
dosimetry for FFF beams.  
The response of the EPID with increasing phantom thickness varies by 14% over 30cm with the 
FFF beam compared to 7% with the cFF beam. This increase in variation is due to the softer 
photon spectrum in the FFF beam and would result in better contrast of MV images. The 
variation of response with off-axis distance was consistent when operating in FFF mode. This 
consistency could result in the possibility of patient specific verification of IMRT treatments 
being easier to implement by simplifying the calibrations required. As the results recorded in 
this study used an additional 3mm of Cu build-up added to the EPID the device would be 
considered a modified medical device. With the release of the VersaHD by Elekta a new design 
of EPID panel was introduced that is suitable for FFF beams, this new panel has a faster readout 
time of 80 lines per pulse compared to the previous 12 lines per pulse so that the panel no longer 
saturates at high doserates. 
Work on an EPID device of a Varian TrueBeam was performed by Nicolini et al. (2013). The study 
found that in order for the panel response not to saturate for the dose-rates of both unmatched 
6 & 10MV FFF beams the panel needed to be deployed at a distance of 150cm SSD. Appropriate 
gain correction was also required in order for the profile shape measured on the EPID to match 
profiles measured with an ion chamber. The study looked at using the panel for pre-treatment 
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QA of VMAT and found that plans passed with over 95% of points passing a gamma index of 2% 
and 2mm. Gamma analysis is a metric used in radiotherapy to compare one dose distribution to 
another. Each reference point is compared to points on the distribution to be evaluated and a 
metric calculated based on the dose deviation and distance to agreement. This metric is 
explained further in the publication by Low et al. (1998). 
2.4. Treatment planning studies on FFF Linacs 
A possible benefit of FFF beams is the increased dose rate available through the removal of the 
flattening filter resulting in a reduction of treatment times for patients, reducing the risk of intra-
fraction movement errors and improving patient throughput. The increase in dose-rate may not, 
however, result in faster delivery times for IMRT treatments as the degree of beam modulation 
required may increase such that the delivery time could instead be extended.  
The softer spectrum of unmatched FFF beams has been proposed as a method of improving 
coverage at the periphery of lung tumours. Vassiliev et al. (2018) performed a study on the 
impact of unmatched FFF beams produced by a Varian linear accelerator on the coverage at the 
periphery of lung tumours. The study used a Monte Carlo model produced in EGS/BEAMnrc to 
calculate the dose to a phantom containing lung and tumour. The model used the phase space 
file provided by Varian for the TrueBeam 6MV FFF beam above the jaws and modelled the 
remainder of the linear accelerator as a Varian 2100C with millennium MLC. The calculation grid 
was set to 1mm voxels for plans with a Gross Tumour Volume (GTV) of diameter 5cm and 3cm 
and voxels of 0.5mm for plans with a GTV of 1cm. Each plan consisted of 7 coplanar beams 
normalised to give 50Gy to the PTV. The Monte Carlo doses were also compared to doses 
calculated with the Analytic Anisotropic Algorithm (AAA) (Sievinen et al., 2005) and Acuros XB 
(AXB) (Bush et al., 2011) dose algorithms used in the commercially available TPS.  
The Monte Carlo calculation showed that for each GTV size the use of 6MV FFF compared to 
6MV cFF improved the surface coverage of the GTV by up to 4% of the prescription dose. This 
improved coverage is likely a result of the softer spectrum of the FFF beam resulting in a more 
rapid build-up of dose moving from the lung to GTV boundary. Comparing the Monte Carlo to 
the commercial algorithms showed that they underestimated this difference by up to a factor 
of 2. 
2.4.1. Treatment planning system benchmarking 
In order for treatment planning studies to be considered reliable, the algorithm used for the 
study should be evaluated to ensure that the doses calculated are correct. Cashmore et al. (2012) 
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looked at the ability of a modified virtual source model and XVMC in the Monaco TPS to calculate 
the dose of an FFF beam produced by an Elekta Synergy linear accelerator. The work showed 
that the profiles calculated matched the measured data in water to within 1% and that 
measurements of the calculated IMRT plans passed with a 2%/2mm gamma criteria using a 
Delta4 detector.  
Lang et al. (2012c) found that for the TrueBeam linear accelerator the dose calculated on the 
Eclipse TPS version 8.9 passed verifications with a result of 99% of points passing a gamma 
analysis tolerance of 3% and 3mm. These measurements were performed with a range of 
radiation devices including Delta4, Gafchromic film, Arccheck, matrix and point dose 
measurements with ion chambers. These results are comparable to the results described by 
Nicolini et al. (2013) when performing verification measurements with the EPID system. 
These studies demonstrate that the commercially available treatment planning systems can 
calculate the dose deposited from FFF beams to sufficient accuracy for clinical use. 
2.4.2. Head and Neck planning studies 
Standard fractionation regimes of approximately 2Gy per fraction are not generally considered 
to benefit from the increased dose-rate of FFF beams as much as hypofractionated regimes with 
large doses per fraction. Head and Neck (H&N) treatments are often in close proximity to 
multiple OARs and require high degrees of modulation to produce a treatment plan. The gantry 
rotation speed and the speed of leaf travel in MLCs is thought to prevent the linear accelerator 
from utilising the high dose-rates of FFF beams. 
Fu et al. (2004) performed a study to determine the change in plan delivery time for IMRT 
treatments of the nasopharynx with the removal of the flattening filter. This is the earliest study 
into FFF treatments for H&N and uses a prototype system.  The treatment delivery time is 
determined by the beam on time, the leaf travel time and the verification and recording time. 
The study modelled a BJ-6B linear accelerator (Beijing Medical Equipment Institute) with the 
MLC devices of a number of different vendors including Varian, Elekta and Siemens. For the 
Elekta machine there is no information as to whether the beam had been tuned. This is unlikely 
as the paper was published prior to the manufacturer’s recommendation of beam tuning 
(ELEKTA, 2010).  
Plans were produced for 10 nasopharynx cases and 10 prostate cases. The treatment volume for 
the nasopharynx cases had a median size of 132cm2. This volume is significantly smaller than the 
median volume treated in St. James’s University Hospital, Leeds. The relatively small size may 
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result in plans with less modulation and therefore fewer segments reducing the leaf travel time 
and leaf position verification time for the treatment, compared to plans with larger volumes. 
The plans produced have all been normalised so that 95% of the PTV receives the 70Gy 
prescription dose, however, there appears to be no attempt to remove hotspots. This could be 
due to the clinical protocol in use at the centre. The plan with the smallest hotspots still has over 
30% of the PTV receiving a dose of over 110%. This would not be acceptable in the clinical 
protocol used in St. James’s University Hospital, Leeds. The lack of modulation to remove 
hotspots could result in the delivery times not being representative of clinical practices 
elsewhere. However, the study found that the average beam-on time was reduced by 43% with 
the flattening filter removed, despite the number of segments in the plans increasing by 1-2%. 
The overall treatment time was not reduced by a significant amount (0.7-1.4mins for a 10-20min 
slot) (Fu et al., 2004). 
A further pre-clinical study on FFF for H&N treatments has been performed by Lechner et al. 
(2013). This treatment planning study compared IMRT and VMAT plans delivered with both cFF 
and FFF 10MV beams. The 10MV beams used were TPR matched as described in previous studies 
(Kragl et al., 2009). The machines used for this study were Elekta Synergy Linacs equipped with 
MLCi treatment heads. The plans were produced in Monaco v3.2 and were produced for 6 head 
and neck cases. The plan quality was comparable for both cFF and FFF beams. The study found 
that higher MU (up to 34%) and more segments were required to compensate for the non-
uniform fluence of the FFF beams. 
Since the commercial release of a linear accelerator for the delivery of FFF beams further 
investigations have been performed into the feasibility of FFF treatments for H&N treatments 
(Zhuang et al., 2013; Nicolini et al., 2012; Yan et al., 2016; Lechner et al., 2013; Gasic et al., 2014; 
Jia et al., 2018). These studies have all been performed with unmatched FFF beams of the 
TrueBeam linear accelerator and the Eclipse TPS (Varian Medical Systems, Palo Alto, CA). The 
Eclipse TPS has been verified to calculate FFF beams sufficiently accurately for clinical use 
(Nicolini et al., 2013). The version of the Eclipse TPS has not been consistent with versions 8.6 
(Nicolini et al., 2012), 10 (Yan et al., 2016; Jia et al., 2018) and 11 (Gasic et al., 2014) being used. 
The grid size used for these studies were 2mm (Zhuang et al., 2013; Gasic et al., 2014; Jia et al., 
2018) and 2.5mm (Yan et al., 2016; Nicolini et al., 2012). For each of these studies the plans were 
optimised and then normalised. The normalisation was so that 95% of the PTV was covered with 
95% of the prescription dose (Zhuang et al., 2013; Nicolini et al., 2012; Yan et al., 2016) and Jia 
et al. (2018) normalising such that 95% of the PTV received 100% of the prescription dose as 
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with Fu et al. (2004). No information is provided as to how the plans produced by Gasic et al. 
(2014) were normalised. This normalisation method is not what is performed at St. James’s 
University Hospital, Leeds as it changes the doses to the OARs and affects the size of hotspots 
after the optimisation has been completed. 
The findings of these studies demonstrates the variation in treatment volumes and treatment 
planning among different institutes with different conclusions on the plan quality when 
comparing cFF to FFF plans. PTV coverage was found to be equivalent in two of the five studies 
(Nicolini et al., 2012; Yan et al., 2016), the PTV coverage was found to be less homogenous in 
three of the studies (Zhuang et al., 2013; Gasic et al., 2014; Jia et al., 2018) and two studies 
(Zhuang et al., 2013; Jia et al., 2018) also found the maximum dose to the PTV to be higher and 
the coverage less conformal for FFF beams. The study by Jia et al. (2018) also allowed up to 1% 
of the PTV to receive a dose of 110% of the prescription dose that would not be clinically 
acceptable at St James’s University Hospital, Leeds. In terms of OAR dose, two of the studies 
found FFF beams improved the OAR sparing (Nicolini et al., 2012; Yan et al., 2016) by up to 9% 
(Yan et al., 2016). One study found that doses to some of the OARs increased with FFF plans 
(Zhuang et al., 2013). Jia et al. (2018) reported that no significant difference was found. 
The delivery efficiency of the FFF plans was commented on by each author with all authors 
stating that an increased number of MU was required for the FFF deliveries, 20% higher (Nicolini 
et al., 2012), 11% (Jia et al., 2018) and 30% higher (Zhuang et al., 2013). This increase in MU 
would be expected. Delivering away from the central axis, the dose per MU drops, requiring 
more MU to deliver the same dose when compared to cFF beams. Despite this increase in MU, 
the treatment delivery time was found to be comparable (Zhuang et al., 2013; Gasic et al., 2014; 
Jia et al., 2018) with the plans optimised by Nicolini et al. (2012) such that the same gantry speed 
was used for both cFF and FFF deliveries. 
A study on an Elekta linear accelerator was performed by Dobler et al. (2017) using matched 
6MV FFF beams. The study was performed on an Elekta Synergy linear accelerator with Agility 
MLC and the treatment plans were produced using Oncentra External Beam version 4.5 (Elekta 
AB, Sweden). The doserate of the 6MV FFF beam was 1700MU/min, which is higher than the 
manufacturer’s recommended doserate of 1400MU/min ± 10%. Plans were produced for both 
IMRT and VMAT with both cFF and FFF beams. However, the plans were optimised with the cFF 
beams and the same parameters used for the FFF beam. This could result in the FFF plans not 
being fully optimised.  
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The study found that all plans produced were clinically acceptable with comparable PTV 
coverage and OAR doses. The exception was that the dose to the brainstem was 7% higher for 
FFF deliveries but still acceptable. Had the plans been fully optimised for the FFF beam this could 
potentially have been further reduced. The delivery times were comparable for both cFF and 
FFF beams demonstrating that gantry rotation and MLC travel speeds are the limiting factors 
rather than doserate. The study did find that peripheral doses were 18% lower with the FFF 
beam, which is consistent with the reduced head leakage demonstrated by FFF beams. 
2.4.3. Prostate planning studies 
Prostate treatment volumes are smaller than H&N volumes and have fewer organs at risk. For 
these reasons the prostate may be a more appropriate site for FFF treatments and a number of 
studies have been performed to investigate this (Vassiliev et al., 2007; Stathakis et al., 2009; 
Lechner et al., 2013; Gasic et al., 2014; Yan et al., 2016). With the exception of one pre-clinical 
study (Lechner et al., 2013) and one clinical study by Treutwein et al. (2017) these studies used 
unmatched FFF beams and two of the studies were performed on pre-clinical prototype 
machines (Vassiliev et al., 2007; Stathakis et al., 2009). The studies on the matched FFF beams 
used a 10MV FFF beam matched to a TPR20/10 value rather than the final clinical 
implementation of the beam being matched to the dose at 10cm deep in water (Lechner et al., 
2013) and a 6MV FFF matched beam (Treutwein et al., 2017). The Lechner et al. (2013) study 
was performed on a prototype Elekta Synergy linear accelerator with an MLCi treatment head 
as opposed to the clinical implementation of a VersaHD linear accelerator with an Agility 
treatment head. Each of the plans was performed using the Monaco TPS version 3.2. The study 
by Treutwein et al. (2017) was performed on an Elekta Synergy machine with Agility head and 
planned using Oncentra External Beam version 4.5. Both studies concluded that the plan quality 
was comparable to cFF plans but required 34% (Lechner et al., 2013) and 10% (Treutwein et al., 
2017) more MU to deliver, the difference in additional MU could be a result of the differing 
energies used in each study. The study by Treutwein et al. (2017) also concluded that treatment 
delivery was 8% faster with the FFF beam when compared to the cFF beam and peripheral doses 
were reduced.  
Each of the studies on unmatched FFF beams used the Eclipse TPS, the studies performed after 
the clinical release of FFF used versions 10 (Yan et al., 2016) and 11 (Gasic et al., 2014) to model 
the unmatched 6 and 10MV FFF beams from a TrueBeam. The pre-clinical studies also 
investigated an unmatched 18MV FFF beam (Vassiliev et al., 2007; Stathakis et al., 2009). The 
pre-clinical study by Vassiliev et al. (2007) found that the number of MUs delivered with FFF 
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beam was half that of the cFF beam for 6MV and was reduced by a factor of 2.6 for the 18MV 
FFF beam. The reduction in MUs would reduce the amount of leakage radiation and dose outside 
the treatment field. The author suggests that the reduction in MU could result in reduced 
treatment delivery times, however no information on the number of segments per field was 
provided. The author states that the FFF treatments had a better conformity index than the cFF 
6MV plans, whereas the 18MV plans had a worse conformity index. The doses to critical organs 
such as the rectum and femoral heads were reduced for the 6MV FFF treatment and comparable 
for the remaining organs. The doses to the organs at risk increased with the 18MV FFF beam. 
The author indicates that this may not be representative of the plan quality achievable as the 
optimisation was not altered for the FFF beams and the same parameters were used for both 
cFF and FFF beams.  
The study performed by Stathakis et al. (2009) concluded that there was no change in plan 
quality through the use of an FFF photon beam but that benefits may be from a reduced number 
of MUs in the treatment delivery reducing the delivery time and peripheral dose through head 
leakage. The reduced MU in each of these clinical studies is due to the calibration of the machine 
such that 1MU delivered more than 1cGy to the dose specification point in contrast to the 
calibration of the cFF beam. 
The two studies on the clinical implementation of unmatched FFF beams found that the PTV 
coverage of the FFF plans was equivalent to the cFF plans. One of the studies found that the FFF 
plans had improved OAR sparing with the exception of the maximum dose to the rectum (Yan 
et al., 2016) whilst the other study found that the OAR doses were dosimetrically equivalent 
(Gasic et al., 2014). In contrast to the pre-clinical studies Yan et al. (2016) found that an increase 
of MU of 30% was required for the FFF plans when compared to the cFF plans (Yan et al., 2016), 
this increase is comparable to the 34% increase (Lechner et al., 2013) found in the pre-clinical 
evaluation of FFF plans for TPR matched FFF beams. The treatment delivery times were found 
to be equivalent in one study (Yan et al., 2016) and 4.9% faster in another (Gasic et al., 2014) 
highlighting that the method in which the plans are produced can result in differing optimisation 
outcomes.  
2.4.4. Stereotactic Ablative Radiotherapy planning studies 
The increased dose-rate available through the use of FFF beams has resulted in many studies 
being performed on hypofractionated treatments such as stereotactic ablative radiotherapy 
(SABR). These treatments require large numbers of MU in order to deliver the high doses per 
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fraction. This can lead to long treatment times increasing patient discomfort and have the 
potential to increase the amount of intrafraction motion.  
The only treatment study on a matched FFF beam was performed by Kragl et al. (2011) where 
the peripheral doses were assessed for both 3DCRT SABR treatments to the lung. This study 
found a reduction in peripheral doses for the FFF plans when compared to the cFF plans. The 
study was performed on a prototype Synergy linear accelerator with an MLCi2 treatment head, 
rather than the clinically released VersaHD. The beams were energy matched to the TPR value 
rather than the dose at 10cm deep in water. No comparison of the plan quality between the 
modes of delivery was performed as part of this study. 
As with previous sites the majority of the literature focuses on unmatched FFF beams produced 
by the TrueBeam linear accelerator. The energies used were 6MV FFF (Gasic et al., 2014; Lang 
et al., 2013; Tambe et al., 2016; Hrbacek et al., 2014; Lu et al., 2015) and 10MV FFF (Gasic et al., 
2014; Prendergast et al., 2012; Tambe et al., 2016; Lang et al., 2013; Hrbacek et al., 2014; Lu et 
al., 2015; Navarria et al., 2013; Scorsetti et al., 2011; Reggiori et al., 2012a). The planning system 
used for these studies was Eclipse versions 8.9 (Hrbacek et al., 2014), 10 (Lu et al., 2015) and 11 
(Gasic et al., 2014; Tambe et al., 2016). The sites investigated were lung (Gasic et al., 2014; 
Prendergast et al., 2012; Lang et al., 2013; Tambe et al., 2016; Hrbacek et al., 2014; Lu et al., 
2015; Navarria et al., 2013; Scorsetti et al., 2011; Tyler and Dowdell, 2018), abdomen (Lang et 
al., 2013), brain (Fiorentino et al., 2017) and liver (Reggiori et al., 2012a; Ogata et al., 2017).  
The majority of these studies that compared the FFF beams to cFF found that plans with both 
beams were clinically acceptable and equivalent with one study noting that, although PTV 
coverage and OAR sparing was equivalent (Gasic et al., 2014; Prendergast et al., 2012; Tambe et 
al., 2016; Lang et al., 2013), the 6MV FFF plans were more conformal than the 6MV cFF and 
10MV FFF plans (Hrbacek et al., 2014). Lu et al. (2015) compared the two beam types in terms 
of Tumour control probability (TCP) and normal tissue complication probability (NTCP) using an 
in-house code written in MATLAB 7.0 (Mathworks, Natick, MA). This study found that the TCP 
of the 6MV FFF and 10MV FFF plans were comparable but that the NTCP of the lungs and chest 
wall were lower for the 6MV FFF plans compared to the 10MV FFF plans. The comparison 
performed by Prendergast et al. (2012) compared IMRT cFF plans to VMAT FFF plans, making it 
difficult to determine if the results are impacted by the change in delivery technique as well as 
the beam type. Gasic et al. (2014) commented that each plan was only optimised once and 
therefore more optimal plans may have been possible.  
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The delivery efficiency of FFF beams compared to cFF for these plans demonstrated that FFF 
beams had reduced treatment delivery times when compared to cFF beams. This reduction in 
beam-on time was reported as 52% (Hrbacek et al., 2014), and 55% (Tambe et al., 2016) faster 
for 6MV FFF compared to 6MV cFF. In the case of 10MV FFF this reduction in beam-on time 
improves to 59% (Hrbacek et al., 2014) and 61% (Tambe et al., 2016). Lang et al. (2013) 
concluded that for treatments over 1000MU or 4Gy per fraction, 6MV FFF had an delivery 
efficiency improvement over 6MV cFF and for treatments over 2000MU or 10Gy, 10MV FFF had 
a delivery efficiency improvement over 6MV FFF.  
An improvement in efficiency of 10MV FFF compared to 6MV FFF with increasing dose was also 
found by Lu et al. (2015) with 10MV FFF deliveries being 32-44% faster than 6MV FFF with 
fraction sizes increasing from 12Gy to 34Gy. Prendergast et al. (2012) concluded that 10MV FFF 
deliveries were faster than cFF deliveries; however this study was comparing FFF VMAT 
treatments to cFF IMRT treatments and included intrafraction imaging. The amount of 
intrafraction imaging varied and 84% of cFF plans received intrafraction imaging whereas only 
24% of FFF treatment received intrafraction imaging. Hrbacek et al. (2014) found this reduction 
in treatment time was achieved despite an increase in MU of 25% for 6MV FFF plans and 21% 
for 10MV FFF plans when compared to cFF plans. Lu et al. (2015) also found that 10MV FFF plans 
required 5-6% less MU than an associated 6MV FFF plan. 
Retrospective studies into the clinical outcomes of unmatched FFF lung SABR treatments were 
performed by Navarria et al. (2013) and Scorsetti et al. (2011) with Fiorentino et al. (2017) 
analysing the impact of FFF beams on brain metastases. Two of these studies found that the FFF 
plans had an earlier radiological response when compared to cFF plans (Navarria et al., 2013; 
Scorsetti et al., 2011). These studies were comparing earlier studies of 3DCRT to VMAT it is 
unclear if this earlier response is as a result of the FFF beams or the treatment technique 
employed.  
Nakano et al. (2018) investigated the effects of FFF beams on non-small cell lung cancer cells. 
The study used an ARTISTE-TM linear accelerator (Siemens, Erlangen, Germany) to deliver 6MV 
cFF and 7MV FFF beams. The doses to the in-vitro cells were calculated with the Xio treatment 
planning system. The study found that the increased doserate of the FFF beams had no effect 
on cell survival. These findings suggest that the earlier response reported previously by Navarria 
et al. (2013) and Scorsetti et al. (2011) was as a result of the change in treatment technique 
rather than the change to FFF beams.  
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The study by Fiorentino et al. (2017) did not compare to cFF beams and looked at the clinical 
outcomes of 45 patients who received radiotherapy with FFF beams. The study found that the 
acute and late toxicities were acceptable and that FFF deliveries were feasible and safe for 
treatment of these brain metastases. The mean follow up time of this study was 12 months and 
therefore longer follow up is required to determine efficacy of treatment. However, this would 
not provide insight into whether FFF beams were beneficial when compared to cFF beams 
without a clinical trial. 
A study into the robustness of treating lung SABR with FFF was investigated by Tyler and Dowdell 
(2018). This study compared 3DCRT and VMAT with 10MV FFF beams with the isocentre 
placement at either the centre of the PTV or on the patient midline. The plans were then copied 
and recalculated 1-2mm offset to determine if isocentre placement or beam modality had an 
impact on the robustness of the treatment plan. The study found that with 3DCRT the delivery 
efficiency was improved with the isocentre placed at the centre of the PTV. This is due to the 
increased fluence of the FFF beam on the central axis relative to off-axis. This same improvement 
in delivery efficiency was not seen when delivering VMAT treatments. The impact of isocentre 
shifts on plan robustness was comparable for both 3DCRT and VMAT deliveries with both 
midline isocentres and isocentres within the PTV. This is likely a result of the profile shape of 
small fields delivered with FFF beams being comparable to those of cFF beams. 
Breath-hold treatments provide the potential to reduce the volume of PTVs and therefore 
normal lung irradiation in lung SABR treatments. This technique increases treatment times when 
delivering with cFF beams to approximately 30mins when using IMRT. Boda-Heggemann et al. 
(2013) performed a study where 10MV FFF beams were used for the same technique. This 
reduced the delivery time for the beam to 8minutes and the treatment time to 15mins. This is a 
significant reduction in treatment time when compared to cFF IMRT. The use of 10MV FFF beams 
has the added advantage of increased dose-rate over 6MV FFF beams (2200MU/min compared 
to 1400MU/min). However, with 10MV FFF the build-up to maximum dose within the GTV would 
be deeper when compared to 6MV FFF potentially reducing coverage/efficacy. 
The feasibility of planning FFF SABR to the liver was investigated by Reggiori et al. (2012b). The 
study looked at VMAT SABR delivering 75Gy in 3fractions using an unmatched 10MV FFF beam 
from a Varian TrueBeam. There was no statistically significant difference between the cFF and 
FFF plans in terms of plan quality.  As with other FFF planning studies, the authors noted that an 
increased number of MU were required for the FFF plans. In this study the average increase in 
MU for FFF compared to cFF was 9%. Despite this increase of MU the beam-on time reduced 
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from 8.2minutes±1minute to 2.2minutes±0.2minutes (73%) for the FFF plans, this reduction is 
greater than the reduction of approximately 60% seen when treating lung SABR with 10MV FFF.  
Another study looking at the optimal leaf margin around the PTV for liver SABR was performed 
by Ogata et al. (2017). This study also used 10MV cFF and FFF beams delivered with a TrueBeam 
and calculated with the Eclipse TPS version 11.0.31. The study used 7 to 9 coplanar 3DCRTbeams 
with leaf margins ranging from -3mm to +5mm and found that for a given leaf margin the dose 
distributions were comparable for both modes of delivery and OAR sparing was equivalent. The 
exception was that the FFF plans were less homogenous than the cFF plans but this is clinically 
acceptable for SABR deliveries. The author concluded that to deliver optimum plans a leaf 
margin of 0 or -1mm should be used. The authors did not report on the delivery times for this 
treatment and do not state why 3DCRT was used rather than VMAT when VMAT has been 
demonstrated to be superior for other SABR sites. 
2.4.5. Treatment planning studies on other sites 
Spruijt et al. (2013a) performed an investigation to determine if FFF beams could be used for 
the treatment of breast radiotherapy. The plans were produced to deliver 50Gy in 25 fractions 
to the whole breast PTV with an integrated boost region to receive 68.75Gy in 25 fractions. Plans 
were produced with the Eclipse TPS and version 8.9.08 for unmatched 10MV FFF and 10MV cFF 
beams delivered by a Varian TrueBeam linear accelerator. The study found that equivalent plan 
quality was delivered with both FFF and cFF beams. The out of field dose was found to be on 
average 10% lower for FFF beams. The treatment times were reduced by 31% for FFF beams 
compared to cFF but required twice the MU.  
Kumar et al. (2017) investigated the effect of unmatched FFF beams at both 6MV and 10MV 
compared to cFF beams for cervix patients. The plans were delivered with a TrueBeam linear 
accelerator and planning using Eclipse version 10. Plans were normalised such that 95% of the 
PTV received 100% of the prescription dose. This differs from the protocols here that require 95% 
of the PTV to receive 95% of the prescription dose. This difference could result in plans with 
higher OAR doses and higher maximum doses within the PTV. The study found that all plans 
produced were clinically acceptable, but found the FFF plans inferior in terms of homogeneity, 
conformality and bladder and rectal OAR doses. The FFF plans were also found to require more 
MU, 20.5% for 6MV FFF and 43.7% for 10MV FFF, when compared to associated cFF plans. This 
increase in MU would be expected as more MU is required to deliver the same dose away from 
the central axis. With cervix plans typically treating large volumes this increase would be more 
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than for sites with smaller PTVs. The increased proportion with 10MV FFF is also expected as the 
profile is more peaked than the 6MV FFF profile increasing this off axis difference. 
2.4.6. Summary of treatment planning study findings 
Studies into the validation of the dose calculation algorithms through verification measurements 
have demonstrated that both unmatched and matched implementation of FFF beams can be 
modelled with sufficient accuracy for clinical use on the Eclipse and Monaco TPS. The majority 
of publications are studies relating to unmatched FFF beams with few studies into matched FFF 
beams. The studies of matched FFF beams have been matched to the TPR20/10 value of the 
associated cFF beams; this is not consistent with the final implementation of matched FFF beams 
that are matched to the percentage depth dose value at 10cm deep in water for a 10cm x 10cm 
field with an SSD of 100cm. 
The conclusions with respect to the plan quality of FFF beams when compared to cFF beams are 
not consistent; this is the case for studies of the same sites with the same implementation of 
FFF beams and the same planning system. However, FFF beams have consistently demonstrated 
a requirement for more MU in order to deliver a plan compared to the associated cFF beam, this 
increase ranges from 9% to 34%. The increase is independent of whether the FFF beams are 
matched or unmatched and is a result of the reduction in dose delivered per MU as the distance 
from the central axis increases. This decreasing dose per MU is a result of the peaked profile 
shape of FFF beams. Despite this increase in MU it is noted that the treatment beam-on times 
are equivalent or shorter for FFF beams. With increasing MU the delivery times decrease such 
that for all hypofractionated treatments there is a reduction of beam on time of up to 70%. 
2.5. Guidelines for FFF beams 
The implementation of FFF beams by early adopters of the technology has preceded much of 
the now available guidance and recommendations. The American Association of Physicists in 
Medicine (AAPM) published their review of the current status of FFF beams in 2015 (Xiao et al., 
2015). The UK Institution of Physics and Engineering in Medicine (IPEM) published their 
guidelines in 2016 (Budgell et al., 2016). Dosimetry protocols for determining the absorbed 
doses in radiotherapy have been set up for the use of cFF beams. The validity of these protocols 
for application to FFF beams has been reviewed by a number of authors (Budgell et al., 2016; de 
Prez et al., 2018; Lye et al., 2016). Lye et al. (2016) performed a Monte Carlo study and found 
differences of 0.2%. De Prez et al. (2018) performed measurements on an Elekta VersaHD linear 
accelerator and found the differences between the correction factors for cFF and FFF beams for 
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TPR20/10 based protocols to be less than 0.19% and for D10cm based protocols less than 0.42%. 
The results of both of these studies shows a similar magnitude to the kfff correction factor 
proposed in Budgell et al. (2016) of 0.997 for the absorbed dose from FFF beams. 
2.6. Summary of findings 
This review of the literature has highlighted areas for investigation with respect to FFF beams, 
where necessary information required to underpin and optimise characterisation, quality 
assurance and clinical use of FFF beams is missing. The implementations that have been adopted 
by the two main manufacturers’ means FFF beams are either unmatched or matched in beam 
quality to their equivalent cFF beam, such that an FFF beam of a given nominal (stated) energy 
has different properties depending on the machine it is delivered on. The potential advantages 
of FFF beams are highlighted in Table 1. Research work to characterise these differences is 
required and will form the basis of chapter 3 of this thesis. 
The literature has highlighted that certain parameters used to characterise cFF radiotherapy 
beams are not suitable for FFF beams. Some work has been performed to determine new 
parameters for the characterisation of FFF beams. A study to determine parameters that can be 
used for both FFF and cFF beams is required and will form the basis of chapter 4 in this thesis. 
A number of Monte Carlo studies have been performed on FFF beams, some of these studies 
have been performed on prototype machines that do not match the final implementation of FFF 
beams by the respective manufacturers. More recent studies on FFF machines have almost all 
been with respect to the Varian TrueBeam linear accelerator and have used a ‘golden’ phase 
space file provided by the manufacturer rather than being a full Monte Carlo simulation. There 
is a lack of studies in the literature of the matched FFF implementation by Elekta on the VersaHD 
linear accelerator and a Monte Carlo model of this implementation will be included in this work 
(chapter 5). 
Since the clinical release of FFF, many studies have been performed on the use of FFF beams for 
clinical treatment. The majority of these studies correspond to the unmatched (Varian) 
implementation of FFF beams and systematic studies into the matched (Elekta) implementation 
are required. A range of relevant planning studies is presented in chapter 6. 
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Table 1: Potential advantages and disadvantages of FFF beams 
Advantages of FFF beams Disadvantages of FFF beams 
Increased doserates from 600MU/min to 
1400MU/min for 6MV FFF and 
2400MU/min for 10MV FFF have the 
potential to reduce treatment times, 
especially for hypo fractionated 
treatments. 
Treatment planning systems have been 
developed for use with cFF beams, do 
current assumptions still apply to 
modelling FFF beams? 
Reduced spectral changes away from 
the central axis have the potential to 
improve modelling of FFF beams. 
FFF profiles are non-uniform, does this 
require additional modulation and 
therefore increase treatment delivery 
times and reduce calculation accuracy? 
With the removal of the flattening filter 
the beams are potentially more stable to 
symmetry changes. 
Not all current QA metrics can be applied 
to FFF beams, can beams be quality 
assured without normalising to cFF 
beams or comparing to ‘golden’ 
datasets? 
The removal of the flattening filter 
reduces the head leakage and head 
scatter with the potential to reduce 
peripheral doses and reduce incidences 
of secondary cancer induction. 
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3. Characteristics of FFF beams 
3.1. Introduction 
With the increase in Intensity Modulated Radiotherapy (IMRT) treatments in radiotherapy there 
has been an improvement in treatment plan quality but often with an increase in treatment 
delivery time (Palma et al., 2008). This is due to the segmented treatment deliveries requiring 
more Monitor Units relative to conventional conformal planning techniques. The use of IMRT is 
not dependant on a flat beam profile, as the beam fluence can be modulated to the required 
distribution by the MLCs. The use of FFF beams is becoming more wide-spread as the increased 
dose-rate available through the removal of the flattening filter has been shown to reduce 
treatment delivery times whilst maintaining plan quality (Spruijt et al., 2013b; Mancosu et al., 
2012; Reggiori et al., 2012a; Scorsetti et al., 2011; Vassiliev et al., 2007). 
There have been a range of studies in the literature into the beam characteristics of FFF photon 
beams with comparison to cFF beams (Cashmore, 2008; Dalaryd et al., 2010; Georg et al., 2010; 
Kragl et al., 2009; Ponisch et al., 2006; Hrbacek et al., 2010; Kry et al., 2009; Kry et al., 2007b; 
Vassiliev et al., 2006b; Stathakis et al., 2009). At the time of this work, this was the first study of 
the beam characteristics of the final High Dose-Rate Mode (HDRM) configuration implemented 
by Elekta (Elekta AB, Stockholm, Sweden), where the FFF beams have been matched to the cFF 
beam by increasing the beam energy. The configuration includes a new filter plate design and is 
implemented on a Linac with an Agility MLC head. To ’match’ the beam energies between FFF 
and cFF beams, requires tuning the accelerator parameters so that the percentage depth dose 
(PDD) matches the cFF beam at a depth of 10cm for a 10cm x 10cm field. For both cFF and  
matched FFF 6 MV beams, this PDD value is matched to within 1% of 67.5% at 10cm deep in 
water at an SSD of 100cm. Existing literature on FFF characteristics largely relates to the Varian 
TrueBeam accelerators that implement FFF beams in an ‘unmatched’ mode, whereby FFF beams 
are produced by removing the flattening filter without any subsequent change in beam energy 
or PDD matching (Ponisch et al., 2006; Hrbacek et al., 2010; Kry et al., 2009; Kry et al., 2007b; 
Vassiliev et al., 2006b; Stathakis et al., 2009). There is some work by Kragl et al. (2009) that has 
considered FFF beams on Elekta machines matching the TPR20/10 value to the associated cFF 
beam. The work presented here compares matched (energy tuned) FFF beams (Elekta 
implementation) to cFF beams and unmatched FFF beams (FFF beams produced by removing 
the flattening filter but without any further changes to the accelerating parameters, equivalent 
to the Varian implementation). The comparison with the unmatched FFF beam seeks to examine 
the differences between the two implementations of FFF beams.  
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3.2. Method 
3.2.1. Implementation 
All work was carried out as part of a pilot implementation project. An Elekta Synergy linear 
accelerator with Agility MLC was modified to enable FFF deliveries. This involved: an update to 
the Synergy control system to Integrity v3.1; installation of a new dose control card to allow 
dose rates of up to 2200MU per min; and replacement of the conical flattening filter with a flat 
disk made of 2mm thick stainless steel. The disk is designed to remove electron contamination 
and produce sufficient secondary electrons for the monitor chamber to function consistently. 
For an ‘unmatched’ FFF beam, no additional tuning or modification of the beam properties were 
made in that the same power conditions for the magnetron and waveguide were used as for the 
cFF beam and the current through the slalom bending magnet system was also left unchanged. 
This would be consistent with the methodology to produce an FFF beam reported by others 
(Georg et al., 2011; Hrbacek et al., 2010; Georg et al., 2010; Kragl et al., 2009; Cashmore, 2008; 
Vassiliev et al., 2006b; Ponisch et al., 2006) and the same as the final implementation of FFF 
beams on Varian TrueBeam Linacs.  However, the Elekta implementation (now commercially 
available on the Versa HD) supports energy tuning of the beam, by alteration of the power 
conditions and gun current to increase the mean electron energy incident on the target and 
changing the bending magnet currents to adjust the electron energy selection window. 
Therefore, these parameters were modified so that the resulting PDD of the matched FFF beam 
was matched to within 1% at 10cm deep in water in a 10cm x 10cm field at 100cm source to 
surface distance (SSD) to the standard cFF beam. International dosimetry protocols such as 
AAPM TG-51 (Almond et al., 1999) use 10cm deep as a reference point for calibration. It was 
therefore decided to use this specific reference for the point of beam matching.   
The nominal energies used in this study are 6MV and 10MV. The ‘unmatched’ beams were set 
up on the Elekta Synergy Linac by keeping the accelerator parameters the same as for the cFF 
beam.  Typical central axis dose rates increase from 580cGy/min at the isocentre for the cFF 
beam to 1300 cGy/min for the FFF 6MV (6MV FFF) and 2000cGy/min for the FFF 10 MV (10MV 
FFF) beam. The bending coarse, bending fine and gun current values for the energy selection of 
the beams are shown in Table 2, power conditions were fully optimised for each accelerating 
potential. Bending course adjusts the bending current across all the slalom magnets of the Linac 
head and, bending fine controls current through the final magnet of the slalom system, the 
relationship between these two parameters affects the focusing of the electron beam once 
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through the slalom onto the target. The removal of the flattening filter results in an increased 
dose per pulse for both FFF beams compared with cFF beams. 
Table 2: Bending magnet and gun current values for the beams studied 
 Energy 
6MV/6MV 
‘unmatched’ FFF 
6MV ‘matched’ 
FFF 
10MV/10MV 
‘unmatched’ FFF 
10MV ‘matched’ 
FFF 
Bending coarse 41 48 62 71 
Bending fine 1.95 2.30 3.2 2.8 
Gun current 7.39/7.32 7.20 7.09/7.01 6.90 
3.2.2. Profiles and PDDs 
Profiles and PDDs were measured at an SSD of 100cm using an MP3-M plotting tank (PTW GmbH, 
Freiburg, Germany). A 60008 photon diode (PTW GmbH, Freiburg, Germany) was used for profile 
measurements as it has a small sensitive volume with circular diameter of 1mm and thickness 
2.5µm that can be used for high resolution scans and minimise the gradient effect across the 
active region. A 31010 semiflex ion chamber (PTW GmbH, Freiburg, Germany) was used for PDD 
measurements as it has a small collection volume of 0.125cc and does not over respond to 
scatter with depth, as the photon diode can. The over response is a result of the mass energy 
absorption coefficient increasing dramatically for silicon (the active component of the diode) 
relative to water at low photon energies. The profiles used for penumbra measurements were 
obtained with a resolution of 0.1mm in the penumbral region so that the inflection point of the 
profiles could be accurately determined with a function developed in Mathworks MATLAB 
2010b. The function used applies a Canny edge detection algorithm to find the inflection point. 
The Canny function was used as it smooths the data with a Gaussian function to remove noise 
from the profile. With sufficiently long dwell times at each measurement point this results in 
few false inflection points being determined. The code written then allows the user to visualise 
the locations of the inflection points, discount the false inflection points and select the correct 
points. Once the function has determined the inflection points the penumbras are determined 
using the normalisation method proposed by Ponisch et al. (2006) (Equation 3). This method 
involves normalising the FFF profiles against the cFF profiles at the inflection points and the 80% 
to 20% of the normalisation dose is used for the penumbra measurements. Profiles were 
obtained at depths of dmax (1.5cm for 6MV, 2.2cm for 10MV), 5.0cm, 10.0cm, 15.0cm and 
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20.0cm for square field sizes of 3cm x 3cm, 5cm x 5cm, 10cm x 10cm, 15cm x 15cm, 20cm x 
20cm, 25cm x 25cm, 30cm x 30cm and 40cm x 40cm the largest field size available for the Agility 
head. 
For the same range of field sizes a central axis PDD with a depth-resolution of 1mm down to a 
depth of 25cm was obtained to investigate the effect of field size on the PDD. The PDD at the 
depth of Dmax, 10cm and 20cm were compared over the same field sizes as the profiles and the 
three beam types. 
3.2.3. Output Factors 
Output factors were measured using the PTW water tank and a semiflex 0.125cc ion chamber  
for the same field sizes as the profiles and PDDs for 5cm x 5cm and larger, and a photon diode 
for field sizes of 4cm x 4cm and smaller. Both detectors were used for the 5cm x 5cm field so 
that the response of the two detectors could be normalised. The measurements were 
performed at 100cm focus to surface distance (FSD) and a depth of 10cm. This is consistent with 
the measurement geometry required for commissioning the beam data of a Monaco treatment 
planning system (Elekta AB, Sweden).  
3.2.4. Head leakage 
Head leakage values at 1m from the X-ray source are required to be below 0.1% of the value of 
an open 10cm x 10cm field at 100SSD.The head leakage is measured as one part of the radiation 
protection critical examination of a linear accelerator installation.  Leakage measurements were 
performed using a 23332 rigid stem 0.6cc ionisation chamber (PTW GmbH, Freiburg, Germany) 
operating at a potential of 300V, with the supplied Perspex build-up cap. The head leakage 
measurements were performed at the locations specified in the IEC documentation (IEC, 1998). 
Leakage measurements were performed in the patient plane at 1 metre distance from the target 
(Figure 6) and in the other conventional planes around the accelerator head at the same 
distances from the electron and photon beam central axes (Figure 7), with the linear accelerator 
operating in FFF mode. The measurements performed were for a 1000MU delivery with the MLC 
in a closed position. 
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Figure 6: Positions for the measurements in the patient plane. Circles represent a 
constant radius from the isocentric position 
 
 
Figure 7: Positions for the non-patient plane leakage measurements. 
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The reading recorded at each of the positions was expressed as a percentage of the reading 
obtained at the isocentric position of a 10cm x 10cm reference field. 
3.2.5. Radiation Protection 
Radiation protection measurements on the leakage through primary and secondary barriers are 
performed as part of the critical exam of all Linacs. A number of measurements were performed 
to determine the dose-rate beyond the primary and secondary barriers and the dose-rate 
through the maze. The locations for the dose-rate measurements are depicted in Figure 8 by 
dots.  
 
Figure 8: Barrier doserate measurement positions 
 
The accelerator bunker was designed to a specification to contain a linear accelerator delivering 
a maximum photon energy of 15MV. Dose constraints are, as specified by UK Ionising Radiation 
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Regulations (2017) (Health and Safety Executive, 2018), to be within 1mSv per year for staff 
working with radiation and 0.3mSv per year for members of the public.  The room was designed 
with the (North) side wall primary barrier constructed from 1.7m thick high-density concrete 
(magnetite, 3.8g/cm3) and the (South) side wall primary barrier constructed from 2.5m thick 
standard concrete (density 2.35g/cm3). The north side barrier was designed so that the 
instantaneous dose rate beyond the barrier would be less than 7.5µSv/hr, the requirement for 
an area to not be designated as controlled. The south side wall is adjacent to a second bunker, 
designated as a controlled radiation area allowing an instantaneous doserate of over 7.5µSv/hr. 
The instantaneous dose rate beyond the south side primary barrier, inside the adjacent bunker, 
was designed to be within 11.3µSv/hr (the specification of the room).  Instantaneous dose rate 
in all other areas beyond the bunker is designed to be less than 7.5µSv/hr in line with 
recommended national guidelines (Health and Safety Executive, 2018).   
Measurements were performed with a 40cm x 40cm field (the largest available) at the highest 
dose-rate available for the selected beam, with the gantry and collimator angles selected in 
order to maximise the dose-rate in each case. For all measurements, except the primary barrier, 
a 30cm x 30cm phantom of solid water was positioned at isocentre and used to simulate patient 
scatter. The dose-rate was measured with a Thermo Scientiffic SmartION Survey Meter MINI 
2120 (Thermo Fischer Scientiffic, Waltham, USA) calibrated against Cs-137. 
3.3. Results 
3.3.1. Profiles 
The inhomogeneity in an FFF beam varies as the nominal energy of the beam changes, with a 
higher energy beam having a more pronounced peak. The change in profiles for a 10cm x 10cm 
field with varying energy is shown in Figure 9, each profile has been normalised to the inflection 
point. 
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Figure 9: A comparison of profile shape with differing beam energies for a 10cm x 10cm 
field at 100cm SSD measured at a depth of maximum dose in water. 
 
The inhomogeneity of the forward-peaked radiation is also a function of field size with the 
amplitude of the forward peaking increasing with greater field size. This effect is more 
pronounced with FFF beams with higher energy. Thus the shape of the FFF profile is less 
consistent with field size than the case for the equivalent cFF beam (Figure 10). The matched 
FFF beams are more forward peaked than the FFF beams without matching. 
With FFF beams, there is less variation of beam quality across the beam with depth in water 
when compared to the differential hardening produced across the cFF beam profiles by the 
flattening filter. Thus, the shape of the profile with depth is more consistent for FFF beams than 
cFF beams (Figure 11). No significant difference was noted between the behaviour of the profiles 
of the matched and unmatched FFF beams as depth was changed. 
The change in  penumbra between  an FFF beam and the equivalent cFF beam was found to be 
negligible when using the method proposed by Ponisch et al. (2006). This can be seen in Figure 
12. The penumbra measured was the same within the experimental error of ±0.4mm for the 3 
modes of operation.  
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Figure 10: A comparison of the change in profile shape with increasing field size for 6MV 
cFF (above) and FFF (below) beams at 100cm SSD and a depth of 10cm in water. 
48 
 
 
Figure 11: A comparison of the change of profile shape with varying depth in water 
(1.5cm, 10cm, 20cm) for 6MV cFF (above) and FFF (below) beams at 100cm SSD with a 
field size of 10cm x 10cm. 
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Figure 12: A comparison of the penumbra for 6MV beams taken at 100cm SSD and a deth 
of maximum dose. The 3cm x 3cm fields (above) the measured penumbra was 2.7mm for 
each mode and for the 25cm x 25cm field (below) the penumbra was 3.1mm for each 
mode. 
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3.3.2. PDDs 
 
Figure 13: 6MV (above) and 10MV (below) PDD difference plots for matched flattening 
filter free (dashed) and unmatched flattening filter free (solid) compared to the associated 
(reference) cFF beam (dotted) measured at 100cm SSD.
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Figure 14: The variation of PDD10 (left) and PDD20 (right) for field sizes of 3cm x 3cm to 30cm x 30cm at 100cm SSD. 6MV (above) 10MV (below)
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The effect on the PDD of removing a flattening filter is to increase the quantity of low energy 
photons in the spectrum, as compared to the equivalent cFF beam. This effect is especially 
prevalent on the central axis due to the removal of the attenuation caused by the flattening 
filter, which results in the unmatched FFF beams having a PDD resembling that of a 4MV cFF 
beam. Matching the FFF beam at 10cm results in the PDD becoming more comparable to the 
associated cFF beam (Figure 13). The change in PDD between the matched and unmatched FFF 
beams with respect to field size and energy is shown in Figure 14. The depth of maximum dose 
is more constant with field size for FFF beams due to the reduction in head scatter compared to 
cFF beams, which results in the depth of maximum dose being deeper for a matched FFF beam 
than that of a cFF beam for field sizes greater than 10cm x 10cm. The variation of PDD10 and 
PDD20 is reduced with FFF beams compared with cFF beams for both 6MV and 10MV beams 
(Figure 14). 
3.3.3. Output Factors 
The output factors are shown in Figure 15 and vary less with field size for both types of FFF 
beams when compared to the cFF beams. This is due to the reduction in head scatter with the 
removal of the flattening filter, which is the dominant source of this variation. The output factors 
are expressed in MU/cGy as is the protocol at this institute. 
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Figure 15: Output factors at 100cm SSD and 10 cm deep in water with varying field size 
for 6MV (above) and 10MV (below) beams for cFF, matched flattening filter free and 
unmatched flattening filter free modalities. 
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3.3.5. Head leakage 
The removal of the flattening filter as a dominant source of scatter has a major effect on the 
leakage through the treatment head. A reduction of at least 50% in leakage radiation is 
measured for both the patient plane beyond 50cm and the non-patient plane. This reduction is 
consistent for FFF beams both with and without matching (Table 3). 
3.3.6. Radiation Protection 
The environmental survey of the areas surrounding the Linac bunker demonstrates that the 
dose-rate through the primary barrier increases more than two-fold when operating the linear 
accelerator in FFF mode. The changes in measured values did not change the designation of any 
area within the UK radiation protection legislation requirements at this centre, or require any 
changes in practical protection measures. At the primary barriers for the 6MV FFF and the 10MV 
'unmatched' FFF beams, the increase in instantaneous dose-rate is less than the proportional 
increased output of the machine. For the 10MV matched FFF the increase in instantaneous dose-
rate is greater than the proportional increased output of the machine (Table 4). For the 
secondary barriers the increased dose-rate is less than proportional to the output from the 
machine for all modes. 
55 
 
Table 3: Leakage measurements for 3 modes of operation, Flattening Filter (cFF), Unmatched Flattening Filter Free (UFFF) and Energy Matched 
Flattening Filter Free (MFFF), in patient and non patient planes (expressed as a % of an open 10cm x 10cm beam). 
Energy Circle 
radius/cm 
Target direction Gun direction Cross plane B  Cross plane A  
cFF UFFF MFFF cFF UFFF MFFF cFF UFFF MFFF cFF UFFF MFFF 
6MV 50 0.009 0.004 0.003 0.018 0.01 0.009 0.014 0.007 0.006 0.015 0.007 0.006 
75 0.008 0.003 0.003 0.028 0.011 0.009 0.015 0.008 0.006 0.016 0.007 0.006 
100 0.008 0.003 0.003       0.018 0.011 0.008 0.015 0.007 0.005 
              
Energy Circle 
radius/cm 
Target direction Gun direction Cross plane B Cross plane A 
cFF UFFF MFFF cFF UFFF MFFF cFF UFFF MFFF cFF UFFF MFFF 
10MV 50 0.014 0.006 0.006 0.036 0.013 0.013 0.023 0.009 0.009 0.024 0.009 0.009 
75 0.01 0.003 0.003 0.04 0.012 0.011 0.023 0.008 0.007 0.023 0.007 0.007 
100 0.01 0.003 0.003       0.028 0.009 0.009 0.023 0.006 0.006 
              
6MV 60° 90° 135° 180° G50 G100 10MV 60° 90° 135° 180° G50 G100 
cFF 0.034 0.026 0.03 0.034 0.025 0.015 cFF 0.019 0.022 0.024 0.038 0.031 0.018 
UFFF 0.011 0.006 0.007 0.013 0.011 0.006 UFFF 0.01 0.011 0.014 0.018 0.013 0.007 
MFFF 0.011 0.006 0.007 0.011 0.008 0.004 MFFF 0.01 0.01 0.014 0.015 0.01 0.005 
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Table 4: Doserate survey results from around the FFF linear accelerator bunker for 
Flattening Filter (cFF), Unmatched Flattening Filter Free (UFFF) and Energy Matched 
Flattening Filter Free (MFFF) 
Energy Output 
cGy/min 
Dose-rate μSv/hr 
(A)  
Primary 
barrier 
(LA01) 
(B)  
Primary 
Barrier 
Outside 
Walkway 
(G90) 
Primary 
Barrier 
Ceiling - 
Plant 
room B1 
(G180) 
(C)  
Door - 
floor level 
(G270 + 
phantom) 
(D)  
Dosimetry 
Cable “rat 
hole”. 
(G270 + 
phantom) 
(E)  
Changing 
room 
(G270 + 
phantom) 
6MV 
cFF 
580 0.2   1.7 0.4  
6MV 
MFFF 
1400 0.2   2.9 1.1 0.1 
6MV 
UFFF 
1300 0.2   2.7 1.1  
10MV 
cFF 
505 1.7   1.4 0.2  
10MV 
MFFF 
2000 (i) Wall 
8.8 
(ii)1m 
from 
wall 3.9 
(iii) 2m 
from 
wall 2.7 
(iv) Iso 
1.7 
0.1 0 2.6 1.3 0.1 
10MV 
UFFF 
1400 3.7   2.7 1.1  
3.4. Discussion 
The general findings are consistent with those of other authors (Ponisch et al., 2006; Cashmore, 
2008; Kragl et al., 2009; Georg et al., 2010) when comparing cFF beams to FFF beams without 
matching. The major difference for the matched FFF modality is that the increase in beam energy 
has no detrimental effect on the previously reported beneficial effects of FFF beams such as an 
increased dose-rate of up to 4 times that of a cFF beam to reduce treatment times, less beam 
shape variation with depth and a reduction of treatment head leakage by approximately 50%. 
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For these matched beams, the increase of beam energy produces a PDD more similar to the 
equivalent cFF beam, potentially making the transition from a cFF beam to a FFF beam more 
consistent with current clinical practice. This increase in energy also has the potential to reduce 
local scatter around the periphery of the target volume, which may have a clinical effect, as 50% 
of radiation induced secondary cancers are reported to occur in the region from 2.5cm within 
the PTV to 5cm outside of the PTV (Dorr and Herrmann, 2002). 
Differences in forward bias of the FFF modalities are a direct result of the forward bias of the 
bremsstrahlung production in the target in order to conserve momentum, now not mitigated by 
the flattening filter. The forward peaking increases with increasing beam energy and so a change 
in beam energy could be inferred from the change in the magnitude of the beam peak. Further 
work should be performed to determine the validity of this as a measure of beam energy. 
The penumbra measured using the normalisation method proposed by Ponisch et al. (2006) 
demonstrated that there was no major difference between the cFF and both FFF modalities. This 
method measured penumbra with an error of ± 0.4 mm demonstrating its suitability for clinical 
use. The method requires that both cFF and FFF beam profiles are taken in order to determine 
the penumbra of an FFF beam. Fogliata et al. (2012b) proposed a method for profile 
normalisation on Varian TrueBeam accelerators that would not require the use of the inflection 
point but instead used empirically derived factors verified over 3 TrueBeam machines and later 
produced information for the use on Elekta Linacs (Fogliata et al., 2016a). A number of other FFF 
beam parameters were discussed including symmetry, unflatness and slope parameters. Further 
investigation into penumbra specification and measurement that is independent of cFF beams 
is required for FFF beams; as future Linacs may not have the option of a cFF beam such as for 
the Elekta MRI Linac (Smit et al., 2014).  
The FFF beams operated at a maximum pulse repetition frequency of 400Hz. This corresponds 
to an interval of 2.5ms between pulses. This differs from the Varian TrueBeam which has a pulse 
interval of 2.8ms and drops a pulse every 4-5 pulses (Lang et al., 2012a). The maximum dose per 
pulse (DPP) for the Elekta FFF beams was 0.83mGy/pulse. The variation in ion collection 
efficiency over the range of DPP was <1% for the semiflex ion chamber and is therefore 
acceptable for relative measurements (Lang et al., 2012a; Budgell et al., 2016).  
The difference in the PDD for cFF and unmatched FFF beams is noticeable due to the increased 
proportion of low energy photons along the central axis of the beam. This reduces the effective 
energy of the beam and may result in reduced plan quality for treatment sites located at depth 
in the patient. The matched FFF beam differs from the cFF beam less in terms of PDD, and would 
be expected to produce similar dose distributions at depth to the cFF beam in a homogeneous 
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medium. The depth of maximum dose is shallower for the FFF beam than for the equivalent cFF 
beam, but varies less with field size, e.g. by 1mm over the range of field sizes measured for the 
FFF beams and 5mm for the cFF beam. The variation of the PDD at 10cm and 20cm in water 
varies less with field size for the FFF beams than the cFF beams, with the difference between 
the two FFF modalities over the range of field sizes being within the experimental error. The 
PDD changes less with increasing field size for FFF beams as a result of the reduction in head 
scatter compared to the cFF beam.  The reduced variation of output factor over a range of field 
sizes may serve to simplify planning system calculations. The effect of this on plan accuracy will 
be investigated further in future work. 
The head leakage when operating the linear accelerator in FFF modes is reduced by >50% 
compared to a cFF beam, the difference between the beams with and without matching was 
within experimental error and demonstrates that the reduction in head leakage is as a result of 
the removal of the flattening filter, the dominant source of such scatter. This agrees with the 
finding of other authors with respect to ‘unmatched’ FFF beams (Cashmore, 2008). The 
increased energy of the matched beam did not result in a higher proportion of leakage radiation 
when compared to the FFF beam without matching. The reduction in head leakage has the 
potential to reduce the amount of out of field dose received by the patient, providing that the 
modulation for FFF beams does not counter this. Further studies are required to determine the 
number of monitor units required to deliver a comparable plan with a FFF beam when compared 
to a cFF beam. FFF beams demonstrate a reduction in head leakage and collimator scatter but 
can contain more low energy photons than cFF beams, thereby increasing the phantom scatter. 
This effect has been modelled by Kry et al. (2010) for unmatched FFF beams, showing an 
increased dose in the region of 3cm - 15cm out of field. The matching of an FFF beam would 
increase the average energy of the beam potentially reducing this effect. This again requires 
further work. 
The radiation protection measurements of the dose-rates through the primary and secondary 
barriers demonstrated that the increase in MU/min for the FFF beam results in an increase in 
dose-rate through the barriers. For both of the 6MV FFF beams and the unmatched 10MV FFF 
beam the increase was less than the proportional increased output of the machine. This is due 
to the softer spectrum of the FFF beams resulting in a greater degree of relative attenuation 
through the barrier. For the matched 10MV FFF beam the increase was more than the 
proportional output. This is due to the tuning of the beam requiring the maximum photon 
energy produced to be approximately 13MV, close to the 15MV cFF category of the barrier. 
These results are not in agreement with Kry et al. (2009) who performed a Monte Carlo study 
and concluded that less shielding would be required for a linear accelerator delivering only FFF 
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beams. The difference in conclusion is due to the differences in radiation protection guidelines 
between the countries of the two authors. In the United Kingdom a threshold instantaneous 
dose-rate is also used whereas Kry et al. (2009) has used the time averaged dose-rate, assuming 
no increase in machine workload would result from the use of FFF beams.  
The change in profile shape with field size demonstrates how FFF beams could be used clinically. 
For field sizes < 5 cm x 5 cm, the beam profiles are relatively flat and there is little variation in 
profile shape with field size. These fields could be used in a similar manner to conventional 3D 
conformal therapy (3DCRT) fields when the beams are on the central axis. With the benefit of 
increased dose-rate from FFF beams, these smaller beams offer potential in reducing the 
treatment time required for SABR (Georg et al., 2011; Lang et al., 2013; Fu et al., 2004).  
For larger field sizes the expectation is that the beam would have to be modulated to achieve 
the desired dose distribution. A number of authors have performed studies on the treatment of 
prostate and larger head and neck target volumes with the majority concluding that a decrease 
in treatment delivery time is achievable with at least comparable plan quality when using 
unmatched FFF beams (Spruijt et al., 2013b; Mancosu et al., 2012; Reggiori et al., 2012a; 
Scorsetti et al., 2011; Vassiliev et al., 2007).  Lechner et al. (2013) performed a planning study 
on an Elekta Synergy platform with an MLCi head and FFF capability. This study concluded that 
a decrease in treatment time was achievable when delivering prostate and head and neck 
treatments with IMRT but that the delivery time increased for VMAT deliveries. Further studies 
are required to determine if the increased leaf speed of the Agility head would be able to 
decrease delivery time with VMAT delivery on matched FFF beams.  
The differences in profile shape and relative off-axis softening for FFF beams compared to 
conventional cFF beams may cause difficulties in modelling FFF beams in treatment planning 
systems, as several assumptions in beam modelling algorithms would no longer be relevant (e.g. 
scatter kernels). The reduced variation of the profile shape with depth has the possibility to 
simplify dose calculations; the impact of the shape change of profiles and the dosimetric 
accuracy of planning systems requires further investigation. 
3.5. Conclusion 
The purpose of this chapter was to answer the research question “What are the properties of 
FFF beams and do these properties differ between the two implementations?” this has been 
achieved and the conclusion is summarised below; 
The matching of an FFF beam to a cFF beam at a depth of 10cm in water by increasing the FFF 
beam energy does not reduce any of the reported benefits of FFF beams. Conversely, there are 
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a number of benefits resulting from matching the FFF beam, e.g. the depth of maximum dose is 
located deeper and the beam quality and penetration more closely resemble the cFF beams 
currently used in clinical practice, making dose distributions in water more alike. Highlighted in 
this work is the fact that some conventional specifications and methods for measurement of 
beam parameters such as penumbra are not relevant and further work is required to address 
this situation with respect to ‘matched’ FFF beams and to determine methods of measurement 
that are not reliant on an associated cFF beam. 
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4. Characterisation of FFF beam properties for initial 
beam set-up and routine QA, independent of Flattened 
Beams 
4.1. Introduction 
The use of FFF beams has become more prevalent in clinical treatment delivery following the 
commercial availability of Linacs fitted with both conventional flattened (cFF) and FFF beam 
energies. For the VersaHD FFF implementation (Elekta AB, Sweden), the beam energy is retuned 
so that the Percentage Depth Dose (PDD) at 10cm deep in water, for a 10 cm x 10 cm beam, is 
matched to that of the associated cFF beam energy matched FFF beam (Paynter et al., 2014). 
This ability to adjust the PDD means that it is possible to  both energy match the FFF beam to 
the cFF beam and also match the beams across a group of Linacs. This can improve service 
continuity and patient management in the event of planned or unplanned equipment down-
time in a centre with multiple FFF enabled Linacs.  
In order to use a single beam energy model for multiple Linacs, a process to match beam data 
across the Linacs is required; in addition, regular quality assurance (QA) will be required to 
ensure that the energies remain matched. Previous authors have used a system of empirically 
derived values to characterise and QA FFF beams from Varian and Elekta Linacs (Fogliata et al., 
2016a; Fogliata et al., 2012b). This chapter develops on previous work (Paynter et al., 2014) to 
propose methods for matching beams on Elekta VersaHD Linacs and a framework for routine 
QA. Insight is gained in understanding how changes to the beam delivery system can affect beam 
characteristics. 
The standard definition of penumbra for cFF beams is the distance between the points on the 
beam edge that mark 80% and 20% of the central axis dose normalised to 100%. This method is 
not appropriate for FFF beams as the 80% of maximum dose can be located within the in-field 
region of the FFF profile. Previously, a number of authors have proposed methods for measuring 
the penumbra and field size of FFF beams (Fogliata et al., 2012b; Ponisch et al., 2006; Budgell et 
al., 2016).These have been based on methods that determine an inflection point in the FFF field 
edge and require reference to the profile of the standard, cFF beam at the equivalent energy. 
As FFF beams become more prevalent for routine clinical treatment, FFF-only Linacs are 
becoming a commercial reality, as is already the case for Cyberknife (Adler et al., 1997), 
Tomotherapy (Jeraj et al., 2004) and MR Linacs (Smit et al., 2014). Therefore, a method to 
characterise, evaluate and QA FFF beam profiles without reference to a cFF profile is presented 
and investigated. 
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4.2. Method 
This work was performed on energy matched FFF 6MV beams, where the percentage depth dose 
(PDD) has been matched to that of a cFF 6MV beam at 10cm deep in water. The work was carried 
out on one VersaHD Linac and one Elekta Synergy, each equipped with Agility collimators. The 
characterisations of these beams has been discussed previously in chapter 3 and published 
(Paynter et al., 2014). During the commissioning of the VersaHD Linac, the beam delivery 
parameters were adjusted so that the 6MV and 6MVFFF beams matched the previously 
commissioned Synergy with Agility FFF system. To do this, the beam energy was altered and the 
effect on both the PDD and profile shape evaluated. The beam steering was then adjusted by 
altering the 2R and 2T steering coil currents (Figure 16) in the Linac control system to investigate 
the effect of steering errors on the profiles. In addition, the profile shape was adjusted using the 
coarse and fine bending magnet currents.   
 
Figure 16: Diagram of electron transport system of an Elekta Linear accelerator. Steering 
coils operate radially (2R) and cross-plane (2T) to the plane of the electron beam path. 
 
Profile and PDD measurements were taken at 100cm SSD in a PTW MP3 plotting tank (PTW, 
GmbH) controlled by the PTW Mephysto MC2 software. A 60008 photon diode (PTW GmbH, 
Freiburg, Germany) was used for profile measurements and a 31010 semiflex chamber (PTW 
GmbH, Freiburg, Germany) used for PDD measurements. The bending coarse, bending fine and 
steering currents were systematically altered in order to induce errors in the beam to investigate 
their effect on the treatment beam characteristics. 
Other manufacturers’ implementations of FFF beams do not support energy matching. Instead, 
the beam that would have been incident on the flattening filter is not further modified when the 
filter is removed (Vassiliev et al., 2006b), resulting in a lower quality beam.  
63 
 
This alternative type of unmatched FFF beam was simulated in this work by not modifying the 
beam delivery parameters after the flattening filter was removed (Paynter et al., 2014).  
To determine the penumbra of the FFF beam profiles, a development on the inflection point 
method is proposed that does not require reference to the equivalent cFF beam profile. To 
investigate how to best utilise the inflection point, the extracted points were normalised 
systematically to 50%, 55% and 60% and the penumbra taken as the distance between the 80% 
and 20% points. Analysis was carried out to determine the optimum normalisation to give 
agreement with current methods where cFF beams are available. The method was evaluated 
against standard methods for cFF beams where the distance between the points of 80% and 20% 
of maximum dose is directly measured. The method was also evaluated against the approach 
proposed by Ponisch et al. (2006) for FFF beams, where the FFF profile is normalised against the 
inflection point of the flat profile (Equation 4) and the measurement between the 80% and 20% 
points of the normalised profile is used as the measure of penumbra. These methods will be 
considered as the ‘gold standard’ for analysis of penumbra. 
Equation 4: 𝑫𝒏 =
𝑫𝒖
𝑫𝒇
𝑫𝑪𝑨𝑿 
 
where Dn is the normalised dose, Du is the dose at the FFF inflection point, Df is the dose at the 
cFF inflection point and DCAX is the dose on the central axis of the cFF beam. 
 The suitability of this method for the determination of field size for cFF beams and FFF beams 
has also been evaluated by measuring between the standard 50%-50% points of the normalised 
profiles. 
Penumbra was further analysed at 10MV, i.e. with reference to a cFF 10MV beam; an unmatched 
FFF beam whereby the flattening filter was removed from the beam without any further beam 
energy matching; and, an FFF beam energy matched at 10cm deep in water tank to the cFF 10MV 
FFF beam. 
4.3. Results 
4.3.1. Profile symmetry 
The profile symmetry in the in-plane direction can be measured using the conventional method 
of maximum ratio between opposite points within the central 80% of the field size (Equation 5) 
as used for cFF beams, 
Equation 5: 𝒔𝒚𝒎𝒎𝒆𝒕𝒓𝒚 = (
𝑫𝒙
𝑫−𝒙
)
𝒎𝒂𝒙
. 𝟏𝟎𝟎% 
where D is dose and x is the distance from the central axis. 
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 However, the effect of changes in cross-plane steering on the symmetry is insensitive to being 
measured in this way for FFF beams. Instead, the cross-plane symmetry can be measured by 
determining the central axis deviation of the beam as steering errors result in the beam shifting 
rather than a symmetry change (Figure 17), this shift is also present in-plane when there is an 
energy change. By obtaining two profile scans at collimator (col) 0 and col 180 it is possible to 
locate the centre of rotation situated at the midpoint between the individual central axis 
positions of each measurement and the central axis deviation from this point. Figure 18 shows 
that a linear relationship exists between the steering current applied by the Linac control system 
and the central axis deviation of the beam. Deviations in central axis (CAX) of more than 1mm 
can result in a rapid reduction in doserate and/or beam termination due to waveguide vacuum 
failure caused by the electron beam impinging on the travelling waveguide structure. 
 
Figure 17: The effect of adjusting 2T bending magnet current on profile shape and CAX 
position for 6MV FFF beams (above) and cFF beams (below) taken at 100cm SSD at a 
depth of maximum dose in water. 
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Figure 18: Profile central axis shift with changing 2T steering currents for a 6MV FFF 
beam at 100cm SSD and at a depth of maximum dose in water. 
4.3.2. Profile flatness 
As the beam energy increases the FFF beam shape changes so that the central peak becomes 
more pronounced. A 2% change in PDD corresponds to a 4% change in the ‘flatness’ of the beam.  
Flatness is described as the ratio of the maximum and minimum dose within the central 80% of 
the field size Equation 6. 
Equation 6: 𝒇𝒍𝒂𝒕𝒏𝒆𝒔𝒔 =
𝑫𝒎𝒂𝒙
𝑫𝒎𝒊𝒏
. 𝟏𝟎𝟎% 
 
This means that the profile shape is more sensitive to an energy change than the PDD (Figure 
19). The central peak can be altered by adjusting the ratio of bending coarse to bending fine 
currents with a minimal effect on PDD. 
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Figure 19: Top: Change in 6MV FFF inplane Profile flatness for a 1% change in PDD at 
100cm SSD and 10cm deep in water. Bottom: Profile shift for a 1% change in PDD at 
100cm SSD and 10cm deep in water. 
4.3.3. Beam energy 
The beam energy (quality) of FFF beams can be measured using the same methods currently 
used for cFF beams (eg PDD at a specified depth, TPR). However, care should be taken as a 
change in the beam energy can off-set the central axis in the in-plane direction due to a change 
in the electron path through the beam steering slalom, Table 5 shows that a 2% change in PDD 
results in a 1mm CAX shift and a 4% change in profile ‘flatness’ (Figure 19). 
Table 5: Relationship between beam energy, profile CAX and beam ‘flatness’ 
PDD10  
(10 cm 
x 10 
cm)(%) 
CAX G-T 
(mm) 
Symmetry 
G-T (%) 
‘Flatness’ 
(%) 
66.4 -0.50 100.40 167.72 
67.3 0.29 100.26 170.68 
68.4 0.89 100.34 171.69 
67 
 
 
 Table 6:  Measured difference in mm between inflection method and current ‘gold 
standard’ penumbra measurement methods for flat (cFF), unmatched flattening filter free 
(UFFF) and matched flattening filter free (MFFF) beams. 
Difference from ‘gold standard’ 6MV profile Dmax (mm) 
Inflection 
point (%) 
Jaw direction MLC direction 
Average 
cFF UFFF MFFF cFF UFFF MFFF 
50 0.447 0.436 0.414 0.704 0.464 0.664 0.537 
55 0.036 0.064 0.043 0.106 0.243 0.071 0.105 
60 0.103 0.114 0.129 0.224 0.457 0.250 0.235 
Difference from 'gold standard' 10MV Dmax (mm) 
Inflection 
point (%) 
Jaw direction MLC direction 
Average 
cFF UFFF MFFF cFF UFFF MFFF 
50 0.646 0.671 0.686 0.817 0.871 0.743 0.758 
55 0.117 0.079 0.079 0.189 0.171 0.121 0.128 
60 0.140 0.064 0.064 0.246 0.079 0.193 0.129 
Difference from 'gold standard' 6MV 20cm deep (mm) 
Inflection 
point (%) 
MLC direction Jaw direction 
Average 
cFF UFFF MFFF cFF UFFF MFFF 
50 2.727 2.236 1.514 2.510 2.943 1.507 2.142 
55 0.211 0.436 0.371 0.180 0.429 0.250 0.335 
60 1.284 1.450 1.136 1.090 1.421 0.914 1.202 
Difference from 'gold standard' 10MV 20cm deep (mm) 
Inflection 
point (%) 
MLC direction Jaw direction 
Average 
cFF UFFF MFFF cFF UFFF MFFF 
50 2.096 2.507 2.014 2.007 2.421 1.679 2.126 
55 0.560 0.471 0.086 0.393 0.436 0.114 0.300 
60 0.681 0.693 0.457 0.629 0.571 0.471 0.564 
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4.3.5. Penumbra 
The profiles were analysed using software developed in house, which locates the inflection point 
of the profiles (Figure 20) using the Canny edge detection algorithm (Canny, 1986). This 
algorithm was used because it helps to remove noise from the profile when locating the edges. 
Any false inflection points are often located away from the true inflection point and the software 
allows the user to manually select the correct inflection points used for the analysis by rejection 
of incorrect positions. The inflection points are then normalised to the pre-defined values of 50, 
55 and 60% for all beam types and the penumbra extracted as the distance between 80 and 20% 
profile points based on each normalisation. The values were chosen as it is often assumed that 
the inflection point lies at 50% of maximum dose for flat beams, this value was then iteratively 
altered to 60% and 55% to achieve the best match to current methods. For the FFF modalities 
the penumbral values determined are compared against the method published by Ponisch as 
this method has been used in previous papers (Ponisch et al., 2006; Cashmore, 2008; Paynter et 
al., 2014). The cFF beam penumbra is compared to the standard 80%-20% (CAX value normalised 
to 100%) method. The difference in measured penumbra averaged over field sizes from 3cm x 
3cm to 40cm x 40cm is shown in Table 6. 
 
Figure 20: Depiction of second derivative determining the position of inflection for 6MV 
cFF (above) and FFF (below) beams for a 20cm x 20cm profile taken at 100cm SSD and 
10cm in water. 
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4.3.6. Field size 
The field size is determined using the same in-house programme, with the inflection points 
normalised to 55%. This was used because this value was observed to achieve the best 
agreement for the penumbra analysis compared to cFF (standard) beams (Table 6).  The field 
size was still determined as the distance between the 50% points. This method was evaluated 
for both the FFF beams and the traditional cFF beams (Figure 21). The results are shown in Table 
7. 
 
Figure 21: Inflection point normalised 25cm x 25cm in-plane profile measured at 100SSD 
and 10cm deep in water. 
4.4. Discussion 
For FFF beams a change of steering current in the 2T direction moves the beam rather than 
affecting the symmetry of the profile (Figure 18). This change in behaviour with respect to the 
symmetry in the cross-plane provides some problems with routine QA of FFF beams compared 
to conventional cFF beams. The position in-plane of the electron beam entering the bending 
magnet system affects the angle that it subsequently exits the system and onto the target. There 
is an optimum path the electrons can travel through the bending magnets, and an in-plane off-
set either side of this can lead to the beam striking the target at a non-perpendicular angle This 
does not occur in the same way in the  cross-plane direction.  Translational off-sets of the 
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electron beam in the cross-plane direction do not lead to an angular change in trajectory when 
arriving at the target. Using measurement points a set distance left and right of the central beam 
axis would not show any symmetry change for an FFF beam with a steering change as the infield 
profile shape does not change in the cross-plane direction (Figure 17). One method for avoiding 
this is to compare the central axis deviation to that of a cFF beam where the central axis is fixed 
by the position of the flattening filter. The problem associated with this method is that whilst 
effective for current Linacs that have both cFF and FFF modes, a new method is required if only 
FFF beams were available on a given Linac. The acquisition of 2 profiles with a difference in 
collimator rotation of 180° allows the centre of rotation to be deduced, removing the setup 
uncertainty. This centre of rotation can then be used to determine the central axis deviation 
without the need for a cFF beam. 
Table 7: Difference in calculated field size for 6MV unmatched Flattening filter Free 
(UFFF) and matched Flattening Filter free (MFFF) beams based on 50% field sizes 
following from the 55% inflection point method compared to measured 50% field size for 
cFF beam. 
Square field 
size (cm2) 
Difference from CFF Field size 
compared to UFFF at depth of 
maximum dose (mm) 
Difference from CFF Field size 
compared to MFFF at depth of 
maximum dose (mm) 
Jaw Direction MLC Direction Jaw Direction MLC Direction 
3 x 3 0.4 0.5 0.4 0.3 
10 x 10 -0.2 -0.2 0.4 0.4 
20 x 20 -0.2 -0.6 -0.4 -0.5 
40 x 40 -0.5 0.2 -0.5 0.0 
 
Square 
field size 
(cm2) 
 Difference from CFF 
Field size compared to 
UFFF at depth of 20cm in 
water (mm) 
Difference from CFF 
Field size compared to 
MFFF at depth of 20cm 
in water(mm) 
 Jaw 
Direction 
MLC 
Direction 
Jaw 
Direction 
MLC 
direction 
3 x 3  -0.5 0.2 -0.4 0.0 
10 x 10  0.5 -0.1 0.1 -0.4 
20 x 20  -0.2 0.1 0.3 0.0 
40 x 40  1.6 1.5 1.0 1.0 
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The shape of the profile can be adjusted by changing the ratio of bending coarse and bending 
fine currents. The bending coarse value affects the energy selection of the bending magnet 
system whilst the bending fine affects the position that the beam strikes the target. By altering 
the ratio of these values, the angle at which the electron beam strikes the target can be altered. 
This can be used to broaden or narrow the forward bias of the bremsstrahlung having the effect 
of producing a flatter (lower energy) or more peaked (higher energy) profile whilst having a 
minimal impact on the PDD. 
After measuring the beam energy it is important to ensure that the beam steering is within 
tolerance for both the symmetry and CAX position as the latter can be altered when adjusting 
beam energy. 
The method of normalising the inflection points of the FFF profiles has been discussed by 
previous authors (Fogliata et al., 2016a; Georg et al., 2011; Fogliata et al., 2012b; Ponisch et al., 
2006). However the method used has been to normalise against a cFF profile so that the 
penumbras can be measured, whereas the approach and results presented here are from 
normalising the inflection points to a fixed value. The results show that normalising to a nominal 
55% value results in measured differences in penumbra of less than 0.5mm for both FFF and cFF 
beams (Figure 21, Table 6). It is therefore suggested that this method could be utilised for all 
types of MV photon radiation beams. As the technique does not need reference to any other 
beam, it can be applied to FFF beams without the need to measure a linked cFF beam, or where 
no such cFF beam is provided.  
The field size of FFF beams and of cFF beams can be determined by normalising the inflection 
point to 55% and then measuring field size between the same 50% of maximum dose points, as 
in currently used methods (Figure 21). This produces a measure of field size that is within 0.6mm 
of the field size measured using 50% maximum of a flat beam for all field sizes with the exception 
of 40cm x 40cm at 20cm deep. This new definition could be used to define field size for all types 
of MV radiation beam (Table 7). 
The methods have only been applied to matched FFF beams implemented on Elekta Linacs and 
further work is required to determine their suitability for unmatched FFF beams produced by 
other manufacturers. However, with the consistency demonstrated between matched FFF and 
unmatched FFF beams, it is anticipated that the methods described would be applicable to other 
manufacturers’ unmatched FFF beams. 
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4.5. Conclusion 
The purpose of this chapter was to address the research question “Can suitable definitions be 
determined in order to characterise and QA all radiotherapy photon beams, cFF and both 
implementations of FFF?”. The finding of this chapter are such that new proposed methods are 
presented that make it possible to independently carry out characterisation, set up and QA 
measurements on beam energy, flatness, symmetry and field size of an FFF beam without the 
requirement for an equivalent cFF beam of the same energy. The methods proposed can also 
be used to carry out this QA for cFF beams, resulting in universal definitions and methods for 
MV beams. This is presented for matched FFF beams such as those produced by an Elekta linear 
accelerator, but is anticipated to apply to unmatched FFF beams produced by other 
manufacturers’.  
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5. Monte Carlo modelling of an FFF Linac with energy 
matching 
5.1. Introduction 
Monte Carlo modelling can be a powerful tool in the assessment of parameters that are 
otherwise difficult to measure experimentally. Monte Carlo models have previously been 
produced for clinical Linacs with FFF beams. In these models, the flattening filter component has 
been removed from an existing benchmarked Monte Carlo model of a Varian linear accelerator, 
delivering a conventionally flattened beam (cFF) (Dalaryd et al., 2010, Xiong and Rogers, 2008, 
Ceberg et al., 2010). However, other implementations of FFF beams , e.g. as supported on the 
VersaHD (Elekta AB, Sweden), include modification of the beam energy. For example, the FFF 
depth-dose beam characteristics at 10cm depth can be matched with the original cFF beam with 
a 10cm x 10cm field in water. This chapter investigates with a Monte Carlo model the techniques 
that can be used to aid matching that are analogous to practical investigations into the effect of 
beam focussing on the beam-shape characteristics of FFF beams (Paynter et al., 2017). 
5.2. Producing the MC model 
All Monte Carlo simulations for this work were performed with the Electron Gamma Shower 
(EGSnrc) user code supplied by the National Research Council Canada (Rogers, D.W.O et al., 
2015). The BEAMnrc user code addition to EGSnrc contains predefined geometries that aid in 
the simulation of radiotherapy Linacs. The beams were simulated to be incident upon a 40cm x 
40cm x 40cm water phantom using the Dosxyz user code (Walters et al., 2015) addition to 
EGS/BEAMnrc. This simulates the conditions of measuring data within a water filled plotting tank. 
5.2.1. Measured data 
In order to develop a Monte Carlo model that can be used for investigations, accurate measured 
data is required to validate the modelled beams. Therefore, beam data was measured at 
standard reference conditions, with a Source-to-surface  distance (SSD) of 100cm in an MP3-M 
plotting tank (PTW, Freiburg). A PTW 60008 photon diode was used in order to reduce the 
volume averaging effect when measuring the profiles and for increased resolution in the 
penumbra region (Metcalfe et al., 1993). Silicon diodes over-respond to low energy scatter and 
therefore are not suitable for Percentage Depth-Dose (PDD) measurements. Therefore, the 
PDDs were measured using a PTW 31010 semiflex ion chamber at a measurement increment of 
1mm. 
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5.2.2. Geometry 
EGS/BEAMnrc contain a number of pre-defined geometries that can be customised to model a 
specific Linac. The geometries used for modelling the Elekta synergy accelerator with an Agility 
head were FLATFILT, SLABS, MIRROR, MLCE and MLCQ. These will be described in more detail 
below. The geometry of the linear accelerator was modelled in EGS/BEAMnrc using technical 
diagrams and specifications provided by Elekta (Elekta AB, Sweden) as part of a non-disclosure 
research agreement.  
The FLATFILT component module was used to model the x-ray target, primary collimator, 
flattening filter and ion chamber. It was selected for these components as it is a flexible module 
that can be used to model both simple and complex geometries composed of multiple materials. 
This is achieved by creating stacked, truncated co-axial cones of which the user can define the 
radius at the top and bottom of each section. The complexity of these component modules 
varied. For example, the ion chamber was constructed of 21 layers, each of which contained up 
to 3 cones (Figure 22). The filter plate consisted of a single layer.  
 
Figure 22: Diagram of the modelled ionisation chamber in the linear accelerator, this 
component was constructed of 21layers with up to 3 cones. 
 
The SLABS component module allows the user to specify uniform layers of materials of varying 
thickness. It was used to model the backplate for the ion chamber and the exit-window of the 
Linac head.  
The MIRROR component module was used to model the field lamp mirror, an angled mirror 
found in Linacs to project a light-field that is co-incident with the radiation field. 
The MLCE component module allows the modelling of MLC leaves with curved ends, and a step 
rather than tongue and groove design. It was used for modelling the 180 leaf collimator in the 
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Agility head. The sides of each leaf in the leaf bank can be angled perpendicular to its direction 
of travel so that it focuses at a specific point within the accelerator head that does not match 
the beam divergence. By focussing the leaves like this, interleaf leakage is reduced without the 
need for ‘tongue-and-groove’ leaf edge design. The Agility head has diaphragms, or ‘jaws’, blocks 
of tungsten that provide bulk shielding of the radiation beam these are orthogonal to the MLC 
leaves. These  have a curved end to define the beam edge rather than focussed as in previous 
Elekta Linacs (Cosgrove et al., 2009). For this reason the jaws were most conveniently modelled 
as two very large leaves with the MLCQ component module. This module allows the modelling 
of curved jaw ends without the additional focussing or step of the MLCE module.  
The interaction cross-sections used for the materials were from the 700icru pegs file provided 
as part of the EGS/BEAMnrc package. The pegs file includes the interaction cross-section data 
for the component materials modelled in the linear accelerator. The 700 denotes the minimum 
energy in keV that the electron interactions will be modelled. The photon cross section data 
extends down to a minimum energy of 10keV. The areas not specified in the model were 
considered to be air (a predefined material in the pegs file). A schematic of the modelled 
accelerator is shown in Figure 23. 
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Figure 23: Figure of linear accelerator head as modelled in EGS/BEAMnrc 
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5.2.4. PDD and profile calculation 
The PDD and profiles produced with the Monte Carlo model were calculated in the DOSXYZnrc 
user code. The phantom simulated in this code was a 40cm x 40cm x 40cm water box surrounded 
by air. The phantom was split so that profiles could be obtained at depths of dmax, 5cm, 10cm, 
and 20cm. The areas between these ‘scoring layers’ were modelled as larger voxels to increase 
calculation efficiency. This is achieved by having the parameter HOWFARLESS on in the user code. 
HOWFARLESS stops modelling the path of an electron or photon if it does not have sufficient 
energy to escape its current scoring voxel and deposits its entire remaining energy in that voxel. 
For each calculation a full BEAMnrc simulation was used as the source, this method negates the 
need to calculate a phase space file of the particle fluence at the end of the accelerator and 
instead tracks particles from striking the target though the accelerator into the phantom to 
produce the required histories for the measurement. Profiles and PDDs were calculated with a 
2mm resolution. The number of histories modelled into the water phantom for a PDD and profile 
was 6104000000. Directional bremsstrahlung splitting was used so that bremsstrahlung photons 
traveling in a direction that would be within a radius 1.5 times the field size from the isocentre 
are split 2000 times to reduce the calculation time. The number of histories used was selected 
to result in a local error on the Monte Carlo profiles of 0.3% inside the field and 3% outside the 
field for a field size 10cm x 10cm at 100SSD and at a depth of dmax.  
5.2.5. Benchmarking 
In order to benchmark the Monte Carlo profiles against the measured data a graphical user 
interface (GUI) was written in Matlab that normalised and displayed the plotting tank data 
against the profiles extracted from the Dosxyz Monte Carlo files. The GUI was designed to extract 
the field size and determine the penumbra using the methods proposed in chapter 4. The two 
profiles could also be compared with a 1D global gamma analysis (Low et al., 1998) that 
highlights the regions of the profile that exceed a global 1%, 1mm tolerance. 
5.2.6. Electron beam characteristics 
In order to model the FFF beam produced by the accelerator, an appropriate electron beam 
incident on the target must be defined. The characteristics of the electron beam can 
substantially influence the characteristics of the photon beam exiting the accelerator (Sheikh-
Bagheri and Rogers, 2002). EGS/BEAMnrc has a number of pre-defined source models that can 
be modified by the user to produce the required electron beam characteristics. The source used 
for this work was ISOURC=19 an electron beam striking the target with a Gaussian distribution 
in X and Y, parallel or with angular spread. This source can be circular or elliptical in shape. The 
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source requires that both spectra parameters and geometric factors need to be set in order to 
model the electron beam striking the target.  
The energy spectrum of the electron beam was iteratively altered in order to produce PDDs that 
matched the measured data collected on the linear accelerator. This was performed with a field 
size of 10cm x 10cm at 100cm source to surface distance (SSD).Once a good match to the PDD 
at this field size was obtained, additional field sizes ranging from 3cm x 3cm to 20cm x 20cm 
were modelled and compared to measured data. 
The dimensions of the focal spot for the electron beam were investigated in order to match the 
measured penumbra of the photon beam profiles. The focal spot is the physical location that 
the electron beam strikes the target. The focussing of the focal spot is determined by the 
electron beam transport system in the Linac. The full width half maximum (FWHM) parameters 
that define the physical size of the electron beam were iteratively adjusted in both the MLC leaf 
and jaw directions in order to obtain the best match of penumbra across the previously defined 
range of field sizes. These parameters affect the penumbra of the photon beam and need to be 
modelled correctly in order to match measured data (Sheikh-Bagheri and Rogers, 2002). 
The ISOURC=19 source can model the electron beam striking the target in parallel or with the 
electrons striking the target with a mean angular spread (Figure 24) (Paynter et al., 2017). 
 
Figure 24: Diagram of angular spread parameter for Monte Carlo modelling 
5.2.7. Field size calibration 
Field sizes were defined in the model, from 3cm x 3cm up to a maximum of 20cm x 20cm. For 
each field size, the Monte Carlo profile data were compared to the measured data. The MLC and 
jaw aperture size in the Monte Carlo model was iteratively adjusted to match the measured field 
size. The final Monte Carlo aperture settings that matched the field size of the measured profiles 
were used to create a calibration for the jaw and MLC settings that would predict the required 
aperture size within the Linac head to produce the required field size at isocentre. 
 Focal spot 
Angular spread 
e
-
 
e
-
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5.3. Results 
5.3.1. Electron beam characteristics  
The electron beam energy was iteratively adjusted from 6MeV to 8MeV, with varying 
increments in order to match the measured PDD. Iteratively changing the energy of the incident 
electron beam on the target affects both the beam profile and PDD dose distributions. Therefore, 
modifying this single parameter will either achieve matching of the profile or the PDD for a given 
6MV FFF beam. Figure 25 demonstrates the impact of electron beam energy on the profile shape 
and PDD. 
However, it was found that by changing the angular divergence of the electron beam on the 
target, the profiles can be further optimised without altering the associated PDD. Once an 
acceptable PDD match was obtained, the angular divergence of the electron beam striking the 
target was iteratively adjusted, starting from 0°, i.e.  (an electron beam with all the electrons 
travelling parallel to each other), to an angular divergence of 2°.The iterative analysis indicated 
a Gaussian energy distribution around 8MeV provides an acceptable PDD distribution for a 
matched 6MV FFF beam on a Versa HD linear accelerator with an angular divergence of 1.3° 
(Figure 26). 
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Figure 25: Impact of nominal accelerating potential on a 20cm x 20cm profile shape 
(above) at 100cm SSD and a depth of maximum dose in water and a 10cm x 10cm PDD at 
100cm SSD (below). 
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Figure 26: Impact of angular spread parameter on a 20cm x 20cm profile shape (above) at 
100cm SSD and a depth of maximum dose in water and a 10cm x 10cm PDD at 100cm 
SSD (below). 
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The focal spot size was systematically altered from a circle of full width half maximum of 0.1cm 
in both the MLC and jaw directions. The best match to measured data was found to be with an 
elliptical spot size of 0.17cm in the MLC direction and 0.08cm in the jaws direction. The results 
for the MLC penumbra investigations are shown in Table 8. 
Table 8: The relationship between the focal spot size of the electron beam and the profile 
penumbra in the direction of the MLCs. 
Focal 
spot 
size 
(cm) 
Calculated 
penumbra (mm) 
Difference 
from 
measured 
penumbra 
(mm) 
0.14 4.3 0.2 
0.18 4.8 -0.3 
0.16 4.3 0.2 
0.17 4.55 -0.05 
 
5.3.2. Field size calibration 
The relationship between the distance the jaw needs to be retracted to form the aperture at the 
level of the aperture in order to match measured data at isocentre is displayed in Figure 27. The 
relationship can be fitted with a power relationship to predict the required move in the Monte 
Carlo model to achieve a 1cm change in field size at isocentre (Equation 7). 
Equation 7: 𝒚 = 𝟎. 𝟒𝟑𝟕𝟓𝒙𝟏.𝟎𝟑𝟕𝟒 
Where y is the aperture size and x is the required distance from the central axis. 
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Figure 27: The relationship between the required move of the jaw in the model in to move 
1cm at isocentre with respect to field size. 
 
A plot of the relationship between the distance moved at the level of the aperture by the MLC 
in the model and the radiation field size, as defined at isocentre is displayed in Figure 
28(Equation 8).  
Equation 8: 𝒚 = 𝟎. 𝟑𝟐𝟖𝟑𝒙𝟏.𝟎𝟑𝟓𝟔 
Where y is the aperture size and x is the required distance from the central axis. 
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Figure 28: The relationship between the required move of the mlc in the model in to move 
1cm at isocentre with respect to field size. 
 
For each of the relationships a fit was produced that could be used to determine the location of 
the MLC/Jaw from the central axis without the need to iteratively adjust to match with measured 
data. The predicted location based on the fit with the residual error in field size is shown in Table 
9 for the jaw location and Table 10 for the MLC location. 
Table 9: The calibration for the jaw aperture size to match measured data at isocentre. 
Location from 
central axis (cm) 1.5 2.5 5 7.5 10 
Required aperture 
location (cm) 0.6630 1.1370 2.3385 3.5265 4.7580 
Predicted aperture 
location (cm) 0.6663 1.1319 2.3232 3.5381 4.7685 
Error in predicted 
field size (mm) 0.07 -0.11 -0.33 0.25 0.22 
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Table 10: The calibration for the MLC aperture size to match measured data at isocentre 
Location from 
central axis (cm) 1.5 2.5 5 7.5 10 
Required aperture 
location (cm) 0.4976 0.8533 1.7350 2.6445 3.5610 
Predicted aperture 
location (cm) 0.4996 0.8480 1.7383 2.6454 3.5635 
Error in predicted 
field size (mm) 0.06 -0.16 0.09 0.02 0.07 
 
For each fit the predicted movement would result in a field-size error at isocentre of less than 
0.5mm. 
5.3.3. Benchmarking 
The investigations above demonstrated the most appropriate electron beam parameters 
needed to match measured data were a Gaussian energy distribution centred on 8 MeV with an 
angular divergence of 1.3°. Using these parameters the Monte Carlo calculated data was 
compared to the measured data at a range of field sizes. The calculations were performed on 
the ‘Medical Advanced Research Computer 1’ cluster (University of Leeds). Each benchmarking 
calculation took 1247hrs of CPU time (3days real time), this time was reduced by completing the 
calculations in parallel utilising multiple CPU cores at once.  
In Figure 29, the benchmarked profiles show good agreement of both field size, penumbra and 
in field dose. The gamma failures greater than a global 1%/1mm are in the region of the out of 
field dose and noise in the Monte Carlo calculated profiles at depth. 
Figure 30 shows the benchmarking of a 20cm x 20cm field.  The failures of the global 1%/1mm 
gamma analysis criteria are as a result of noise in the Monte Carlo profiles. The out of field doses 
meet the gamma analysis criteria. 
Figure 31 shows the benchmarking results of the 3cm x 3cm field, the gamma failures are in the 
region of the out of field doses with the field size, penumbra and infield dose meeting the 
1%/1mm criteria. 
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Figure 29: Benchmarking results for the 10cm x 10cm Monte Carlo calculated profiles (blue) against measured data profiles (red). The red circles mark 
where the difference between the profiles is greater than a global 1%/1mm gamma tolerance. The displayed profiles are (a) at a depth of maximum dose 
collimated by the jaws (b) at a depth of maximum dose collimated by the MLC (c) at a depth of 20cm collimated by the jaws (d) at a depth of 20cm 
collimated by the MLC. 
a b 
c d 
87 
 
 
 
Figure 30: Benchmarking results for the 20cm x 20cm Monte Carlo calculated profiles (blue) against measured data profiles (red). The red circles mark 
where the difference between the profiles is greater than a global 1%/1mm gamma tolerance. The displayed profiles are (a) at a depth of maximum dose 
collimated by the jaws (b) at a depth of maximum dose collimated by the MLC (c) at a depth of 20cm collimated by the jaws (d) at a depth of 20cm 
collimated by the MLC.
a b 
c d 
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Figure 31: Benchmarking results for the 3cm x 3cm Monte Carlo calculated profiles (blue) against measured data profiles (red). The red circles mark 
where the difference between the profiles are greater than a global 1%/1mm gamma tolerance. The displayed profiles are (a) at a depth of maximum dose 
collimated by the jaws (b) at a depth of maximum dose collimated by the MLC (c) at a depth of 20cm collimated by the jaws (d) at a depth of 20cm 
collimated by the MLC.
a b 
c d 
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Figure 32: A 3cm x 3cm field calculated (blue) 10cm offset from the central axis in the 
MLC direction compared to measured data (red) at 100cm SSD and a depth of maximum 
dose in water. 
 
Figure 32 shows a 3cm x 3cm field calculated 10cm off the beam central axis and compared to 
an equivalent measured profile. The in-field and penumbra match show good agreement with 
measured data. The out of field dose discrepancy is consistent with the on-axis 3cm x 3cm 
profiles. 
5.3.3.1. Out of field doseː investigation of model parameters 
The benchmarking results demonstrated that the model had less agreement with 
measurements for the out of field dose for small field sizes. Further investigations were 
performed in order to help in determining the cause of this discrepancy and improve the Monte 
Carlo model. The parameters systematically adjusted to investigate this discrepancy were the 
thickness of the primary collimator, the thickness of the filter plate and the minimum electron 
energy modelled in the Monte Carlo simulation. The depth selected for these investigations was 
a depth in water of 10cm, which was selected as the mid-point between the dmax 
measurements and 20cm measurements in the benchmarking and to eliminate any uncertainty 
at performing the measurements at dmax. The same behaviour was observed for profiles 
90 
 
collimated by the jaws and the MLCs therefore the investigations were performed with the field 
collimated by the jaws only. 
 
Figure 33: A benchmarked 3cm x 3cm Monte Carlo profile collimated by the jaws with the 
thickness of the primary collimator increased. 
 
Figure 33: Shows that adjusting the primary collimator thickness in the MC model from the 
original 12.0cm thickness to 12.1cm to reduce the out of field dose had a negligible impact on 
the benchmarking of a 3cm x 3cm field at a depth of 10cm. 
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Figure 34: The impact or increasing and decreasing the thickness of the filter plate on the 
out of field dose 
 
Figure 34 shows that by both increasing and decreasing the thickness of the filter plate by 0.5mm 
the impact on the profiles is negligible and is not the source of the out of field discrepancy. 
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Figure 35: The impact of changing the electron transport cutoff energy on the out of field 
dose (above) comparing the cutoff energies of 512keV and 700keV (below) comparing the 
512keV Monte Carlo profile against measured data. 
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Figure 35 shows that by modelling lower energy electrons the out of field dose decreases relative 
to the infield dose. This reduction was not significant enough to impact on the benchmarking to 
measured data. 
The out of field dose near the field-edge is related to the transmission of the radiation through 
the leaf/jaw tips. Both the leaves and jaw tips in the Agility head are curved and therefore the 
effect of reducing this curvature to the extreme where the jaws have a straight edge was 
modelled. This altered the penumbra of the beam but did not affect the out of field dose (Figure 
36). 
 
Figure 36: Comparison of Monte Carlo calculated profile with straight jaw edge (blue) 
compared to measured data (red). 
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Figure 37:  Profiles measured with semiflex3D (red) compared to Monte Carlo (blue) for field sizes of 3cm x 3cm (upper) and 10cm x 10cm (lower) at the 
depth of maximum dose (left) and at 20cm deep (right). 
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In order to determine whether the discrepancies observed were as a result of the original diode 
profile measurements performed on the Linac, further measurements were performed with a 
semiflex3D (PTW, Freiberg), a small ionisation chamber with active volume of 0.07cm3. The 
comparisons (Figure 37) demonstrate that the measurements are not the source of the 
discrepancy. The semiflex3D measurements were performed so that the profiles extended 
further from the field edge. The agreement improves further out of field. This highlighted that 
the leaf/jaw tip modelling could be the cause of the issue. 
5.3.3.2. Out of field dose: Investigation of back-up collimation 
settings. 
Later detailed discussion of the results with the thesis assessors then prompted a re-
investigation of any other likely causes of the out-of-field dose differences, including going back 
to the basic Linac settings in the model.   A discrepancy was discovered in the Monte Carlo model. 
This discrepancy relates to the position of the MLCs out of the field. In the model described 
previously in this chapter the MLC leaves not being used to shape any field did not appropriately 
close when positioned underneath the jaw (Figure 38). They remained set at the nominal field 
size, resulting in extra transmission and scatter dose out of field.   The result of this would be 
that modelled beams have higher doses out of field than measured, as seen in the profile figures 
earlier in section 5.3.3  and that these effects would be proportionally greater in small fields, as 
also observed.   A series of further simulations were performed with those leaves appropriately 
closed underneath the jaw to evaluate this effect in detail. 
 
Figure 38: Back-up collimation settings (a) original model (b) corrected model 
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Figure 39: Benchmarking results for the 3cm x 3cm Monte Carlo calculated profiles (blue) 
against measured data profiles (red) at 100cm SSD. The red circles mark where the 
difference between the profiles are greater than a global 1%/1mm gamma tolerance. The 
displayed profiles are (above) at a depth of 10cm in water collimated by the jaws (below) 
at a depth of 10cm in water collimated by the MLC. 
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Figure 40: Benchmarking results for the 10cm x 10cm Monte Carlo calculated profiles 
(blue) against measured data profiles (red) at 100cm SSD. The red circles mark where the 
difference between the profiles are greater than a global 1%/1mm gamma tolerance. The 
displayed profiles are (above) at a depth of 10cm in water collimated by the jaws (below) 
at a depth of 10cm in water collimated by the MLC. 
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Figure 41: Benchmarking results for the 20cm x 20cm Monte Carlo calculated profiles 
(blue) against measured data profiles (red) at 100cm SSD. The red circles mark where the 
difference between the profiles are greater than a global 1%/1mm gamma tolerance. The 
displayed profiles are (above) at a depth of 10cm in water collimated by the jaws (below) 
at a depth of 10cm in water collimated by the MLC. 
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Figure 39 shows that for the 3cm x 3cm field the new Monte Carlo simulation slightly 
underestimates the dose in the direction collimated by the jaws with excellent agreement with 
the measured data in the MLC direction. There are no significant areas where the Monte Carlo 
fails the gamma analysis criteria of 1%/1mm. 
Figure 40 shows that for the 10cm x 10cm field the updated Monte Carlo simulations 
underestimates the out of field dose in the jaw direction, by around 1.5% at the limits of the 
measured profile and has good agreement in the MLC direction. The failures present in the out 
of fields in the MLC direction are not significant as they are caused by an interpolation error in 
the analysis software.  
Figure 41 shows that for the 20cm x 20cm field the Monte Carlo simulations show good 
agreement with the measurements in both the jaw and MLC collimated directions. 
5.4. Discussion 
The change in shape of the profiles with respect to energy is a result of the conservation of 
momentum increasing the forward bias of the bremsstrahlung when moving to higher energies. 
However, by changing the divergence of the beam on the target this forward bias can also be 
modified so that it is distributed more evenly around the central axis, resulting in a profile shape 
that is comparable to that of a lower energy beam. A beam divergence on the target of 1.3° was 
found to best match the measured profile data across the range of clinical field sizes. Reducing 
the energy to match the profile would reduce in a larger discrepancy to the match in the PDD. 
From Figure 26 it can be seen that this angular divergence does not have a significant effect on 
the out of field dose. Conversely previous studies on Monte Carlo simulations of cFF beams have 
shown insignificant impact of the electron beam divergence on profile shapes and so this 
parameter is often neglected when modelling MV beams (Sheikh-Bagheri and Rogers, 2002). 
One previous study postulated that by producing a beam with an extremely large divergence a 
fully flat beam could be produced (Tsiamas et al., 2011). 
The beam divergence parameter is analogous to the bending currents that are used in practice 
to adjust the beam steering (Paynter et al., 2017). In this work, the bending coarse value of the 
bending magnet system was found to affect the energy selection of the incident electron beam. 
However, the bending fine current affects the position that the beam strikes the target. By 
altering the ratio of these values, the divergence of the electron beam striking the target can be 
altered. This can be used to broaden or narrow the forward bias of the bremsstrahlung, having 
the effect of producing a flatter (lower energy) or more peaked (higher energy) profile whilst 
having a minimal impact on the PDD. 
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The size of electron spot on the target was determined to be elliptical with dimensions of 0.08cm 
by 0.17cm; this size provided the best matching of the penumbra for the range of field sizes from 
3cm x 3cm to 20cm x 20cm. These dimensions are comparable to the range of dimensions 
reported by other authors (Sham et al., 2008) with the elliptical shape reported by previous 
Monte Carlo models of Elekta machines (Almberg et al., 2012). 
The fitting of the plots for the field-size calibration in the Monte Carlo model is such that the 
predicted movement of the leaves and jaws in the Monte Carlo model produces a field size that 
matches the measured data within 0.2mm for the MLCs and within 0.4mm for the jaws. This 
matching meets the required gamma analysis criteria for the benchmarking performed in this 
work and would meet the recommendations for radiotherapy planning system performance 
tolerances as defined in IPEM81 (IPEM, 2018). 
The out of field doses in the Monte Carlo calculations were initially observed to be higher than 
the measured doses for field-sizes less than 20cm x 20cm. A number of parameters were 
investigated to attempt to locate the source of this difference. As the dose increase was 
observed in both the inplane direction (collimated by the jaws) and the cross-plane (collimated 
by the MLCs, the investigations focussed on geometric parameters that were independent of 
the jaws and MLCs such as the thickness of the primary collimation system and of the filter plate 
that replaces the flattening filter in FFF machines. These investigations showed that the 
thickness had an insignificant effect on the out of field dose in the Monte Carlo calculations. 
These parameters were investigated as they would alter the amount of scatter radiation within 
the treatment head that could lead to increased leakage radiation as demonstrated by the 
reduction of out of field dose when the flattening filter is removed (Murray et al., 2015; Paynter 
et al., 2014). 
The cut-off energy for the electron transport in the Monte Carlo was also investigated to 
determine if the error was caused by the Monte Carlo calculation properties rather than the 
geometry. By reducing the cut-off energy from 700keV to 512keV lower energy electrons would 
be modelled reaching the phantom, as FFF beams have a wider spectrum of energy as a result 
of the removal of the hardening effect of the flattening filter. The reduction in this cut-off energy 
showed an improvement in the out of field dose but the reduction was not significant enough 
to remove the discrepancy from the measured dose. The mechanism for this improvement is 
that the lower energy electrons would reach the open portion of the beam and increase the 
infield dose proportionally more than the out of field dose having the effect of reducing the 
relative out of field dose in comparison to the infield dose.  
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Following later discussions, additional modelling was performed as in section 5.3.3.2. In the 
original model (results discussed in section 5.3.3.1) the out of field MLC leaves were positioned 
at the nominal separation for the required field size across the full leaf bank. It was not originally 
thought that this would have a significant impact on the out of field dose when investigating 
profiles in the MLC direction, as the reduction in transmission through the jaw would have been 
of the order of 0.24% more (Thompson et al., 2014) with the MLCs fully closed over the jaw. 
However, the results of the newer full simulations with the MLCs closed behind the jaws show 
excellent agreement with the measured data and reduce the out of field dose by more than the 
expected amount. By further collimating the beam in these simulations the scattered radiation 
in the treatment head is reduced and can no longer contribute to the out of field dose. With the 
leaves fully closed the out of field dose in the jaw direction is reduced more than required 
resulting in some small gamma failures (at the 1%/1mm level) in that direction. The differences 
between the original model and the new model in this out of field region increase as the field 
size decreases. This is due to the measured profiles of larger field sizes receiving a greater 
contribution from head scatter than smaller field sizes. This explains why the change in the 20cm 
x 20cm profile is not as significant as the 3cm x 3cm profile. With the majority of the 
benchmarking showing that the Monte Carlo profile matches the measured profile using the 
1%/1mm gamma criteria, the model is now considered accurate enough for further Monte Carlo 
investigations.  
5.5. Conclusion 
The modelling of FFF beams with Monte Carlo in EGS/BEAMnrc is possible with the appropriate 
technical information provided by the vendor. The relationship between the field size and the 
movement of the jaws and MLCs is not linear and therefore needs to be characterised in order 
to be able to model more complex field shapes. When modelling FFF beams in Monte Carlo, the 
divergence of the electron beam at the point of striking the target is a useful parameter to help 
achieve a realistic model of the incident electron beam on the x-ray target, with a match for 
both PDD and beam profile distributions. The divergence of the electron beam on the target has 
minimal impact on the PDD, so once a Gaussian distributed beam energy has been found to 
produce appropriate PDDs for the clinical range of field sizes, the profile shapes can be further 
optimised using the divergence parameter. The out of field doses in the original model were not 
in agreement with measurements for the smaller field sizes and this was investigated by 
changing a series of model parameters. Further investigations into the model located a 
discrepancy in the modelled positions of the MLC leaves outside of the field. Running additional 
simulations with these positions corrected improved the model so that it could now be used for 
further investigations. The completed model will be used to investigate the out of field dose for 
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matched FFF beams as previously investigated by Kry et al. (2010) for unmatched FFF beams. 
The full Monte Carlo simulation will also be compared to the fast Monte Carlo algorithms used 
in clinically available treatment planning systems in order to benchmark them. The model can 
also be used to further investigate the out of field doses at a distance to investigate additional 
treatment sites to the prostate as investigated by Murray et al. (2015). 
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6. Pre-Clinical evaluation of matched FFF treatments 
on Elekta Linacs 
6.1. Introduction 
FFF beams have been proposed as a method of external beam radiotherapy treatment delivery 
that could decrease the time for hypofractionated treatments, particularly stereotactic ablative 
body radiotherapy (SABR). The smaller field-sizes generally required for the PTVs encountered 
for this type of treatment (Consortium, 2016) results in the FFF beam profiles closely matching 
those of cFF beams, with the advantage of an increased doserate over the target and reduced 
dose outside of the treated area (Murray et al., 2015). Also, in general, PTV volumes are often 
not that irregular in shape, therefore, low levels of beam modulation are only likely to be 
required, leading to fast, efficient treatment deliveries.  
The work contained in this chapter was novel at the time of completion and was presented as a 
poster presentation at ESTRO (Paynter et al., 2013) and also as an oral presentation at the IPEM 
FFF meeting (Paynter, 2014). 
6.2. FFF beams for hypofractionated SABR  treatments for lung 
and other sites 
6.2.1. SABR lung fractionations 
The hypofractionated regimes investigated for this work are 54Gy in 3 fractions, 55Gy and 5 
fractions and 60Gy in 8 fractions. The fractionation regimen is determined by the location of the 
GTV within the lung. The 54Gy in 3 fraction regimen with the highest dose per fraction is used 
for GTVs that are not attached to the chest wall or in close proximity to any other OARs. The 
55Gy in 5 fractions is used for when the GTV is attached to the chest wall. The 60Gy in 8 fraction 
regimen is used for when there are OARs in close proximity to the GTV. 
6.2.2. Method 
To determine whether there are efficiency or dosimetric advantages when using FFF beams for 
SABR lung treatments, FFF VMAT plans were compared to the current standard of care, i.e. 3-
dimensional conformal radiotherapy (3DCRT), as well as cFF VMAT plans. Five lung radiotherapy 
patients who had previously received 55Gy in 5 fractions SABR treatments were selected. 
Patients were selected to cover a range of PTV sizes and locations within the lung. They were 
originally, planned on CMS Xio v4.33 with 7-beam 3DCRT treatments on an Elekta SynergyTM 
linear accelerator equipped with an MLCi2 head. Each of these patients was planned on a 2mm 
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dose grid with the superposition algorithm (Miften et al., 2000). The 3DCRT plans were planned 
with a midline isocentre with 7 beams typically equally spaced around the patient. A midline 
isocentre places the treatment isocentre at the centre of the patient both left-right and 
anteriorly-posteriorly treating the target volume off axis. This minimises the risk of collisions 
between the Linac head and/or XVI imaging system and the patient or treatment couch.  
3DCRT beam orientations could be adjusted, if required, to facilitate OAR sparing. In cases where 
OAR sparing is difficult to achieve with this arrangement non-coplanar beams could be added 
(Hallemeier et al., 2013). 
These patients were re-planned in Monaco v3.2 using a 2mm dose grid and a 1% Monte Carlo 
variance per plan, on an Elekta Synergy linear accelerator equipped with an Agility head using a 
VMAT technique with a cFF 6MV beam. Further plans were produced in Monaco v3.3 using the 
same VMAT technique but with a 6MV FFF beam.  
The VMAT plans used a 200° arc, also with a midline isocentre. Some specific details as to how 
the plans were defined within the Monaco planning system are as follows. For the fluence 
optimisation, VMAT arcs were calculated with angle increments of 5°. The minimum segment 
width was set at 1cm. The VMAT plans consisted of an IMRT prescription using the target penalty 
cost function, set to cover 95% of the PTV with 55Gy.To constrain hot spots within the PTV, a 
quadratic overdose cost function was used on the PTV with a reference level of 65Gy and a Root 
Mean Squared (RMS) excess over this value allowed of 1Gy. The dose was kept conformal by 
using the ‘conformality cost function’, acting on the patient and with two quadratic overdose 
functions. These functions were set at 54Gy, with an RMS of 0.1Gy, with a 0cm ‘shrink margin’ 
and a 24Gy quadratic overdose cost function with an RMS of 0.25Gy and a shrink margin of 2cm. 
A shrink margin within the Monaco TPS restricts the area that the cost function applies to a user 
specified distance from any higher priority target structure. For example, the patient cost 
function with a 2cm shrink margin applies 2cm away from the PTV. When planning the patients, 
the RMS values and conformity iso-constraint were iteratively reduced or increased in order to 
produce the most optimum plan. However, the reference levels, which are the point from which 
the RMS is calculated, were left unchanged as is the practice at this centre. 
The plan quality was compared using dose constraint criteria from the UK SABR consortium 
guidelines (Consortium, 2016), based on constraints from the ROSEL trial (Hurkmans et al., 2009). 
Treatment delivery times were also compared. The consortium guidelines contain constraints to 
control the conformality of the treatment plans that change depending on the size of the target 
volume; these are described in Table 11. 
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Table 11: Description of conformality constraints for lung SABR treatments. 
Constraint Description Effect on constraint of 
increasing target volume 
R100 The ratio of the volume covered by the 100% 
isodose to the volume of PTV 
As the volume of the PTV 
increases the constraint 
decreases 
R50 The ratio of the volume covered by the 50% 
isodose to the volume of the PTV 
As the volume of the PTV 
increases the constraint 
decreases 
D2cm The maximum dose 2cm away from the PTV As the volume of the PTV 
increases the constraint 
increases 
L_V20 The volume of lung minus the volume of GTV 
receiving 20Gy expressed as a percentage 
As the volume of the PTV 
increases the constraint 
increases 
 
A further 3 lung patients were retrospectively re-planned using a 54Gy in 3 fraction treatment 
regimen. The IMRT prescription cost function reference levels and starting iso-constraint values 
for these patients were: target penalty set to 54Gy, with the quadratic overdose, to constrain 
hotspots, set with a reference level of 67.5Gy and an RMS of 1Gy. The quadratic overdoses used 
to maintain conformality were 44Gy with an RMS of 0.2Gy and 23Gy with an RMS of 0.2Gy. 
The most technically challenging lung SABR plans are planned with a fractionation of 60Gy in 8 
fractions. Due to the variability of these plans, 8 patients were retrospectively planned for this 
work. Patients were selected to cover a range of PTV positions with different OARs in proximity 
to the PTV. The PTV quadratic overdose was set with a reference level of 75Gy and an RMS of 
1Gy, the conformality overdoses were set at 50Gy with an RMS of 0.4Gy and 25Gy with an RMS 
of 0.4Gy.Where maintaining a conformal dose distribution was not sufficient to meet OAR 
constraints, additional cost functions were added to the IMRT prescription as a serial cost 
function with a ‘k’ value of 14 and a reference dose of 65% of the maximum dose allowed to the 
OAR or 85% of the maximum dose allowed to 0.5 or 1cc of the OAR. The ‘k’ value determines at 
which points along the Dose volume histogram (DVH) curve the cost function works to reduce 
the dose. A high ‘k’ value works more on the high doses of the DVH whereas a lower ‘k’ value 
works more evenly along the DVH curve. The range of ‘k’ values available are from 1 to 20. The 
‘k’ values selected for this cost function allow the maximum dose to be controlled whilst 
providing a suitable dose gradient to achieve coverage and ease of setup during treatments. 
These reference doses were then iteratively changed to produce the desired dose distribution. 
These plans were compared against the 3DCRT plans produced for the patient treatment in 
terms of plan quality and delivery efficiency. 
106 
 
In addition to lung SABR treatments, commissioning through evaluation (CTE) SABR for 
oligometastases in the bone and lymph nodes contained in the pelvis were investigated. 
Commissioning through evaluation (CTE) is a programme that allows patients to access 
treatment options that a not funded as part of the NHS. The programme aims to provide 
treatments that show significant promise whilst collecting data so that these treatments can be 
evaluated by the National Institute of Healthcare Excellence (NICE). The treatments in this 
programme are for oligometastatic disease where cells from the primary tumour have travelled 
in the body to form small tumours in other organs. 
This was performed to evaluate whether target coverage and OAR constraints could be achieved 
with FFF beams. As this was a new treatment site, and the SABR lung investigation had already 
demonstrated that FFF VMAT could produce clinically acceptable plans, no comparison to 3DCRT 
or cFF beam VMAT was made.  
A total of seven patients were planned, including a patient with two metastases in the pelvic 
region. The plans covered a range of PTV sizes with differing levels of overlap with OARs. The 
plans could be produced with three different dose fractionations. If the PTV was distal to the 
primary treatment site the plans were planned at 40Gy in 3 fractions. If it was not possible to 
meet OAR constraints at this fractionation, they were planned as 30Gy in 3 fractions. For PTVs 
that were considered as re-irradiation due to the proximity to the original treatment site the 
dose fractionation was reduced to 30Gy in 5 fractions. 
The VMAT prescription used for planning these patients contained the target penalty cost 
function on the PTV set to cover 95% of the volume with the prescribed dose. A quadratic 
overdose cost function was used with the reference level set 1Gy above the prescription dose 
and an RMS dose excess of 2Gy. Should the conformality of the dose to the PTV not be sufficient 
to spare the OARs, such as when they overlap with the PTV, additional cost functions are added 
to the prescription. For the bladder and large bowel, a quadratic overdose with a reference level 
of 27Gy and an RMS of 0.1Gy was used. For the small bowel a quadratic overdose of 24Gy was 
used with an RMS of 0.1Gy. 
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6.2.3. Results 
6.2.3.1. 55Gy in 5# lung SABR 
Table 12: Average results for the five patients planned for the FFF planning comparison. 
Stated VMAT delivery times are reported by the treatment planning system, 3DCRT times 
are delivery times as reported by the record and verify system. 
 
 
   
3DCRT plan 6MV 
cFF 
VMAT plan  
6MV cFF 
VMAT plan  
6MV FFF 
Parameter Units   Aim Average SD Average SD Average SD 
V_PTV cc   N/A 28.42 10.69 28.42 10.69 28.42 10.69 
D to 95% of PTV Gy ≥ 55.00 55.26 0.36 55.08 0.05 55.18 0.08 
D to 99% of PTV Gy ≥ 49.50 52.42 0.69 53.37 0.41 53.18 0.68 
R100   ≤ 1.15 1.11 0.04 1.11 0.04 1.08 0.05 
R50   ≤ 9.00 4.67 0.61 5.04 0.70 5.03 1.00 
D2cm Gy ≤ 38.50 29.56 3.32 31.63 1.53 28.44 2.28 
Dlung mean Gy   N/A 3.20 1.28 3.13 1.14 3.27 1.27 
V_L 30 %   N/A 1.82 0.79 1.82 0.73 1.90 0.86 
V_L 20 % ≤ 6.00 3.52 1.56 3.41 1.37 3.57 1.54 
V_L 12.5 %   N/A 7.54 3.22 6.65 2.54 6.92 2.83 
V_L 10 %   N/A 10.13 4.29 8.49 3.14 8.97 3.63 
V_L 5 %   N/A 18.10 7.48 14.47 6.09 15.97 6.91 
Dptv max Gy   60.5 - 77 69.53 0.50 69.28 2.50 68.21 1.64 
Dptv min Gy   N/A 47.77 2.16 51.29 1.34 50.71 1.36 
Dptv mean Gy   N/A 62.34 0.90 60.20 0.69 61.01 1.04 
Dmax CORD (pt) Gy ≤ 25.00 8.24 0.78 8.53 1.02 5.90 3.05 
Dmax HEART (1cc) Gy ≤ 27.00 12.66 7.80 11.94 7.05 9.04 6.34 
Dmax OESOPH 
(1cc) 
Gy ≤ 
27.00 9.35 0.67 7.42 0.93 7.31 2.05 
Dmax AIRWAY 
(1cc) 
Gy ≤ 
32.00 9.43 3.60 9.46 4.06 8.85 4.97 
Dmax PLEXUS 
(1cc) 
Gy ≤ 
27.00 3.70 7.27 4.48 8.55 3.62 6.88 
Total MU       1868.46 78.62 1685.64 191.14 1925.03 172.42 
Delivery time       ≈12min   182.80s 20.11s 106.39s 9.08s 
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The average results across the five patients planned for this comparison are shown in Table 12. 
The 95% PTV coverages across all three treatment techniques were comparable. Both the VMAT 
techniques indicated an improved minimum dose to the PTV and 99% coverage of the PTV with 
the minimum dose improving from approximately 48Gy for the 3DCRT technique to 51Gy for 
the VMAT technique. The dose received by 99% of the PTV increasing from approximately 
52.5Gy to 53Gy. The sample sizes for this study were not large enough to determine statistical 
significance. The conformality indices of R100, R50 and D2cm were within tolerance despite the 
improved coverage of the PTVs. The R100 and R50 refer to the relative volume encompassed by 
the 100% isodose and the 50% isodose lines compared to the volume of the PTV. The D2cm dose 
constraint refers to the maximum dose at a distance greater than 2cm away from the PTV. The 
dose received by the lung is assessed by looking at what volume of the lung receives specific 
doses, as shown in the table as the volumes of lung receiving 30Gy, 20Gy, 12.5Gy 10Gy and 5Gy. 
All the OAR doses were within tolerance for the three treatment techniques. The VMAT 
technique used does not have dose entering through the contralateral lung.  Therefore, the 
contralateral lung doses were lower for the VMAT techniques when compared to the 3DCRT 
techniques. In order to adequately separate the 3DCRT beams out around the patient, beams 
entering through the contralateral lung are necessary. The VMAT techniques, therefore, reduce 
the volume of contralateral lung receiving 5Gy from 8% to 1-2%.  
109 
 
 
Figure 42: Transaxial slices of the three different techniques for one of the patients investigated. (a) 3DCRT treatment plan, (b) cFF VMAT plan, (c) FFF 
VMAT plan, (d) DVHs for PTV (blue), right lung (yellow), left lung (green) for each of the treatment techniques (a)solid line (b) dashed line (c) dotted line. 
a 
b c 
d 
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The R100, R50, D2cm and V_L_20 tolerances are dependent on the volume of the PTV treated. 
Because of the beam matching, the selection of beam energy from a cFF 6MV beam to an FFF 
6MV beam does not impact on overall plan quality. However, the difference in dose rate 
between cFF and FFF beams, 600MUmin-1 and 1350MUmin-1 respectively, reduces treatment 
time by approximately a third. Transaxial images of the different plans are displayed in Figure 
42. The dose from the 3DCRT beams through the contralateral lung is apparent. 
6.2.3.2. 54Gy in 3# lung SABR 
Table 13: Average results for the three patients planned for the FFF planning 
comparison. Stated delivery times are reported by the treatment planning system. 
  
3DCRT plan 6MV 
cFF VMAT plan 6MV FFF 
Parameter Units  Aim Average SD Average SD 
V_PTV Cc   N/A 10.5 3.1 10.4 2.9 
D to 95% of PTV Gy ≥ 54.0 53.3 0.6 54.2 0.2 
D to 99% of PTV Gy ≥ 48.6 52.1 0.7 52.5 0.2 
R100   ≤ 1.25 1.0 0.0 1.2 0.0 
R50   ≤ 12.00 10.5 2.7 10.3 1.0 
D2cm Gy ≤ 35.1 28.8 1.3 34.0 2.6 
Dcontra_mean Gy     1.3 0.0 1.1 0.1 
VcontraL_5 %     8.9 0.7 3.0 1.4 
Dlung mean Gy   N/A 3.4 0.3 3.3 0.4 
V_L 30 %   N/A 1.8 0.3 1.8 0.6 
V_L 20 % ≤ 5.0 4.1 0.6 3.8 0.9 
V_L 12.5 %   N/A 8.1 1.1 7.4 0.9 
V_L 10 %   N/A 10.7 1.2 9.2 0.9 
V_L 5 %   N/A 18.9 0.9 15.3 1.0 
Dptv max Gy   59.4 - 
75.6 
68.0 0.4 74.2 1.3 
Dptv min Gy   N/A 50.4 0.6 49.8 0.5 
Dptv mean Gy   N/A 57.7 0.7 60.0 0.2 
Dmax CORD (pt) Gy ≤ 18.0 10.5 2.6 8.5 2.5 
Dmax HEART (1cc) Gy ≤ 24.0 15.0 3.4 14.9 3.0 
Dmax OESOPH 
(1cc) 
Gy ≤ 24.0 9.7 0.7 8.1 1.4 
Dmax AIRWAY 
(1cc) 
Gy ≤ 30.0 7.0 4.5 8.4 6.3 
Dmax PLEXUS 
(1cc) 
Gy ≤ 24.0 0.1 0.1 0.2 0.0 
Delivery time    ≈12min  204.4s 20.6s 
 
The results of the comparison of the 55Gy in 5 fraction regime demonstrated that VMAT plans 
produced with FFF were comparable to those produced with cFF beams but with a reduced 
treatment delivery time. Table 13 shows the average results for the highest dose per fraction 
regime used for lung SABR treatments, 54Gy in 3 fractions. The FFF VMAT plans were able to 
achieve improved coverage of the PTV increasing the dose received by 95% of the PTV to the 
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prescribed dose of 54Gy whilst the 3DCRT technique achieved 53.3Gy. Given the small sample 
size it is not possible to determine if this improved coverage is statistically significant. The 
maximum doses received in the VMAT plans were higher with an average maximum dose of 
74.2Gy compared to 68Gy for the 3DCRT plan. This increased maximum dose was within 
tolerance parameter and is not considered clinically significant due to the ablative nature of 
these planned treatments. The conformality tolerances of the VMAT plans were still within 
tolerance for the R100, R50 and D2cm.The R50 were equivalent at 10.5 despite the improved 
coverage. The D2cm showed an increase to 34Gy from 28.8Gy when compared to the 3DCRT 
plan, but this is likely due to the improved coverage of the VMAT plan. The other OAR doses 
were within tolerance for both techniques, with the FFF VMAT technique having improved 
contralateral lung doses, reducing from 8.9% for the 3DCRT technique to 3% for the VMAT 
technique. Transaxial images of one of the plans where improved coverage was achieved is 
shown in Figure 43. 
6.2.3.3. 60Gy in 8# lung SABR 
Due to the variability of SABR plans for individual patients, particularly with respect to proximity 
to OARs, it is not helpful to produce a table of average results for the 60Gy in 8-fraction plans.  
Table 14 shows results for 7 patients with the PTV in close proximity to a range of OARs, planned 
with both the 3DCRT technique and with FFF VMAT. The cells of the table are highlighted as 
either yellow or red to draw attention to when a DVH objective has not been met, yellow 
corresponds to a minor deviation from the clinical protocol and red corresponds to a major 
deviation from the clinical protocol. An objective value is considered a minor deviation if it 
breaches the optimal constraint and a major deviation if it breaches a mandatory constraint. 
Treatment plans can still be accepted if breaching a mandatory constraint with clinician approval. 
Patient 1 is an example of a treatment at the anterior apex of the lung abutting the brachial 
plexus. The PTV coverage of both plans was acceptable with the VMAT plan having better dose 
conformality. The R100 value for the 3DCRT technique was over the objective value but was 
classified as a minor deviation from protocol. The D2cm for the 3DCRT technique was classified 
as a major deviation from protocol at over 50Gy. It was not possible to get the D2cm within the 
objective value with the VMAT technique but the dose was reduced to a minor deviation. The 
brachial plexus doses in both techniques were below the tolerance but the VMAT technique was 
able to produce better sparing for the brachial plexus with a 1cc dose of 24.9Gy compared to 
26.7Gy for the 3DCRT technique.  
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Figure 43: Transaxial slices of the two different with FFF VMAT (b) compared to 3DCRT (a).
a b 
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Patient 2 has a PTV located close to the spinal cord and oesophagus. Both techniques meet the 
target coverage objectives (Consortium, 2016). The VMAT plan has better conformality, with the 
D2cm value considered a minor deviation rather than the major deviation in the 3DCRT plan. 
The 3DCRT plan also has a minor deviation on the volume of lung receiving 20Gy, whereas, the 
VMAT plan is within tolerance for this parameter. In order to reduce these deviations the VMAT 
plan has a higher dose to the oesophagus but this is within tolerance. Both plans keep the dose 
to the spinal cord below tolerance. 
Patient 3 has a PTV located close to the aorta. This is the only example where the VMAT plan 
had lower PTV coverage than the 3DCRT technique. This was a consequence of the VMAT plan 
achieving the aorta tolerances when compared to the 3DCRT plan. The D2cm was also reduced 
from a major deviation to a minor deviation. All other OAR tolerances were met with both of 
the techniques.  
Patient 4 is another example of a PTV in close proximity to spinal cord. Both plans have major 
deviations on R100 with the 3DCRT plan having an improved value of 1.23 compared to 1.29 for 
the VMAT plan. For the VMAT plan the D2cm is reduced from a major deviation to a minor 
deviation.  
Patient 5 has the PTV abutting the cardiac wall. Both techniques have minor deviations on the 
cardiac OAR tolerances and lung V20Gy.  
Patient 6 has a PTV close to both spinal cord and the airways. Both techniques fail to achieve the 
objective coverage in order to meet the OAR constraints. The VMAT plan has a slightly improved 
D2cm and lung V20Gy, although still a major and minor deviation respectively. The VMAT plan 
does improve on the 1cc dose constraint on the airway reducing the value to being in tolerance 
compared to the minor deviation with the 3DCRT technique.  
Patient 7 is a case where the PTV is close to the major vessels. The VMAT plan kept the OAR 
constraints for the vessels within the OAR tolerance and also reduced the D2cm from a minor 
deviation to being within objective levels. Figure 44 shows transaxial slices comparing the plans 
produced. 
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   Patient 1 Patient 2 Patient 3 
    6MV cFF 6MV FFF  6MV cFF 6MV FFF  6MV cFF 6MV FFF 
Parameter Units   Aim Value Value Aim Value Value Aim Value Value 
V_PTV cc   N/A 81.6 81.4 N/A 114.6 114.2 N/A 56.9 57.0 
D to 95% of PTV Gy ≥ 60.0 60.1 60.1 60.0 60.3 60.0 60.0 58.7 55.2 
D to 99% of PTV Gy ≥ 54.0 54.7 56.1 54.0 56.0 56.7 54.0 50.0 44.1 
R100   ≤ 1.10 1.15 1.04 1.10 1.08 1.00 1.10 1.19 0.95 
R50   ≤ 5.00 4.81 4.48 4.50 3.89 3.71 6.00 5.90 5.86 
D2cm Gy ≤ 38.5 52.2 39.1 38.5 45.4 41.1 38.5 48.5 41.5 
Dcontralung mean Gy   N/A 2.4 2.6   2.4 2.8   1.5 2.1 
Vcontralung_5 %   N/A 18.2 23.5   19.9 23.0   12.8 18.2 
Dlung mean Gy   N/A 7.6 7.5 N/A 6.8 6.9 N/A 4.5 5.2 
V_L 30 %   N/A 9.2 8.4 N/A 5.5 4.0 N/A 4.9 5.4 
V_L 20 % ≤ 10.0 13.1 13.5 10.0 10.3 8.8 10.0 7.1 8.9 
V_L 12.5 %   N/A 18.8 16.5 N/A 18.4 18.2 N/A 10.4 11.2 
V_L 10 %   N/A 21.6 17.9 N/A 22.1 21.1 N/A 12.3 13.6 
V_L 5 %   N/A 28.1 29.8 N/A 33.9 36.7 N/A 19.3 22.6 
Dptv max Gy   66 - 84 76.6 83.6 66 - 84 79.7 82.7 66 - 84 75.2 82.8 
Dptv min Gy   N/A 41.3 38.7 N/A 46.4 51.1 N/A 29.5 25.0 
Dptv mean Gy   N/A 69.2 70.7 N/A 70.3 70.8 N/A 68.2 67.4 
Dmax CORD (pt) Gy ≤ 25.0 6.4 17.0 25.0 24.9 24.7 25.0 12.0 20.2 
Dmax HEART (1cc) Gy ≤ 50.0 10.6 16.7 50.0 28.4 27.8 50.0 1.9 1.5 
Dmax OESOPH (1cc) Gy ≤ 27.0 16.9 19.1 27.0 19.5 26.5 27.0 26.2 26.8 
Dmax AIRWAY (1cc) Gy ≤ 32.0 18.3 22.3 32.0 28.8 25.8 32.0 29.0 26.1 
Dmax PLEXUS (1cc) Gy ≤ 27.0 26.7 24.9 27.0 0.2 0.2 27.0 25.5 23.5 
Dmax Aorta (pt) Gy ≤       66.0 71.6 64.7 
Dmax Aorta (1cc) Gy ≤       60.0 64.1 54.9 
Dmax Aorta (10cc) Gy ≤       49.0 41.3 41.6 
 
Table 14 continues on next page 
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   Patient 4 Patient 5 Patient 6 Patient 7 
    6MV cFF 6MV FFF  6MV cFF 6MV FFF  6MV cFF 6MV FFF  6MV cFF 6MV FFF 
Parameter Units   Aim Value Value Aim Value Value Aim Value Value Aim Value Value 
V_PTV cc   N/A 60.0 60.0 N/A 36.1 35.83 N/A 77.0 76.8 N/A 41.0 40.8 
D to 95% of PTV Gy ≥ 60.0 60.0 60.0 60.0 60.0 60.0 60.0 58.5 58.7 60.0 60.7 60.2 
D to 99% of PTV Gy ≥ 54.0 57.2 56.6 54.0 58.8 58.3 54.0 54.1 54.9 54.0 58.1 56.7 
R100   ≤ 1.10 1.23 1.29 1.15 1.00 1.09 1.10 1.08 1.06 1.10 1.10 1.08 
R50   ≤ 6.00 5.87 5.96 9.00 5.13 5.84 5.00 4.45 4.84 6.00 4.87 5.23 
D2cm Gy ≤ 38.5 46.6 41.1 38.5 31.6 32.7 38.5 49.8 45.8 38.5 39.3 37.7 
Dcontralung mean Gy   N/A 2.1 2.0 N/A 1.8 1.5   2.7 3.1 N/A 1.8 1.9 
Vcontralung_5 %   N/A 18.2 15.3 N/A 14.8 5.6   18.4 30.9 N/A 15.4 12.4 
Dlung mean Gy   N/A 4.4 4.5 N/A 5.1 5.3 N/A 6.9 6.8 N/A 5.1 5.3 
V_L 30 %   N/A 3.8 4.0 N/A 3.1 3.5 N/A 5.8 5.7 N/A 4.1 4.4 
V_L 20 % ≤ 10.0 6.6 6.4 6.0 7.7 7.7 10.0 11.7 10.3 10.0 7.5 8.3 
V_L 12.5 %   N/A 9.8 9.5 N/A 14.3 15.2 N/A 20.4 16.1 N/A 12.2 11.4 
V_L 10 %   N/A 12.2 11.5 N/A 17.3 17.1 N/A 23.0 19.3 N/A 15.8 13.3 
V_L 5 %   N/A 20.5 19.4 N/A 26.7 22.8 N/A 31.2 34.4 N/A 25.9 24.3 
Dptv max Gy   66 - 84 75.3 82.1 66 - 84 75.2 77.6 66 - 84 76.0 83.9 66 - 84 75.3 82.0 
Dptv min Gy   N/A 53.8 51.1 N/A 54.6 55.7 N/A 47.3 47.3 N/A 53.5 49.1 
Dptv mean Gy   N/A 67.6 67.9 N/A 65.9 66.2 N/A 67.7 69.2 N/A 67.6 69.8 
Dmax CORD (pt) Gy ≤ 25.0 22.3 24.7 25.0 12.2 11.8 25.0 25.0 23.0 25.0 12.1 13.8 
Dmax HEART (1cc) Gy ≤ 50.0 1.3 1.2 50.0 57.5 56.8 50.0 23.5 26.1 50.0 20.1 18.7 
Dmax OESOPH (1cc) Gy ≤ 27.0 26.8 20.3 27.0 18.0 15.7 27.0 22.4 23.9 27.0 18.6 16.7 
Dmax AIRWAY (1cc) Gy ≤ 32.0 24.5 17.8 32.0 2.3 2.3 32.0 32.2 31.6 32.0 14.4 14.2 
Dmax PLEXUS (1cc) Gy ≤ 27.0 12.2 22.5 27.0 N/A N/A 27.0 17.4 4.0 27.0 0.7 0.9 
Dmax Aorta (pt) Gy ≤          68.0 69.3 67.6 
Dmax Aorta (1cc) Gy ≤          60.0 48.3 45.8 
Dmax Aorta (10cc) Gy ≤          10.0 3.0 2.7 
 
Table 14: DVH prameters for 7 patients with PTV in close proximity to OARs,  planned with FFFcompared to the parameters obtained using a 3DCRT 
technique with a cFF beam. Stated delivery times are reported by the treatment planning system.
116 
 
 
Figure 44: Transaxial slice for the two techniques of one 60in8# plan sparing the spinal cord for patient 7.
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6.2.3.4. Commissioning through evaluation (CTE) for pelvic lymph 
node and bone SABR 
Clinically acceptable plans were produced for all the patient plans, with coverage only failing to 
meet 95% objective when significant OAR overlap was present. Coverage details and OAR doses 
are shown in Table 15.  
Figure 45 shows how the plans avoid OARs and the areas where coverage of PTVs are not met 
for the patient with the dual site SABR. The white OAR located between the two PTVs was the 
‘bowel bag’, a volume defined to enclose the mobile small bowel. This structure was assigned 
the OAR constraints of the colon and therefore the prescription dose was not allowed to enter 
this region. 
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Patient 
  PelvLN1 PelvLN2 PelvLN3 PelvLN4 Pelvbone1 Pelvbone2 
CTE_PNodesP 
PTVR 
CTE_PNodesP 
PTVL 
Plan   3 newPTV3 30in5 30in5 1 40Gy 2ssoQO40s 2ssoQO40s 
Fractionation   30/3# 30/3# 30/5# 30/5# 30/3# 40/3# 30/3# 30/3# 
  Aim Achieved Achieved Achieved Achieved Achieved Achieved Achieved Achieved 
PTV (95%) Px 30.3 25.5 31.1 31.5 29.8 40.2 27.3 30.6 
PTV (mean)   34 31.6 32.6 33.3 33.2 42.4 33 34.8 
PTV (min)   25.5 14.8 30.4 28.9 25.3 37.3 25.5 26.2 
PTV (0.5cc) 39/40 38.2 37.4 34.4 35.5 38.3 47.9 39.5 39 
Small Bowel (0.5cc) 25.2 25.1 23.9 - - 23.7 14.5 - - 
Small bowel (5cc) 17.7 11.7 17.6 - - 8.9 11.8 - - 
Large bowel (0.5cc) 28.2 6.8 16.3 - - 28.1 16.7 28.1 28.1 
Bladder (0.5cc) 28.2 13.06 28 - - - 15.5 - - 
Bladder (15cc) 16.8 7.9 14 - - - 8.9 - - 
Large bowel 5# (0.5cc) 32 - - 7.4 4.8 - - - - 
Bladder 5# (0.5cc) 38 - - 10.4 18.8 - - - - 
Bladder 5# (15cc) 18.3 - - 6.7 8 - - - - 
Table 15: DVH parameters for 7 patients  with metastatic disease  in the pelvis planned with FFF SABR against the OAR constraints, including one 
patient with two PTVs to be treated concurrently 
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Figure 45: Transaxial slice of the plan treating two PTVs concurrently
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6.2.4. Discussion 
6.2.4.1. Plan quality 
With the investigation into 55Gy in 5 fraction SABR treatments, the change in planning system 
and modality was first investigated by re-planning patients that had received treatment with 7 
beam 3DCRT radiotherapy with VMAT and a cFF beam. Due to limitations within the planning 
systems used it was not possible to plan 3DCRT using Monaco v3.2 or v3.3, neither was it 
possible to plan VMAT using CMS Xio. Each system has been appropriately benchmarked and 
therefore the differences in plan DVHs will be the result of the treatment technique rather than 
dose calculation algorithm. Benchmarking is performed by comparing calculated and measured 
PDDs and dose distributions to ensure that beam models used for planning match the delivered 
dose distributions (Lopez-Tarjuelo et al., 2014; Luo et al., 2013). Plan benchmarking is performed 
by comparing the delivered plan doses to measurements performed with ion chambers, film and 
Delta4 (Calvo et al., 2009). 
The plan qualities in terms of PTV coverage and OAR doses was comparable between the 7 beam 
3DCRT technique and VMAT plans with the exception of the doses to the contralateral lung. An 
improvement is seen with the VMAT technique as it uses a 200degree partial arc that does not 
enter through the contralateral lung. With the 7 beam 3DCRT technique this is not possible 
without reducing the high dose conformality around the PTV. No clinically significant differences 
in plan quality were identified between the FFF VMAT technique and cFF VMAT technique, that 
cannot be accounted for with the variation of running multiple optimisations on an inverse 
planning system that uses a Monte Carlo dose algorithm. The 1% statistical uncertainty in the 
Monte Carlo calculation results in identical input parameters, obtaining slightly different results 
when repeat optimisations are performed.  
The results of the 55Gy in 5 fraction treatment techniques investigations showed that the 
differences between planning VMAT with a cFF beam and FFF beam were not significant. 
Comparable plan quality for cFF and FFF VMAT has been previously reported for SABR 
treatments on Varian TrueBeam Linacs using ‘unmatched’ FFF beams (Gasic et al., 2014; Hrbacek 
et al., 2014; Scorsetti et al., 2011), with some authors stating improved OAR sparing with FFF 
beams compared to cFF beams (Tambe et al., 2016; Lu et al., 2015; Navarria et al., 2013). 
Therefore, further studies only compare the plan quality between the 7 field 3DCRT technique 
and FFF VMAT technique. In order for a patient to be prescribed a treatment of 54Gy in 3 
fractions the target volume must not be attached to the chest wall and must not be in close 
proximity to OARs. Therefore, only 3 different patients were investigated as the variability in 
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plan geometries are small. The VMAT plans produced had improved PTV coverage with a lower 
dose conformality. This reduction in dose conformality is due to the 3DCRT plans not covering 
95% of the PTV with the prescription dose. The conformality index of the VMAT plans was within 
clinically acceptable limits for all of the plans produced. 
The most complex lung SABR plans are planned with the lowest dose per fraction in order to 
improve OAR sparing. The majority of plans produced with FFF VMAT had improved coverage 
and OAR sparing when compared to the 7 field 3DCRT plans. The two plans with reduced 
coverage when planned with FFF were planned so that the vessels or aorta OAR doses resulted 
in lower risk of side effects, these additional constraints were not achievable with the 3DCRT 
technique. In order to produce clinically acceptable plans, the 3DCRT plans for these patients 
had non-coplanar beams added. This resulted in additional dose superior and inferior to the 
target region when compared to the VMAT FFF plans. 
For all of the VMAT SABR plans, the maximum doses within the PTV were higher. With 3DCRT 
planning the plan is normalised at a point to calculate the required monitor units, which results 
in plans having a more consistent maximum dose based on this normalisation. The VMAT plans 
apply no normalisation to the plans and therefore the maximum dose can be higher. The 
maximum dose is instead constrained using a cost function to keep the maximum dose within 
140% of the prescription dose. As these doses are for ablative treatments the increased doses 
in the PTVs were clinically acceptable. The doses could have been further reduced with the 
VMAT technique but this would have increased the plan complexity and may have resulted in 
interplay issues during delivery. These interplay issues and how they have been resolved will be 
discussed in a following section. 
For SABR plans in the pelvis there is a wide range of OARs that could be in close proximity to or 
overlapping with PTVs. The cases that were planned ranged from PTVs with no overlap and 
without any OARs in proximity, to PTVs where large amounts of overlap required compromise 
to the coverage. The case ‘pelvbone2’ had no overlap, with the closest OAR (small bowel), which 
was far enough away from the PTV for a conformal dose distribution to allow the dose to be 
escalated to 40Gy in 3 fractions. The plans where it was not possible to cover 95% of the PTV 
with the prescription dose had volumes of the PTV that overlapped with the OARs. The right-
hand volume of the case ‘CTE P’ had a large portion of the PTV that overlapped with the colon 
(Figure 45). The relationship between the overlap of the OAR and the PTV is shown in Figure 46. 
For volumes of overlap under 1.5cc it was still possible to achieve coverage of the prescription 
dose to 95% of the PTV. This is due to the overlapping OAR being a parallel organ; rather than a 
maximum point dose constraint an area of 0.5cc was able to receive over the stated maximum 
dose. In order to achieve the OAR doses for the case with two PTVs, both PTVs needed to be 
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treated in the same plan, so that the optimiser could account for the doses delivered as a result 
of treating the second PTV whilst minimising the contribution from the beam treating the 
opposing PTV. This was achieved by using two beams with different isocentres each only 
optimised to treat one of the PTVs. The isocentre for each beam was positioned in the centre of 
the associated PTV and constrained to allow the leaves only a margin of 5mm around the PTV. 
This resulted in both beams contributing doses to the OAR, but the contribution from the second 
beam being dose from the low dose transmission of the opposing PTV. By planning in this way, 
if the PTVs migrated relative to each other the dosimetric impact would be low. 
 
 
Figure 46: The relationship between OAR overlap and the dose to 95% of the PTV 
6.2.4.2. Delivery efficiency 
The primary drive for the use of FFF beams in radiotherapy is to reduce treatment times and 
therefore improve the efficiency of machine use. With the projected increase in demand for 
radiotherapy (CRUK, 2015) services it is desirable to improve treatment efficiency to increase 
treatment capacity. Plans that require large MU settings to deliver high doses per fraction are 
where this increased dose-rate is likely to have the largest impact on treatment times. Table 12 
shows that treating with an FFF beam compared to a cFF beam reduces the beam-on time for 
these lung SBRT treatments from 180seconds to 106seconds, a reduction of 42%, other studies 
have reported reduction in treatment times of 59% (Hrbacek et al., 2014) and 61% (Tambe et 
al., 2016), both these studies used an isocentre placed at the centre of the PTV allowing the 
maximum doserate to be utilised more effectively.. The reduction in beam on time observed in 
this study is less than the ratio of the dose-rates available for each beam (600MU/min for cFF, 
1400MU/min for FFF), which implies the expected reduction would be 57% if this ratio was the 
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only factor in the delivery. However, the plans with FFF beams required almost 15% more MU 
than the cFF beams. This is the same as the efficiency loss when comparing the dose-rates of 
the two modalities. The increase in MU required for FFF beams when compared to cFF beams 
has been reported by other authors as 34% (Lechner et al., 2013) and 25% (Hrbacek et al., 2014). 
This increase is greater than that found in this study, as possible cause is that in this work the 
energy of the FFF beam was matched to the cFF beam resulting in greater penetration. 
The energy matching performed on the Elekta implementation of FFF beams means that a 
reduction in beam penetration does not explain why more MUs are required for the FFF plan. 
The profile shapes of cFF and FFF beams for field sizes less than 5cm x 5cm are comparable for 
FFF beams therefore additional modulation is also unlikely to be the cause.  
The reason for this reduction in efficiency is a result of the method of planning SABRs at this 
institute. For these treatments, a ‘mid-line’ isocentre technique is used. This is where the 
isocentre is placed in the middle of the patient on a plane that bisects the PTV. The advantage 
of placing the isocentre in this location is that it is less likely that the location of the isocentre 
will cause a collision between the patient or couch and the touch guard on the linear accelerator 
head during cone beam CT image acquisitions. In some situations, particularly for a laterally 
located PTV, placing the isocentre within the PTV risks causing a collision during the cone beam 
CT scan, or requires the reduction of the scan acquisition to a 180degree arc, resulting in reduced 
image quality of the scans. The disadvantage of the mid-line isocentre technique with respect 
to FFF beams is that a portion of the beam is not delivered on the central axis and due to the 
profile shape of FFF beams the output off axis is not 1cGy per MU and therefore more MU are 
required to deliver the same dose (Figure 47). 
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Figure 47: Dose in cGy/MU with respect to off axis distance for 40cm x 40cm 6MV FFF 
and cFF beams taken at 100cm SSD at a depth of maximum dose 
6.2.4.3. Interplay effects 
Section 6.2.4.1 concluded that plan quality may have been improved further if the impact of 
interplay had not been a concern. Interplay is the relationship between the segments used to 
deliver the treatment field and the motion of the target within the PTV (Shepherd et al., 2018). 
For lung SABR treatments, the motion due to breathing can be large: up to 2cm (Edvardsson et 
al., 2018; Kubo et al., 2018)) and the size of the GTV compared to the PTV can be small as a result 
of breathing motion (Figure 48). 
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Figure 48: Three of the possible GTV locations within one respiratory cycle 
 
This is of a greater concern for FFF beams as, due to the efficiency of the delivery, the treatments 
are delivered in a shorter time-frame and therefore over fewer respiratory cycles. As the number 
of respiratory cycles decreases, the impact of interplay increases (Kubo et al., 2018). In order to 
minimise this effect, the plans were produced with ‘uncomplicated’ segments, which results in 
higher doses to the GTV because the planning system is unable to modulate the beam to cool 
down these hot areas (Figure 49). The complication of the segments was reduced by setting the 
minimum segment width to 1cm as well as having a small fluence increment. The small fluence 
increment means that the leaves travel quickly from one side of the field to the other, thereby 
reducing the opportunities to produce complicated modulation. This results in higher doses to 
the GTV because the planning system is unable to modulate the beam to reduce the dose 
delivered to these ‘hot’ areas (Figure 49). The plans were also produced with segment shape 
optimisation set to ‘off’. With this function setting the segment shapes were not changed 
multiple times during the optimisation. A study by Boda-Heggemann et al. (2013) looked at the 
use of FFF beams for breath hold treatments to mitigate the impact of interplay. The study found 
that with FFF and 3DCRT treatments for lung SABR that the plans could be delivered in a 
15minute timeslot compared to a 30min timeslot for cFF beams. This demonstrates a time 
efficiency improvement in comparison to cFF beams but not to VMAT deliveries. 
 
GTV ITV 
PTV 
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Figure 49: Example of a modulated segment and an open segment, the outer contour 
represents the PTV and the inner contours represent the ITV and GTV. The shaded areas 
show the beam aperture. 
6.3. Standard fractionated treatments 
With the increased dose-rate of FFF beams, most studies have focussed on hypofractionated, 
high dose per fraction treatments, as the increased dose-rate can produce significant reduction 
in treatment times (Hrbacek et al., 2014; Lang et al., 2013; Tambe et al., 2016). The potential 
issues with using FFF beams for standard (2Gy per fraction) fractionated treatments are that 
additional modulation may be required to produce a uniform dose within the PTVs due to the 
profile shape of FFF beams. This additional modulation would result in more MU being required 
relative to cFF beams. However, other efficiencies can be achieved if FFF beams are also used 
for standard applications. For example, using fewer beam energies for clinical applications 
means planning system and linear accelerator quality assurance can be reduced. Chapter 4 has 
discussed how an FFF beam can be quality assured without the need for a clinical cFF beam. 
Here treatment planning studies have been performed in order to determine if plans with lower 
doses per fraction can be produced with FFF beams. 
6.3.1. Head and Neck 2Gy/# 
6.3.1.1. Method 
In order to determine the feasibility of using FFF beams for treating head and neck cancers, four 
patients were planned on Monaco v3.3 with both a cFF 6MV beam with an MLCi2 head and an 
FFF 6MV beam on an Agility head. The aim was to identify if differences in plan quality or delivery 
efficiency were observed when planning with FFF. The plans were produced on the two different 
heads for the different modalities because an appropriately benchmarked and verified cFF 
model was not available on Monaco for the Agility treatment head.  
The beam arrangement used was two 180degree arcs starting at gantry 0 and going clockwise 
or counter clockwise then returning to gantry 0. This produced a total arc length used for the 
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optimisation of 720°. This arrangement provides the same arc length as two 360degree arcs with 
the advantage of double to MLC start positions. The advantage of this is that it allows a break in 
the treatment delivery so that the MLCs can be moved to start in more optimal positions for the 
return portion of the arc. In addition to this it also results in the plan finishing with the gantry 
starting and ending at 0° improving the efficiency of getting the patient on and off the treatment 
couch. Each case was produced using a 3mm dose grid and a Monte Carlo variance of 1% per 
plan, this grid size is comparable to those used in other published studies such as Lechner et al. 
(2013) that used a grid size of 4mm for H&N treatments (Lechner et al., 2013). The increased 
number of OARs and PTV dose levels in head and neck treatments, along with the non-ablative 
nature of the treatment, results in IMRT prescriptions that are more complex than for the SABRs 
previously described. The primary PTV uses a target penalty cost function set at the prescription 
dose, which was not altered during optimisation. A quadratic overdose with a reference level 
set at the prescription dose with an RMS of 1.5Gy.The RMS was adjusted to prevent hotspots 
within the PTV. Elective PTVs were planned with a target penalty cost function set at the elective 
prescription dose. To control the fall-off of dose from the higher dose PTVs into the elective PTV, 
a quadratic overdose with a 0cm shrink margin set at the elective dose with an RMS of 2Gy was 
used. This shrink margin means that the constraint works up to the edge of the PTV. To control 
the dose received by 50% of the volume (D50%) of the elective PTV, a second quadratic overdose 
that acts on areas of the PTV 0.9cm away from higher dose PTVs was used, set at the elective 
prescription with an RMS of 0.8Gy. Elective PTVs cover at risk regional areas that are treated 
with a lower target dose to the primary PTV. 
To prevent having any areas of 110% of the prescription dose, a maximum dose constraint is 
applied to the entire patient volume set at 110% of the prescription dose minus 0.5Gy. This 
patient structure also has a conformality cost function that constrains dose outside the PTVs and 
has a higher dose penalty the further dose is from the PTV. Organs at risk are positioned below 
the patient cost functions in the IMRT constraints, with the cost functions applied to them set 
to optimise over all voxels in the structure. Serial cost functions are applied to the cord plus 
3mm structure and brainstem with ‘k’ values of 20; the reference level for these is set to 38Gy 
and 38.5Gy respectively, this ‘k’ value determines where on the DVH curve the constraint works, 
a ‘k’ value of 20 means that the constraint works at the higher end of the DVH curve and acts 
more like a maximum dose. Larynx and midline structures use the conformality cost function to 
reduce the dose spill into these organs where they do not overlap with a PTV. The parotids use 
a conformality cost function and a serial cost function with a reference dose of 95% of the 
prescription dose to reduce the dose in the parotid outside of the PTV and prevent hotspots in 
the OAR that overlaps with the PTV. The plans were compared in terms of plan quality and 
delivery time. 
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6.3.1.2. Results 
Clinically acceptable plans were achieved for each of the planning cases investigated for both 
delivery modalities. Trans-axial slices showing the dose distribution achieved on two of the cases 
are shown in Figure 50. 
The DVH values obtained for the same two planning cases are shown in Table 16. Case 1 has 
comparable coverage of the target when comparing FFF to cFF with 95% of the PTV being 
covered by 68.4Gy for the cFF plan and 68.0Gy for the FFF plan. The maximum dose to 5% of the 
PTV and maximum dose to 2% of the PTV are identical in both the cFF and FFF plans. The 
coverage of the elective PTV is also comparable with 95% coverage of 56.3Gy for the cFF plan 
and 56.4Gy for the FFF plan. Organ at risk doses were comparable for each plan. The OAR doses 
for each plan were comparable, with neither technique resulting in a significant change in OAR 
dose that would cause an OAR to be in or out of tolerance with respect to the other technique.
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Figure 50: Transaxial slices from two of the planning cases comparing the dose distribution between the two modes of delivery. Upper left FFF, Upper 
right cFF, Lower left cFF, lower right FFF. Above: a plan with a 70Gy PTV close to optical OARs. Below: a plan with a large high dose region with lower 
dose elective region to the right hand side of the patient. 
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Table 16: DVH values obtained for two patients planned with both cFF and FFF beams. 
Patient 1 refers to a patient with the high dose region in close proximity to optical OARs, 
patient 2 refers to a patient with a large high dose region. Red text highlights OAR doses 
that exceed dosimetric aim.  
 Patient 1 Patient 2 
Parameter Units   Aim  6MV 
cFF 
6MV 
FFF 
Aim 6MV 
cFF 
6MV 
FFF 
PTV - radical target     70.0     66.0     
D99% ≥ 90%  Gy ≥ 63.00 66.80 66.80 59.40 62.90 63.40 
D95 ≥ 95% Gy ≥ 66.50 68.40 68.00 62.70 64.60 64.70 
D5% ≤ 105% Gy ≤ 73.50 73.00 73.00 69.30 69.00 69.00 
D2% ≤ 107% Gy ≤ 74.90 73.60 73.60 70.62 69.50 69.50 
                  
Elective target 1                 
Prescribed dose Gy = 57.0     56.0     
D99% ≥ 90%  Gy ≥ 51.3 55.00 55.30 50.4 54.90 55.10 
D95 ≥ 95% Gy ≥ 54.2 56.30 56.40 53.2 56.00 56.10 
Spinal canal Max Gy ≤ 48.0 42.7 43.9 48.0 39.7 42.4 
Cord PRV dose to 1cc Gy < 48.0 43.7 43.8 48.0 42.9 42.8 
                  
Brainstem Max Gy ≤ 54.0 51.9 53.6 54.0     
Mean Gy ≤ 40.0 31.8 29.0 40.0 26.5 24.9 
Dose to 1cc Gy < 60.0 42.9 42.5 60.0 19.4 16.0 
                  
Ipsilateral Parotid mean Gy ≤ 26.0 55.2 55.2 26.0 N/A  N/A  
Contralateral Parotid mean Gy ≤   52.2 52.3 26  23.2 23.9 
                  
Larynx mean Gy ≤ 45.0 46.2 47.4 45.0  N/A N/A  
Oral Cavity  mean Gy ≤ 45.0     45.0 50.7 47.7 
                  Other OAR                 
RT eye mean Gy ≤ 45.0 34.7 33.2    N/A N/A  
LT eye mean Gy ≤ 45.0 39.2 36.4   N/A  N/A  
RT retina mean Gy ≤ 45.0 28.4 29.0   N/A  N/A  
LT retina mean Gy ≤ 45.0 31.7 29.2   N/A  N/A  
RT lens max Gy ≤ 6.0 39.4 33.5    N/A N/A  
LT lens max Gy ≤ 6.0 45.6 40.7   N/A  N/A  
RT optic nerve max Gy ≤ 60.0 56.5 57.2   N/A  N/A  
LT optic nerve max Gy ≤ 60.0 57.2 57.5   N/A  N/A  
Chiasm max Gy ≤ 60.0 55.1 55.9   N/A  N/A  
6.3.1.3. Discussion 
Clinically acceptable plans were achieved for each of the planning cases investigated. Other 
studies performed on the Varian TrueBeam linear accelerator have demonstrated that the plan 
quality comparison can be variable in cases of H&N. Some studies have concluded that PTV 
coverage is equivalent but with improved OAR sparing for FFF plans (Nicolini et al., 2012; Yan et 
al., 2016). Other studies have found that FFF plans have poorer homogeneity than cFF plans 
(Zhuang et al., 2013; Gasic et al., 2014). The same optimisation constraints and beam 
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arrangement were used for both the cFF MLCi2 and FFF Agility plans. The average number of 
MUs for the cFF plans was 847MU with a standard deviation of 98MU, the MUs required for the 
FFF plans was 1081MU with a standard deviation of 158MU, this increase in MU of 30% is most 
likely due to the reduced cGy/MU off axis distance rather than increased plan complexity. This 
increased number of MU required per plan for FFF beams have also been found by other authors 
(Gasic et al., 2014) with values stated as 30% (Yan et al., 2016) and 20% (Nicolini et al., 2012) 
more. Despite this increase the FFF plans would still deliver lower doses outside of the treatment 
field, reducing the risk of radiation induced secondary cancers (Murray et al., 2015; Paynter et 
al., 2014; Cashmore et al., 2011). The average delivery time for the cFF plans was 302.9seconds 
with a standard deviation of 6.5seconds. The average delivery time for the FFF plans was 
206.5seconds with a standard deviation of 4.2seconds. The FFF plans were able to be delivered 
32% faster than the cFF plans. This reduction in delivery time is most likely a result of the higher 
dose rate coupled with a differing maximum leaf speed between the two treatments heads. The 
Agility head has a maximum leaf speed 43% faster than the MLCi2 treatment head when not 
employing the dynamic leaf guides which gives an increased speed of 70%. With this taken into 
account it is assumed that the FFF plans would take 10% longer to deliver than the cFF plans if 
they were delivered on an Agility head if the increased dynamic leaf guide speed is not fully 
utilised. Other authors have performed studies on the Varian TrueBeam Linac finding that the 
delivery speed for cFF and FFF plans is comparable (Zhuang et al., 2013; Nicolini et al., 2012; 
Gasic et al., 2014). When using FFF beams for this type of treatment the treating centre would 
need to determine if this 10% increase in delivery time is justified with the reduction of 
overheads associated with maintaining additional beam models.  
6.4. Conclusion 
This chapter answers the research question “How can FFF beams be implemented in the clinic 
and are they suitable for a range of treatment sites?” by performing planning studies on a range 
of treatment sites with comparison to current standard of care treatments with cFF beams. 
The use of FFF beams for treatment planning and delivery has the largest benefits when planning 
hypofractionated treatments as the increased dose-rate provides significant reduction in 
treatment delivery times. For treatments with standard dose per fractionation of approximately 
2Gy, the increased dose-rate does not improve delivery efficiency as the factor dominating the 
delivery speed is the leaf speed of the collimating device. The plans produced are of equivalent 
quality. The treatment centre would need to determine whether maintaining multiple beam 
models and clinical beam energies on the treatment machines justifies the reduction of delivery 
efficiency when using FFF beams for all treatment sites. Larger patient studies were not 
performed as this work was part of a feasibility study to determine if FFF beams could produce 
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clinically acceptable plans. The work on non-hypofractionated deliveries has resulted in in a 
policy that all of the VMAT treatments at our centre are to be planned with FFF beams. There 
are currently 21 clinical sites delivered using VMAT in this way, for which the author has had a 
significant contribution to the class solution of 7. These are paranasal sinus, breast, bilateral 
H&N, single sided head and neck, lymphoma, lung SABR and pelvic SABR. 
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7. Summary and future work 
The aim of this thesis was to investigate FFF beams from initial characterisation through to the 
final implementation in the clinical setting. This was done through the following chapters; 
1. A literature review of current publications and their findings with respect to FFF 
beams. 
2. The characterisation of the two implementations of FFF beams by the two main 
manufacturers of Linacs. 
3. The setup and quality assurance of FFF beams and proposed new suitable definitions 
of beam parameters. 
4. The Monte Carlo modelling of FFF beams and how this can be achieved. 
5. The implementation of FFF beams in a clinical setting including feasibility studies for 
different treatment sites and dose fractionations. 
The literature review highlighted the need for clarification and comparison of the two different 
implementations of FFF beams by the two main Linac manufacturers. For a reader without prior 
knowledge of these differences, conclusions could be drawn that might not be relevant for the 
implementation from a different manufacturer. In addition, earlier publications on FFF beams 
where the energy had been matched to the equivalent conventionally flattened (cFF) beam were 
performed with a match of the beam quality specifier TPR20/10 and not the clinical 
implementation of percentage depth dose at 10cm depth. Chapter 3 investigated the 
characteristics of both implementations of FFF beams by performing measurements on FFF 
beams that had not been energy matched (Varian approach) and those that had their energy 
matched at a depth of 10cm in water at 100cm SSD in a 10cm x 10cm field (Elekta approach). 
The matching of a FFF beam to a cFF beam at a depth of 10cm in water by increasing the FFF 
beam energy does not reduce any of the reported benefits of FFF beams. However, there are a 
number of benefits resulting from matching the FFF beam, e.g. the depth of maximum dose is 
located deeper and the beam quality and penetration more closely resemble the cFF beams 
currently used in clinical practice, making dose distributions in water more alike. Highlighted in 
this work is the fact that some conventional specifications and methods for measurement of 
beam parameters, such as penumbra, are not relevant. Further research was identified to 
address this situation with respect to ‘matched’ FFF beams and to determine methods of 
measurement that are not reliant on an associated cFF beam. This was investigated in Chapter 4. 
The quality assurance (QA) of FFF beams has been discussed by other authors primarily for the 
implementation of FFF beams without energy matching (Fogliata et al., 2012a) and later 
subsequently applied to matched beams (Fogliata et al., 2016b). These studies defined new 
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parameters that are required for the QA of FFF beams in addition to the parameters used for 
characterising cFF beams. Other national recommendations relied on the acquisition of ‘gold’ 
standard data that is used for the subsequent analysis and QA of beams. In Chapter 4, new 
proposed methods are presented that make it possible to independently carry out 
characterisation, set up and QA measurements on beam energy, flatness, symmetry and field 
size of an FFF beam. This is without the requirement for an equivalent cFF beam of the same 
energy or ‘gold’ standard data. The methods proposed can also be used to carry out this QA for 
cFF beams, resulting in universal definitions and methods for MV beams. This is presented for 
matched FFF beams produced by an Elekta linear accelerator, but is anticipated to equally apply 
to unmatched FFF beams from other manufacturers’. The above work has contributed to UK 
national recommendations for FFF beams (see below). 
A well-produced and benchmarked Monte Carlo model can be a powerful tool in investigations 
that may otherwise prove difficult to perform through physical measurements. The majority of 
the literature relating to Monte Carlo models is on the guidance of producing models for cFF 
beams. The majority of the literature on FFF beams is through modifications of cFF models on 
beams that are not energy matched. Chapter 5 investigated the production of an FFF Monte 
Carlo model from first principles for an energy matched FFF beam, with the aim of producing 
new guidance on modelling of FFF beams and allowing further investigations in out of field doses, 
a potential benefit of FFF beams. The modelling of FFF beams with Monte Carlo in EGS/BEAMnrc 
is possible with the appropriate technical information provided by the vendor. The relationship 
between the field size and the movement of the jaws and MLCs is not linear and therefore needs 
to be characterised in order to be able to model more complex field shapes. When modelling 
FFF beams in Monte Carlo, the divergence of the electron beam at the point of striking the target 
was shown to be a useful parameter to help achieve a realistic model of the incident electron 
beam on the x-ray target, with a match for both PDD and beam profile distributions. The 
divergence of the electron beam on the target has minimal impact on the PDD, so once a 
Gaussian distributed beam energy has been found to produce appropriate PDDs for the clinical 
range of field sizes, the profile shapes can be further optimised using the divergence parameter. 
The modelling produces good agreement with measurements for a wide range of field sizes and 
can be used for further studies into peripheral doses and secondary cancer induction. 
The implementation of IMRT and VMAT in most radiotherapy centres has the potential to 
remove the requirement of a cFF treatment beam for radiotherapy planning. Previous planning 
studies in the literature have focussed on hypofractionated treatments as the increased 
doserate of FFF beams is seen as an advantage for these sites. Also, most of the planning studies 
in the literature are for the non-matched FFF implementation. Chapter 6 contains feasibility 
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studies for the use of FFF beams for the planning of both hypofractionated treatment regimens 
and standard treatment fractionations with the aim of demonstrating that a single FFF beam 
model is suitable for all IMRT and VMAT treatments. The use of FFF beams for treatment 
planning and delivery has the largest benefits when planning hypofractionated treatments as 
the increased doserate provides significant reduction in treatment delivery times. For 
treatments with standard radical dose fractionations of approximately 2Gy per fraction the 
increased doserate does not improve delivery efficiency, as the factor dominating the delivery 
speed is the leaf speed of the collimating device and the gantry rotation speed. The plans 
produced are of equivalent quality and the treatment centre would need to evaluate whether 
maintaining multiple beam models and clinical beam energies on the treatment machines 
justifies the reduction of delivery efficiency when using FFF beams for all treatment sites. Larger 
patient studies were not performed as this work was part of a feasibility study to determine if 
FFF beams could produce clinically acceptable plans. The work on non-hypofractionated 
treatments has resulted in a policy that all of the VMAT plans at our centre are delivered with 
FFF beams. There are currently 21 clinical sites delivered using VMAT in this way, for which the 
author has had a significant contribution to the class solution of 7. These are paranasal sinus, 
breast, bilateral H&N, single sided head and neck, lymphoma, lung SABR and pelvic SABR. 
The work presented in this thesis has highlighted further areas of study in relation to FFF 
beams. These areas are described below. 
 There is no consistent definition of FFF beams, with multiple publications proposing new 
methods for analysing FFF beams and performing QA. A further study is required that 
compares the proposed methods in this thesis with methods proposed by Fogliata et al. 
(2016b) and Budgell et al. (2016). This work should be performed using data collected 
from multiple vendors of FFF to ensure that the final proposed methodology is suitable 
for all radiotherapy photon beams. 
 Monte Carlo models can be used along with a model of a cFF beam from the same linear 
accelerator to investigate if the use of FFF beams can be utilised to reduce the incidence 
of radiotherapy induced secondary cancers both distal to and in the near field region of 
radiotherapy treatments. 
 Further larger scale treatment planning studies comparing cFF and FFF beams for more 
treatment sites and fractionation regimes should be investigated to determine if the use 
of FFF beams should become the standard of care for IMRT and VMAT treatments. 
In summary the work in this thesis has provided information regarding the characterisation of 
FFF beams with respect to the implementation of both main manufacturers, Elekta and Varian. 
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The work contained in section 3 has been published in a peer review publication (Paynter et al., 
2014) and has already received multiple citations from other authors in the field. The work on 
the QA and setup of FFF beams in section 4 has been published in a peer review journal (Paynter 
et al., 2017) and has directly helped to influence the practice at Leeds Teaching Hospitals NHS 
Trust. The work on the clinical implementation has contributed towards the implementation of 
FFF within St James’s University Hospital, Leeds and currently all VMAT and IMRT treatments 
are delivered using FFF beams. At the time of writing St James’s University Hospital, Leeds is in 
the process of an equipment refresh, each new accelerator installed will have FFF functionality. 
Following on from publication and conference talks on the FFF work contained in this thesis I 
was asked to contribute to the UK national recommendations on FFF beams and this work was 
published in the journal Physics in Medicine and Biology (Budgell et al., 2016) see Appendix A. 
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